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Abstract 
Over expression of lens epithelium derived growth factor (LEDGF) is described in a 
number of different tumours. In addition, self-antibodies against this protein are 
detectable in patients with lymphomas and chronic lymphocytic leukemia (CLL). 
Alternative splicing of LEDGF results in a number of different isoforms, and thus the 
initial aim of this thesis was to determine the variability in LEDGF isoform 
expression in a cohort of CLL cases. Utilising RT-PCR, it is shown that CLL cells 
variably express four different LEDGF isoforms. The study was then extended to 
quantitate the expression levels of these four isoforms in individual CLL cases, and 
to compare them to normal B cells. RT-qPCR analysis showed that the longest of 
these isoforms, p75, is significantly over expressed, whilst the shortest form, 
p52bΔE6 is significantly under expressed in CLL, compared to normal B cells. All four 
isoforms of LEDGF are generally over expressed in CD38 positive CLL cases 
compared to those that are deficient for surface expression of this molecule. 
Alternative splicing occurs as a result of the inclusion or exclusion of different exons 
within the mRNA. This process is governed by the splicing machinery, of which 
Splicing Factor 3B, subunit 1 (SF3B1) is a critical component. Recently, it has been 
shown that mutations within SF3B1 are recurrent in CLL. Such mutations impact on 
the splicing of a significant array of genes within the cell. One of the genes 
predicted to be affected is LEDGF. Therefore, the mutational status of SF3B1 was 
examined in the same cohort of CLL cases and correlated with the expression of the 
LEDGF isoforms. As well as the commonly reported mutations in SF3B1, a novel 
nonsense mutation was identified. Although not statistically significant, cases with 
unmutated SF3B1 have higher levels of all isoforms of LEDGF and a possible 
explanation for this is discussed. 
 That two of the major isoforms of LEDGF (p75 and p52) have differing functions 
within the cell is well documented and can be explained by virtue of their 
participation in distinct protein complexes. In order to identify components of the 
complexes generated by the four LEDGF isoforms identified in this study, stable cell 
lines exogenously expressing these isoforms were generated. Each of the isoforms 
was ‘double-tagged’, and a purification protocol optimised that would allow 
successful characterisation of the complex associated with each isoform. 
The results provide useful insights and provoke thought for the role of alternative 
splicing in the altered phenotype of cancer cells and its contribution as an additional 
epigenetic mechanism in normal and malignant gene regulation. 
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Table - A Table of cell lines used for the investigations presented in this thesis.  
The use of each cell line is described.
1 
 
Chapter 1 : General 
Introduction 
 
1.1. Lens Epithelium Derived Growth Factor 
LEDGF is so called as it was isolated from a human lens epithelial library1. It is also 
known as PC4- and SFRS1-interacting protein 1 (PSIP1) by virtue of existing as a 
product of this gene located on chromosome 9p22.32. LEDGF is primarily expressed 
in 2 alternative splice forms - LEDGF/p75 and LEDGF/p52. Both protein products 
have identical N-terminal sequences up to amino acid residue 325. The C terminal 
domain of LEDGF/p75 is 205 amino acids, resulting in a protein that is 530 amino 
acids in length. In contrast, LEDGF/p52 has a smaller C-terminal tail of 8 residues 
(333 amino acids). 
 
1.1.1. Transcriptional regulation of LEDGF  
It has been shown that the expression of LEDGF/p75 and p52 occurs from two 
separate transcriptional start sites (TSS) (Figure 1-1)3. Using Luciferase reporter 
experiments the promoter region for LEDGF/p75 (-723/+59) was shown to be ~12x 
more active than the region around the LEDGF/p52 TSS (+140/+781)3. The minimal 
promoter regions required to drive expression of p75 and p52 are located between 
-112/+59 and +609/+781 respectively. More interestingly, a region located between 
2 
 
+319/+397 appears to regulate the ratio between LEDGF/p75 and LEDGF/p52 
expression.  
  
 
Figure 1-1: Model for transcriptional regulation of the PSIP1 gene.  
The promoter region of the gene is shown with the positions of the Enhancer (E) 
and Silencer (S) sequences highlighted. Expression of the two major isoforms of 
LEDGF, p75 and p52 are from separate TSS. Regions of the promoter that are 
involved in increasing or decreasing the transcription of LEDGF/p75 are shown. 
Stimulation is shown by arrows whereas repression is shown by a bar. 
 
1.1.2. Structure of LEDGF 
The common N-terminus of LEDGF/p75 and p52 encodes a PWWP domain (residues 
1-93), a nuclear localisation signal (NLS) (residues 145-156), a pair of AT-hooks (178-
198) and three charged regions (CR). The C-terminus of LEDGF/p75 contains a 
3 
 
further two charged regions as well as an integrase binding domain (IBD) (339-442) 
(Figure 1-2)4. 
  
 
Figure 1-2: Representation of LEDGF/p75 and p52 protein structure.  
The two isoforms are identical in sequences up to and including residue 325. Each 
isoform has a unique C-terminal tail. The common domains of the two isoforms are 
PWWP domain (PWWP), charged regions 1-3 (CR1-3), nuclear localisation signal 
(NLS) and AT hooks. The unique C-terminus of LEDGF/p52 is composed of 8 
residues. The unique C-terminus of LEDGF/p75 is composed of charged regions 4 
and 5 (CR4 and 5) and an integrase binding domain (IBD). The numbers designate 
the amino acids that form each domain. 
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Domain 
Presence in 
LEDGF/p75 and p52 
Function of domain 
PWWP Yes Targets the protein to chromatin 
Charged region 1 Yes Aids the chromatin binding of 
LEDGF 
Charged regions 2 and 3 Yes Influence the activity of the AT 
hooks 
Nuclear localization Yes Directs the proteins to the 
nucleus 
AT hooks Yes Help protein dock onto minor 
groove of DNA at AT-rich region. 
Integrase binding 
domain 
LEDGF/p75 only Docking platform for other 
proteins 
Charged regions 4 and 5 LEDGF/p75 only Role is unknown. 
 
Table 1-1: Summary of the roles of the different domains in LEDGF.   
The name of each domain in LEDGF is detailed on the left and the role of each 
domain is detailed on the right. 
 
The PWWP domain, first identified in the Wolf-Hirschhorn syndrome candidate 1 
protein (WHSC1)5, is so called because of a conserved quartet of proline-
tryptophan-tryptophan-proline residues. Although the ‘PWWP’ sequence is 
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generally conserved, there are critical variations (Figure 1-3)6 that explain the ability 
of this family of proteins to interact with a variety of targets.  
Initially the PWWP domain was predicted to be responsible for protein-protein 
interactions7. However, in 2002 it was demonstrated that mammalian DNMT3B 
binds to DNA via this domain8. Accumulating evidence suggests that as well as its’ 
DNA binding ability, the PWWP domain can bind to methylated histones9. More 
recently, affinity for methylated lysines is described10-12.  
 
 
Figure 1-3: Structure-based sequence alignment of human PWWP domains.  
The green box shows the conserved PWWP quartet of residues. The letters 
highlighted by a red box are invariant whilst other coloured residues (red in a blue 
outline box) have high global similarity scores.  
 
Proteins containing the PWWP domain are histone modification ‘readers’. That is, 
they are responsible for eliciting the correct response to the presence or absence of 
the histone marks13. Histones are primarily modified on their basic N-terminal tails 
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and these modifications affect the ability of the nucleosomes to interact with both 
DNA and other proteins14. Histone modifications read by domains such as the 
PWWP domain are acetylation of lysine residues and methylation of lysine and 
arginine residues. 
Histone post-translational modification is a form of epigenetics. Epigenetics is an 
umbrella term encompassing molecular mechanisms that result in a change of 
phenotype without an alteration in DNA sequence. First proposed in 1939 by C.H 
Waddington15, the definition has since been updated to include heritable changes in 
gene expression that are not due to any alteration in the DNA sequence16. 
Historically, epigenetics refers to DNA methylation, non-coding RNA (ncRNA) 
expression, histone post-translational modifications and alternative splicing. 
Epigenetic regulation is a fine tuned process and likely explains the variability in the 
phenotypes observed within populations. Dysregulation of the epigenome is now 
well documented in cancer and significantly contributes to neoplastic cell 
behaviour, variability in therapeutic responses and disease outcomes. 
The Hepatoma-derived growth factor (HDGF) related proteins include HDGF-related 
proteins-1 to 4, LEDGF and HDGF. All members of this group share a common N-
terminal PWWP domain-containing region (also called homologous to amino 
terminus of HDGF, (HATH) region) but their C-terminii vary in length and charge17. 
This group of proteins have functional roles inside and outside the plasma 
membrane. The PWWP domain of LEDGF, however, has a strong tethering effect 
that directs the protein to chromatin, and hence LEDGF is found to be constitutively 
localised in the nucleus18. 
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The NLS sequence of LEDGF, described independently by Maertens et al. and 
Vanegas et al. 19, 20, conforms to the classical basic family. Lysine150 was shown to be 
the critical residue and its mutation abolished nuclear localisation19. Interestingly, 
LEDGF with a mutant NLS was shown to be localised in the cytoplasm but upon 
passage, the mutant becomes captured and is then chromatin bound20.  
CR1 aids the chromatin-binding pattern of LEDGF, whereas CR2 and CR3 influence 
the AT hooks21. These are small DNA-binding motifs, centred around an arginine-
glycine-arginine-proline sequence, that enable the protein to dock on the minor 
groove of DNA at AT-rich regions and alter the architecture of the DNA, thus 
allowing the access of transcription factors22. Turlure et al. illustrated that the two 
AT hooks and the NLS together mediate the binding of LEDGF/p75 to DNA, although 
the degree of contribution to this binding varied (AT2>NLS>AT1)23. The PWWP 
domain was also shown to contribute to the binding of LEDGF to chromatin, as a 
domain mutant was shown to affect the distribution of the protein in the nucleolus 
during cell division23.  
More recently, using a rat brain cDNA library, Tsutsui et al. illustrated that 
LEDGF/p75 recognises negatively supercoiled DNA via a novel DNA binding domain 
they termed supercoiled-DNA recognition domain (SRD) (residues 200-326) which is 
located within CR2 and 318. The SRD was divided into a core region (200-274) which 
recognises the supercoiled DNA and an enhancer (275-336) which potentiates the 
interaction. It should be noted that whilst the work of both Turlure et al. and 
Tsutsui et al. focused on LEDGF/p75, Tsutsui et al. also show that both LEDGF/p75 
and LEDGF/p52 are able to bind negatively supercoiled DNA18, 23. 
8 
 
The PWWP domain, particularly that of LEDGF/p75, is important in targeting the 
protein (and associated binding partners) to specific sites on chromatin6. Thus, 
whilst other domains in the protein (the NLS, AT hooks etc.) are involved in aligning 
the protein with protein and DNA, the specificity of the binding location is 
determined by the PWWP domain. Pradeepa et al. suggest that the PWWP domain 
of LEDGF binds to the Histone 3 Lysine 36 trimethylation mark (H3K36me3)24. This 
has since been confirmed by Eidahl et al. and van Nuland et al.6, 25. More 
importantly, Eidahl et al. demonstrated that the PWWP domain binds to purified 
mononucleosomes via interactions with core histones6. Using nuclear magnetic 
resonance, they identified two distinct regions of LEDGF PWWP domain structure, 
viz. a basic surface (made up of seven lysine residues and one arginine) that 
interacts non-specifically with DNA, and a hydrophobic cavity that interacts with the 
H3K36me3 (Figure 1-4)6. 
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Figure 1-4: The binding of the LEDGF PWWP domain to a modified histone tail. 
The double stranded DNA molecule (purple) wrapped around the histone core 
(black) is shown on the left. The modified histone tail protruding from the histone 
core is shown binding to the PWWP domain of LEDGF (blue, right). 
  
LEDGF/p75 and p52 are shown to have distinct localisation within the cell that is 
dependent on the cell cycle. Nishizawa and colleagues used green fluorescent 
tagged proteins transfected into live CHO-K1, MDCK and NRK cells to show that 
LEDGF/p75 and p52 were both predominantly in the nucleus26. Whereas LEDGF/p75 
was uniformly distributed, LEDGF/p52 was segregated into distinct nuclear 
compartments. In Gap 1 phase (G1), LEDGF/p75 was present diffusely throughout 
the nucleoplasm, whereas LEDGF/p52 was located at the nuclear periphery and 
towards late G1 phase, formed a speckle-like pattern. As the cell entered S-phase, 
LEDGF/p75 began to cluster around the chromosomes. In contrast to this, 
LEDGF/p52 formed speckles at the nuclear periphery but these became larger in 
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size and progressed towards the nuclear centre. During Gap 2 phase (G2) when the 
chromosomes have started to condense and the centromeres are visible, the 
speckles formed by LEDGF/p52 coalesced into a cylindrical pattern but LEDGF/p75 
segregated with chromatin. During prophase, the distribution pattern of LEDGF/p75 
was retained, whereas for LEDGF/p52, the speckled pattern was lost, and the 
protein formed a complete cylindrical shape around the chromatin. In metaphase, 
when the chromosomes are aligned halfway between the two poles of the nucleus, 
the pattern of LEDGF/p52 remained but LEDGF/p75 developed a striped pattern. 
During telophase, both LEDGF/p75 and LEDGF/p52 moved to the poles of the 
nucleus. When the nucleus then divided (cytokinesis), equal amounts of each 
isoform were present in each daughter cell and LEDGF/p52 kept the cylindrical 
pattern but for LEDGF/p75, the nuclear positioning became diffuse.  
 
1.2. Role of LEDGF 
The unique C-terminal tails of the two isoforms helps mediate their differing 
interactions with cellular proteins (reviewed in chapter 5). It is this binding to 
distinct proteins that helps LEDGF/p75 and p52 perform their distinct and unique 
roles in the cell.  
 
1.2.1. Role of LEDGF/p52 
The list of described and potential binding partners of LEDGF/p5224, 27 (discussed in 
chapter 5) suggests that this isoform has a role in the alternative splicing of class II 
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genes, and it has been proposed to coordinate activated transcription and pre-
mRNA splicing by binding to, and modulating the activity of SRSF1 (formerly SFRS1 
and ASF/SF2)27. By showing the interaction between LEDGF/p52 (via its’ PWWP 
domain) and H3K36me3, Pradeepa et al. provided evidence for a link between 
LEDGF/p52, chromatin and mRNA splicing24. By using a mutant LEDGF/p52 which 
lacked the C-terminal region, they showed that alternative splicing of target genes 
was affected, and that these effects were reversed by wild type LEDGF/p52. 
However, it should be noted that the mutant would fail to bind SRSF1 with 
implications for mRNA splicing.  
 
1.2.2. Role of LEDGF/p75 
Both LEDGF/p52 and p75 were shown to be transcriptional coactivators of the 
general transcription machinery following their purification with PC428. However, in 
comparison to LEDGF/p52, LEDGF/p75 is a weaker coactivator. Whilst the 
downstream targets of the transcriptional activity of LEDGF/p52 are largely 
unknown (although Heat shock protein 27 (Hsp27) has been suggested as one)29, 
those for LEDGF/p75 are discussed later.  
LEDGF/p75 is suggested to have a role in growth and development, as highlighted 
by the lethality and abnormalities that result from its deletion as described by 
Sutherland et al.30.  
Integration of Lentiviruses, such as Human Immunodeficiency Virus type 1 (HIV-1), 
equine infectious anaemia virus and feline immunodeficiency virus into the host 
12 
 
genome is dependent on LEDGF/p75. Depletion of the protein renders cells immune 
to infection by these agents31, 32. Cuiffi et al. prepared cells depleted in LEDGF/p75 
and showed that integration into optimal regions of the genome was reduced 
thereby suggesting that the choice of integration site is dictated by LEDGF/p7533.  
LEDGF/p75 acts as a dual tether by binding the integrase enzyme of HIV (HIV-IN) via 
its’ C-terminal IBD, and chromatin/DNA via its N-terminal PWWP domain, and 
directs the HIV pre-integration complex to transcriptionally active regions of the 
host genome. By swapping the N-terminal region of LEDGF for other chromatin 
binding domains (namely the plant homeodomain (PHD) finger and 
chromodomain), Ferris et al. showed that the targeting of HIV-IN can be re-
directed34. In addition to the tethering function, LEDGF/p75 protects HIV-IN from 
proteolytic degradation35.  
Mixed lineage leukemia (MLL) is a Histone 3 Lysine 4 (H3K4) trimethylase that, via 
LEDGF/p75, associates with the tumour suppressor menin. LEDGF/p75 functions to 
direct the MLL/menin complex allowing it to place the transcriptionally active 
Histone 3 Lysine 4 trimethylation mark (H3K4me3) on chromatin (Figure 1-5)36 . 
Therefore, the MLL/menin complex is a histone writer complex.  
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Figure 1-5: LEDGF/p75 binds to menin and MLL and directs the complex to 
chromatin.  
Formation of the complex is necessary to allow the placement of the activation 
mark, H3K4me3 on this chromatin. This results in regulated gene expression. 
 
MLL binds, via its’ LEDGF binding domain next to the binding site of menin, 
specifically to the IBD domain in the C-terminus of LEDGF/p7537. Menin is a 
ubiquitously expressed nuclear protein that acts as a TSG38. Menin binds to the very 
N-terminus of MLL and to the IBD of LEDGF/p75. Loss of function results in multiple 
endocrine neoplasia type 1 (MEN1)39.  
MLL is a member of the trithorax group (Trx-G) of transcriptional activators, and is 
one of three types of complexes that methylate H3K440. The N-terminus is involved 
in directing the complex to specific sites, whereas the C-terminus encodes the 
enzymatic activity. By regulating expression of the homeobox (HOX) transcription 
factors, MLL plays an important role in the generation of the body plan and 
haematopoiesis41, 42. In addition MLL is involved in regulating cell cycle progression 
and is itself regulated by the cell cycle42.  
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To date, more than 70 known translocations involving MLL have been described40. 
Such translocations are detected in ~10% of all leukemias, but the majority are 
found in infant patients (>70% infant Acute Lymphocytic Leukemia (ALL)), and are 
associated with a poor prognosis43. MLL translocations always involve fusion of the 
N-terminus of MLL (breakpoints occur between exons 8 and 12) to the C-terminal 
region of a partner gene such that MLL loses its PHD fingers, Taspase I cleavage site, 
transactivation domain and the Su(var)3-9 and 'Enhancer of zeste' (SET) 
methyltransferase domain42. However, with the retention of the N-terminus, the 
fusion protein can still bind LEDGF/p75 (and menin) and is therefore targeted to 
chromatin, whilst the C-terminal region of the fusion partner is still able to recruit 
their respective complexes (Figure 1-6)36. For example, fusions of MLL and AF9, ENL 
or AF10 are still able to interact with Dot1L, leading to up regulation of HOX genes 
and ultimately leukemogenesis44. 
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Figure 1-6: Translocations of MLL resulting in abnormal fusion proteins leads to 
abnormal gene expression.  
The C-terminus of MLL is subject to translocations but retains its’ N-terminus. 
Therefore, MLL can still form a complex with LEDGF/p75 and menin and is directed 
to chromatin. The fusion protein will recruit different binding partners compared to 
the complex containing wild type MLL and results in abnormal constitutive gene 
expression leading to leukemogenesis. 
  
In addition to translocations, MLL can be disrupted by the inclusion of a partial 
tandem duplication (PTD) of N-terminal exons which causes repetition of the DNA 
binding domains and increased recruitment of binding partners to these domains. 
This abnormality has been described in acute myeloid leukemia (AML) and 
myelodysplastic syndrome (MDS)41.  
During micro-environmental stress (for example, serum starvation, thermal and 
oxidative stress), LEDGF/p75 has been shown to bind to stress response elements 
(STRE) and heat shock elements (HSE) in the promoter regions of target genes45. 
This results in the induced expression of downstream targets such as Hsp27 and the 
stress-related proteins αβ-crystallin, AOP2 and alcohol dehydrogenase46. 
Furthermore, LEDGF/p75 has been shown to transactivate the expression of anti-
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apoptotic genes, thus enhancing cell survival46. A simple mechanism of the survival 
promoting action of LEDGF is shown in Figure 1-746. 
 
 
Figure 1-7: Mechanism of action of LEDGF following the encounter to 
environmental stress.  
Upon stress, the expression of LEDGF/p75 is up regulated. This causes the activation 
of stress related proteins including heat shock proteins, anti-oxidant protein 2 and 
alcohol dehydrogenase. These proteins allow the cells to overcome the stress and 
survive.   
 
More recently, it has been shown that following thermal and oxidative stress of 
H1299 cells, LEDGF/p75 binds to the STRE of Vascular endothelial growth factor 
(VEGF)-C thereby inducing its expression47. LEDGF/p75 has also been implicated in 
hormonal up-regulation of VEGF-C in tumours, leading to angiogenesis and 
lymphangiogenesis48.  
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Isoform Roles of each of the isoforms 
LEDGF/p75  Transcriptional co-activator 
 Growth and development 
 Molecular tether targeting the MLL 
complex and HIV-IN to chromatin 
 Promote cell survival against thermal 
and oxidative stress. 
LEDGF/p52  Alternative splicing of class II genes 
 Coordinate transcription and splicing 
 Transcriptional co-activator 
 
Table 1-2: Summary of the roles of LEDGF/p75 and p52 within the cell. 
LEDGF/p75 and p52 are two alternatively spliced products of the same gene yet 
they have differing roles within the cell. These roles are detailed above. 
 
1.3. Cleavage of LEDGF by Caspases 
LEDGF/p75 and p52 are both cleaved by caspase enzymes29. Initially, Wu et al. 
showed that LEDGF/p75 was cleaved by caspases 3 and 7 resulting in a disruption of 
the PWWP domain, thus diminishing its pro-survival function49. LEDGF/p52 is also 
cleaved by these caspases into a 38 kDa pro-apoptotic fragment which inhibits the 
ability of LEDGF/p75 to transactivate Hsp2729, a known downstream target of 
LEDGF/p75, as discussed in Chapter 1.1.2. 
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Disruption of the PWWP domain of the two isoforms has opposing affects in the 
cell. Thus, whilst deletion of an N-terminal portion of LEDGF/p75 increased its 
ability to transactivate Hsp2745, disruption of the PWWP of LEDGF/p52 by caspase 
cleavage inhibits its ability to transactivate Hsp2729. Therefore, the PWWP domain 
may have a transcriptional repression function in LEDGF/p75, but may be essential 
for LEDGF/p52 mediated transcriptional activation function29. Additionally, 
LEDGF/p52 was shown to have a pro-apoptotic effect that contrasts to the pro-
survival function of LEDGF/p75.  
 
1.4. Role of LEDGF in Leukemia 
Over expression of LEDGF is suggested to have a role in tumourigenesis. Thus, 
LEDGF/p75 is a cancer-associated protein and is over expressed in many cancers, 
whilst LEDGF/p52 over expression has been demonstrated in tumour cell lines29 
(reviewed in Chapter 3). Both LEDGF/p75 and p52 are involved in translocations 
with Nucleoporin 98 (NUP98) in AML, chronic myeloid leukemia (CML) and 
biphenotypic leukemia50-56. As a consequence of these translocations, the 
glycine/leucine/phenylalanine/glycine (GLFG) repeats of NUP98 fuse to the C-
terminus of LEDGF which results in disruption or loss of the PWWP domain. It 
should be noted that the breakpoints in LEDGF in each case are different. 
Furthermore, four different isoforms of LEDGF have been described in AML57 
(reviewed in Chapter 3).  
Due to the presence of antinuclear autoantibodies that target LEDGF/p75 (but not 
LEDGF/p52) it has been suggested this protein also plays a role in autoimmunity58. 
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Antibodies against LEDGF/p75 have also been identified in patients with CLL and 
other lymphomas, suggesting this is a tumour associated antigen59. 
 
1.5. Chronic Lymphocytic Leukemia 
CLL is a common leukemia characterised by an accumulation of long lived CD5+ B 
lymphocytes in the peripheral blood with involvement of the bone marrow and/or 
lymphoid organs. It can either be a rapidly progressing and aggressive disease that 
is often refractory to treatment, or it can follow a benign indolent course with 
patients requiring little or no intervention. To date, no single pathognomonic 
translocation or mutation that gives rise to the disease has been identified, but 
several cytogenetic abnormalities including deletion of 11q, 13q, 17p, trisomy 12, 
tumor protein 53 (TP53) mutations and aberrant microRNA (miRNA) expression are 
commonly described.  
The disease occurs due to a failure of apoptosis which causes the accumulation of 
clonal mature lymphocytes. Important to this process are lymphoid organs such as 
the lymph nodes and spleen, where the CLL cells receive pro-survival signals from 
cytokines and growth factors within the micro-environment60, 61. In CLL cells, 
stimulation of the B-cell receptor (BCR) is important for the activation of several 
downstream kinase enzymes (Src family, PI3 Kinase etc.) which in turn lead to 
activation of transcription factors such as NF-κB resulting in malignant cell 
proliferation and survival61.  
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Due to the heterogeneity of disease behaviour, several prognostic markers have 
been identified. Traditionally, patients were classified according to either the Rai or 
Binet staging system, which graded disease severity based on the absence or 
presence of organomegaly and suppression of normal bone marrow function. 
However, it is now routine for B cells to be analysed for their IGHV status (class and 
deviation from germline sequence), CD38% and ZAP-70 expression and presence of 
cytogenetic abnormalities such as those outlined earlier. Notably, certain prognostic 
factors can be associated with a long survival time. Namely, Low Rai and Binet 
staging (for example, 0 and A respectively) (12+ years), 13q- (133 months), mutated 
IGHV (293 months compared to 117 months for patients with unmutated IGHV), 
CD38- and ZAP70-62. 
CLL currently remains incurable, although recent advances in therapy allows for 
effective treatment in some patients. Treatment of the disease (reviewed by Hallek 
et al.61) was initially with the alkylating agent Chlorambucil (CLB). However, the 
introduction of newer therapies such as Fludarabine and monoclonal antibodies 
such as Rituximab (anti-CD20) or Campath/Alemtuzumab (anti-CD52) has resulted 
in more durable remissions and complete responses than has previously been 
observed. Notably, these different classes of drugs are increasingly administered in 
combination with each other (for example fludarabine combined with 
cyclophosphamide and fludarabine used in conjunction with rituximab). There is 
also increasing interest in inhibiting pathways important in the survival of CLL cells, 
for example, the use of kinase inhibitors.  
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As mentioned earlier, no single genetic abnormality has been identified that gives 
rise to CLL. Recently, however, whole genome and whole exome sequencing have 
pointed to the presence of recurring mutations in patients with CLL. An initial report 
published by Wang et al. described nine genes that were significantly and 
recurrently mutated in patients with CLL63. One of these, the SF3B1 gene, was the 
second most frequently mutated gene (15%) (after TP53) in the cohort investigated. 
All of the mutations described were missense, with K700E being the most common. 
Subsequent reports have confirmed that this site is one of the most commonly 
occurring in the gene and a change from lysine to asparagine (K700N) has also been 
demonstrated64. Interrogation of the Catalogue of Somatic Mutations in Cancer 
(COSMIC) database suggested that SF3B1 was recurrently mutated in cancer (for 
example, breast 1.52%, liver 1.82% and eye 17.86%) and that it was the most 
frequently mutated gene in CLL (Table 1-3).  
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Gene name Mutation frequency in CLL 
SF3B1 13% 
NOTCH1 11% 
ATM 11% 
TP53 10% 
MYD88 4% 
POT1 3% 
XPO1 2% 
CDKN2A 2% 
BCL11B 2% 
 
Table 1-3: Summary of the ten most frequently mutated genes in CLL. 
Data available in the COSMIC database describes genes recurrently mutated in CLL. 
The table above details the top ten genes that are recurrently mutated in CLL and 
their frequencies. 
 
There has been a focussed effort to analyse different cohorts of patients with CLL to 
determine the mutational status of the SF3B1 gene and uncover any correlations 
with clinical variables. For example, Jeromin et al. (2013) published a 
comprehensive study of 1160 untreated CLL patients and identified several 
correlations between SF3B1 mutation and other prognostic factors64. Thus, mutated 
SF3B1 was highly correlated with unmutated IGHV. With regards cytogenetic 
abnormalities, SF3B1 mutation was associated with deletion of 11q. Mutated SF3B1 
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was shown to have an adverse effect on both time to first treatment and overall 
survival. Mutations in SF3B1 tended to be more common in males, in patients with 
high white cell counts, advanced Binet stage and CD38 positivity greater than 30%. 
It has been suggested that the degree of variability in the reported correlations 
between SF3B1 mutational status and clinical factors is due to the heterogeneity of 
CLL65.  
 
1.6. SF3B1 
SF3B1 is a member of the splicesome which catalyses the removal of introns from 
pre-mRNA and is predicted to have an effect on the alternative splicing of the PSIP1 
gene. The spliceosome is a large multi-subunit complex, of which there are 2 in 
mammals: the major (U2-type) and the minor (U12-type)66. Both types of 
spliceosome contain the SF3b complex67, of which SF3B1 is the largest 
component68. During the removal of introns by the U2 splicesosome, SF3B1 binds 
via its N terminus to the branch-point sequence at the 3´ end of the intron. This aids 
with the recruitment of the U2 small nuclear ribonucleotide protein (snRNP) to the 
branch point, one of the initiating steps in the assembly of the spliceosome69.  
The protein is composed of a hydrophilic N-terminal RNA binding domain and the C-
terminal contains 22 Huntington, Elongation factor 3, protein phosphatase 2A, 
Targets of rapamycin 1 (HEAT) repeats (Figure 1-8)70. The HEAT repeats are 
predicted to wrap around and stabilise the U2snRNP67 and act as a docking site for 
other components of the spliceosome to assemble71. 
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Figure 1-8: Structure of the human SF3B1 protein.  
The structural domains of the protein are detailed. The protein has an N-terminal 
U2AF2 interaction domain followed by SF3B14 interaction domain. The C-terminus 
of the protein is composed of 22 HEAT repeats. As an example, mutations in the 
SF3B1 gene described by Quesada et al.70 are noted. All mutations described are in 
the HEAT repeat region of the protein. The frequency of each mutation within the 
cohort is inferred by red stars. In this cohort, K700E is the most common mutation. 
 
As discussed earlier, recurring mutations of SF3B1 have been described in CLL. The 
majority of these mutations are localised to the HEAT repeats, more specifically 
exons 14-1670. In this report, the authors also identified a number of genes with 
differential exon inclusion between mutated and wild type SF3B1 samples, one of 
these being LEDGF (PSIP1) with a p-value of 0.0001 suggesting the mutational status 
of the SF3B1 gene will have a direct effect on the splicing of LEDGF. The idea that 
SF3B1 mutations might alter the splicing of other genes that affect the pathobiology 
of CLL was also suggested by Wang et al.63. Further, Furney et al. showed that 
mutations within SF3B1 have a direct impact on differential alternative splicing of 
other genes in uveal melanoma72.  
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Given that SF3B1 is one of the most recurrently mutated genes in CLL, and that such 
mutations are generally associated with a poor prognosis and shorter overall 
survival and time to treatment, there are suggestions to include the mutation status 
of this gene in a prognostic index73. This notion is still not fully accepted as different 
groups have described different criteria for their index64, 73. In addition, the number 
of patients investigated needs to be increased in order to ensure the index (and 
inclusion of the mutated genes) is suitable for use74. Nonetheless, with the 
correlations that have been suggested for SF3B1 in CLL65, it is felt important to 
consider inclusion of SF3B1 (and other mutated genes) mutational status in a 
potential index75. 
 
1.7. Alternative Splicing 
The mechanism of alternative splicing has been shown to be sensitive to chromatin 
architecture. Luco et al. (2010) examined alternative splicing of the human 
fibroblast growth factor receptor (FGFR2) and showed that in human mesenchymal 
stem cells, H3K36me3 and Histone 3 Lysine 4 monomethylation (H3K4me1) were 
enriched around the alternatively spliced region of FGFR2 where exon IIIb is 
repressed, whereas the Histone 3 Lysine 27 trimethylation mark (H3K27me3), 
H3K4me3, and the Histone 3 Lysine 9 monomethylation mark (H3K9me1) were 
reduced when compared to PNT2 cells, where the exon is included76. The exclusion 
of exon IIIb was shown to be dependent on the binding of polypyrimidine tract–
binding protein (PTB) to silencing elements around the exon, resulting in its 
repression. In HEK293 cells, over expression of the SET2 enzyme responsible for the 
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H3K36me3 mark resulted in reduced inclusion of this exon in FGFR2. The change in 
splicing pattern was not due to change in FGFR2 or other factors illustrating it was a 
result of the histone modifications. 
Alternative splicing is also regulated by the presence or absence of splicing 
enhancer and silencer sequences (cis-acting elements) present within the exons or 
introns that either promote or prevent the use of a particular splice site via the 
recruitment of serine/arginine (SR) proteins or heterogeneous nuclear 
ribonucleoproteins (hnRNP) (trans-acting splicing factors) respectively77. These 
splicing factors are themselves regulated by their expression levels and post-
translational modification status (for example, methylation)78.  
 
1.7.1. Alternative Splicing as an Epigenetic Mechanism of Gene Regulation 
Alternative splicing is a major mechanism of epigenetic regulation within the cell 
(Figure 1-9)79. The definition of an epigenetic mechanism is one which leads to a 
change in phenotype without changing the genomic sequence. By altering the 
inclusion or exclusion of exons, alternative splicing gives rise to different mRNA 
sequences, and hence, proteins with potentially different functions, from the same 
original coding DNA. Alternative splicing, like DNA methylation, histone modification 
and ncRNAs, is a fine-tuned mechanism that generates diversity within the cell. 
There is also increasing evidence of cross-talk between alternative splicing and the 
other accepted epigenetic mechanisms, further supporting that alternative splicing 
may be considered as an epigenetic phenomenon. 
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Figure 1-9: Epigenetic processes and regulation of gene expression. 
The interplay of DNA methylation, post-translational modification of histones, and 
ncRNA expression are key for the integrity of the epigenome. Epigenetic processes 
regulate the expression of proteins (as well as their post-translational modifications 
and alternative splicing), which in turn affect the chromatin landscape of a cell. 
 
 
 
 
 
 
 
ncRNAs 
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1.8. Aims 
The aims of my work were: 
1. To determine the presence/absence of the different isoforms of LEDGF in 
CLL cells and normal B cells using RT-PCR. 
2. To determine if the isoforms have different expression levels (using RT-
qPCR) and correlate these with known clinical variables. 
3. To assess the mutational status of the HEAT repeats in the SF3B1 gene in CLL 
samples and determine if this correlates with the expression pattern of the 
LEDGF isoforms. 
4. To establish stable cell lines expressing tagged isoforms of LEDGF identified 
in Aim 1 above. 
5. To develop a method that would enable each of the isoforms and their 
associated complexes to be purified thus allowing future identification of 
components of these complexes. 
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Chapter 2 : General Materials 
and Methods 
 
This chapter is divided into 3 sections. Chapter 2.1 describes the cell culture 
techniques used throughout this study, Chapter 2.2 outlines the molecular 
techniques employed and Chapter 2.3 details the methods used for protein analysis. 
Details of techniques that are specific to each chapter, or where general techniques 
were modified slightly, are addressed in the relevant chapter. 
Aqueous solutions were made using reverse osmosis purified water. Where 
required, solutions were sterilised either by autoclaving at 15 psi for 15 minutes or 
by filter sterilisation through 0.22 micron syringe filters. 
 
2.1. Cell Culture 
2.1.1. Culturing of cell lines 
Cell lines were cultured in a sterile environment ready for use. Complete Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma Aldrich, UK) was prepared by the addition 
of FCS (final 10% v/v; Sigma Aldrich, UK), L-glutamine (2 mM; Hyclone, UK), 
penicillin and streptomycin (1000 units and 1 mg respectively; Sigma Aldrich, UK) to 
the DMEM base media. 
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2.1.2. Thawing of cryopreserved cell lines 
Cells stored at -150 °C were revived by thawing and cultured ready for use. One vial 
of the cell line was removed from -150 °C storage and thawed in a waterbath set to 
37 °C. The volume of cells was then washed in pre-warmed complete media and 
pelleted for 5 minutes at 500 x g, at room temperature (RT). Supernatant was 
discarded and the pellet resuspended in 5 mL complete media. The cell suspension 
was transferred to a T-25 cm2 vented culture flask and incubated at 37 °C, 5% CO2, 
in a humidified incubator.  
 
2.1.3. Cell line passage 
Cell lines were passaged bi-weekly to maintain their viability and suitability for use. 
Suspension cells were passaged by dilution. Cells were transferred to a suitable 
culture flask at a ratio of 1:5 (cells:media) of the required final volume and 
complete media was added. Adherent cells were passaged following trypsinisation. 
Briefly, media was discarded and the cell monolayer was washed with PBS. Trypsin-
EDTA (Sigma Aldrich, UK) was added (1 mL to a T-25 cm2 flask, 2 mL to a T-75 cm2 
flask and 3 mL to a T-175 cm2 flask) and the cells incubated at room temperature for 
5 minutes. Cells were dislodged by tapping the culture flask and the trypsin 
neutralised by the addition of complete media. The cell suspension was collected 
and pelleted for 5 minutes at 500 x g, RT. Supernatant was discarded and the pellet 
resuspended in complete media. Cells were transferred to a suitable culture flask 
and made up to the required volume, with complete media. All cultures (adherent 
and suspension) were incubated at 37 °C and 5% CO2 in a humidified incubator. If 
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cell counts were required, they were performed manually using a Haemocytometer 
with Trypan Blue dye (Sigma Aldrich, UK) in order to determine the cell viability. 
 
2.1.4. Cryopreservation of cells 
A number of vials of cells were prepared and stored at -150 °C to provide a cell bank 
for future work. Cells were cultured as described. A manual cell count was 
performed and the required volume of cells to give a density of 1x107 viable cells 
(v.c) per vial was calculated. The cells were pelleted for 5 minutes at 500 x g, RT, 
and supernatant was discarded. The cell pellet was washed in PBS and then 
resuspended in complete media containing 10% DMSO (Sigma Aldrich, UK). The cell 
suspension was aliquoted into cryovials (1 mL per vial) (Sigma Aldrich, UK) and 
stored at -150 °C. 
 
2.2. Molecular Biology  
2.2.1. RNA Extraction 
RNA extraction is the purification of RNA from biological samples. Total RNA was 
extracted from cells using the RNeasy Mini Kit (Qiagen, UK) following the protocol 
‘Purification of Total RNA from Animal Cells Using Spin Technology’. Briefly, the cell 
pellet was resuspended in Buffer RLT supplemented with β-mercaptoethanol (Sigma 
Aldrich, UK) then transferred to a QIAshredder column within a 2 mL collection 
tube. This was centrifuged for 2 minutes at maximum speed. An equal volume of 
70% ethanol (Sigma Aldrich, UK) was added to the flow-through and mixed. Seven 
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hundred microlitres of the lysate was transferred to an RNeasy spin column which 
had been placed within a 2 mL collection tube, and centrifuged for 15 seconds at 
≥8000 x g. The flow-through was discarded and the step repeated for the remaining 
volume of lysate. Buffer RW1 (350 µL) was added to the RNeasy spin column and 
centrifuged for 15 seconds at ≥8000 x g. DNase I was prepared by mixing 10 µL 
DNase I stock solution and 70 µL Buffer RDD. This was transferred directly to the 
membrane of the RNeasy spin column and incubated for 15 minutes on the 
benchtop. After the incubation, 350 µL of Buffer RW1 was added to the RNeasy spin 
column. The tube was centrifuged for 15 seconds at ≥8000 x g and the flow-through 
discarded. The RNeasy spin column was washed by adding 500 µL buffer RPE and 
centrifuging for 15 seconds at ≥8000 x g and the flow through discarded. This was 
repeated but centrifuged for 2 minutes. The RNeasy spin column was carefully 
transferred to a clean 2 mL collection tube and centrifuged for 1 minute at full 
speed. The RNeasy spin column was then transferred to a clean 1.5 mL 
microcentrifuge tube and 30 µL of nuclease-free water (NFW) was added directly to 
the membrane. This was centrifuged for 1 minute at ≥8000 x g. The eluate was 
collected and replaced onto the membrane of the RNeasy spin column in the same 
1.5 mL microcentrifuge tube and centrifuged for 1 minute at ≥8000 x g. The 
extracted RNA was stored at -80 °C ready for downstream applications. All volumes 
described were for the extraction of RNA from one cell pellet of 1x107 viable cells. 
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2.2.2. cDNA synthesis 
cDNA synthesis is the generation of DNA from a template of RNA. cDNA was 
prepared using 1 µg of total RNA to which was added 1 µL of Oligo(dT)12-18 Primer 
(Life Technologies, UK), 1 µL 10 mM dNTP Mix (Life Technologies, UK) and NFW to 
give a final volume of 12 µL. The solution was mixed and heated for 5 minutes at 65 
°C after which, 2 µL 0.1 M DTT (Life Technologies, UK) and 4 µL 5x First-Strand 
Buffer (Life Technologies, UK) was added. The solutions were mixed then heated for 
2 minutes at 42 °C. After heating, 1 µL SuperScript II Reverse Transcriptase (Life 
Technologies, UK) enzyme was added. The solutions were mixed then incubated for 
50 minutes at 42 °C followed by a further 15 minutes at 72 °C. The resultant cDNA 
was stored at -80 °C. All volumes described were for one reaction. A negative 
control was always prepared with 1 µL NFW added instead of 1 µL SuperScript II 
Reverse Transcriptase enzyme. 
 
2.2.3. RT-PCR Amplification 
RT-PCR is the amplification of a specific target of DNA. Primers for RT-PCR were 
designed using software available at 
http://eu.idtdna.com/Scitools/Applications/Primerquest/ such that at least one of 
the primers crossed exon-exon boundaries but still retained the required 
properties. All primers were purchased from Eurofins MWG Operon (Germany).  
Master mixes for the required number of RT PCR reactions were always prepared. 
Each individual reaction required 22 µL Platinum PCR SuperMix High Fidelity (Life 
Technologies, UK) and 1 µL of each forward and reverse PCR primer (stock 
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concentration 2.5 µM, final concentration of 0.1 µM each). The mastermix was 
aliquoted into the number of tubes required and 1 µL of template was added. A 
negative control using 1 µL of NFW, instead of sample, was always prepared. Unless 
specified, samples were run on the following cycle: 
94 °C 2 minutes (x1) 
94 °C 30 seconds, Annealing temperature 30 seconds, 68 °C for 15 seconds 
(x35) 
68 °C 5 minutes (x1) 
Hold at 4 °C 
The optimum annealing temperature of primer pairs was determined using cDNA 
prepared from cell lines and an annealing temperature gradient approximately 5 
degrees below to 5 degrees above the annealing temperature recommended by the 
primer manufacturer (specific temperatures are given in the relevant sections). A 
negative control was always included. 
 
2.2.4. Agarose Gel Electrophoresis 
Agarose gel electrophoresis is a technique used to separate a DNA molecules based 
on their size. Agarose gels were prepared by melting the required amount of 
agarose (Web Scientific, UK) in 150 mL 0.5% TBE buffer (Sigma Aldrich, UK) using a 
microwave. The molten agarose was allowed to cool slightly then 8 µL of 10 mg/mL 
Ethidium Bromide (Promega, UK) was added. The agarose was poured into a 
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prepared gel tray and allowed to set. When solid, the gel was transferred to a 
running tray and overlayed with 0.5% TBE buffer. Samples were diluted in 6x 
loading buffer (10 mM Tris-HCl (Fisher Scientific, UK) pH 8.0, 50 mM EDTA (Sigma-
Aldrich, UK), 15% Ficoll-400 (Sigma Aldrich, UK), 0.5% orange G, (Sigma Aldrich, UK)) 
then loaded. Gels were run for 1 hour (hr) at 120 V, then visualised using a manual 
gel documentation system (InGenius, Syngene, UK). 
 
2.2.5. Gel and PCR Purification 
DNA amplified in PCR reactions alone, or following electrophoresis on an agarose 
gel, is required to be purified from contaminants. Excised gel slices and PCR 
reactions were cleaned up using the Wizard SV Gel and PCR Clean Up Kit (Promega, 
UK) according to the manufacturer’s instructions. Briefly, the weight of the gel slice 
was determined and Membrane Binding Solution was added at a ratio of 1 µL/1 mg. 
The mixture was vortexed then incubated for 10 minutes at 60 °C to allow the gel to 
dissolve. The gel mix was transferred to a SV Minicolumn in a 2 mL collection tube 
and incubated for 1 minute at room temperature. For a PCR product, an equal 
volume of Membrane Binding Solution was added to the product and mixed. This 
was transferred to a SV Minicolumn in a 2 mL collection tube. For both templates, 
the method was then the same. The SV Minicolumn (in a 2 mL collection tube) was 
centrifuged for 1 minute at 16000 x g and the flow-through discarded. To the SV 
Minicolumn, 700 µL of Membrane Wash Solution was added and centrifuged for 1 
minute at 16000 x g. The flow-through was discarded and 500 µL of Membrane 
Wash Solution was added to the SV Minicolumn. This was centrifuged for 5 minutes 
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at 16000 x g and the flow-through was discarded. The SV Minicolumn within a 2 mL 
collection tube was centrifuged for 1 minute at 16000 x g, with the lid off. The SV 
Minicolumn was carefully transferred to a clean 1.5 mL microcentrifuge tube and 30 
µL NFW was added directly to the column membrane. This was incubated for 1 
minute on the benchtop then centrifuged for 1 minute at 16000 x g. The purified 
DNA was stored at -20 °C. All volumes described were for the purification of one 
sample. 
 
2.2.6. Cloning of PCR products into pGEM-T vector 
Cloning is used to create multiple identical copies of DNA fragments. pGEM-T is a 
linearised vector suitable for such purpose. Purified PCR products were ligated into 
pGEM-T (Promega, UK) at an insert:vector molar ratio of 3:1 as recommended by 
the manufacturer. The volume of DNA to achieve this ligation ratio is calculated 
using the formula: 
 
ng pGEM-T vector x kb size of insert  x  insert:vector molar ratio = ng of  
                 kb size of vector       insert 
 
 
 Briefly, to a microfuge tube, 5 µL 2X Rapid Ligation Buffer, 1 µL pGEM-T (50 ng) 
vector and 1 µL T4 DNA Ligase was added (all from Promega, UK). The PCR product 
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was then added and the volume made up to 10 µL with NFW. The contents were 
mixed and incubated overnight at 4 °C. 
 
2.2.7. Transformation 
Transformation is the direct uptake of foreign DNA into a bacterial cell. As a result, 
the DNA will be propagated. Four microliters of the plasmid DNA to be transformed 
was mixed with 20 µL of competent cells and incubated for 30 minutes on ice. The 
cells were heat shocked for 20 seconds at 42 °C in a waterbath then returned to ice 
for 2 minutes after which 0.5 mL sterile SOC media (Sigma Aldrich, UK) was added. 
The cells were then incubated at 37 °C with shaking at 225 rpm for 2 hours. 
Following this, cells were pelleted for 30 seconds at 12500 x g and 380 µL of the 
supernatant removed. The pellet was resuspended in the remaining supernatant 
and 10% of the volume was spread onto an LB agar plate containing no antibiotic 
(control). The remaining volume was spread onto an LB agar plate containing the 
appropriate antibiotic and the plates were incubated overnight at 37 °C. 
 
2.2.8. Plasmid DNA mini-prep 
Plasmid DNA is purified from the bacterial cell following its’ transformation, by a 
mini-prep procedure. Single positive colonies were picked and inoculated into 5 mL 
LB broth (Sigma Aldrich, UK) plus antibiotic and incubated overnight at 225 rpm, 37 
°C. The following morning, 0.5 mL of culture was transferred to a cryovial, an equal 
volume of 50% glycerol (Sigma Aldrich, UK) was added and this glycerol stock stored 
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at -80 °C. Plasmid was purified from the remaining volume of culture using the 
Zyppy Plasmid Mini Prep Kit (Cambridge Bioscience, UK). Briefly, the culture was 
centrifuged for 30 seconds at maximum speed until the whole volume was pelleted 
in a 2 mL tube. The pellet was resuspended in 600 µL PBS and 100 µL 7x Lysis Buffer 
was added and mixed by inverting the tube. Following this, 350 µL cold 
Neutralization Buffer (supplemented with RNase A) was added and mixed by 
inverting the tube. Precipitated material was removed by centrifugation for 2 
minutes at 16000 x g and the supernatant transferred to a Zymo-Spin IIN column in 
a 2 mL collection tube. This was centrifuged for 15 seconds at maximum speed and 
the flow-through discarded. Endo-Wash Buffer (200 µL) was added to the Zymo-
Spin IIN column within a 2 mL collection tube and centrifuged for 15 seconds at 
maximum speed. Zyppy Wash Buffer (400 µL) was added to the Zymo-Spin IIN 
column and centrifuged for 30 seconds at maximum speed. The Zymo-Spin IIN 
column was carefully transferred to a clean 1.5 mL microcentrifuge tube and 30 µL 
NFW was added directly to the membrane of the column. This was incubated for 1 
minute on the bench top followed by centrifugation for 15 seconds at 12000 x g. 
The concentration of the purified plasmid was determined using a NanoDrop 2000c 
analyser (Thermo Scientific, UK). Eluted DNA was stored at -20 °C. 
 
2.2.9. Plasmid DNA midi-prep 
A midi-prep procedure is used to purify out large quantities of DNA from 
transformed bacterial cells. Midi-prep plasmid purifications were performed using 
the Hi-Speed plasmid Midi kit (Qiagen, UK). The required glycerol stock was 
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removed from -80 °C and thawed on wet ice. From the cryovial, 50 µL was removed 
and inoculated into 5 mL LB broth plus antibiotic and incubated for 8 hours at 225 
rpm, 37 °C. After 8 hours, 500 µL of the first culture was inoculated into 50 mL LB 
broth plus antibiotics and incubated overnight at 225 rpm, 37 °C. The next day, the 
cells were harvested by centrifugation for 15 minutes at 6000 x g, 4 °C. The 
supernatant was discarded and the pellet resuspended in 6 mL of Buffer P1 
containing RNase A. When completely resuspended, 6 mL of Buffer P2 was added 
and the volume mixed by inverting the tube. The contents of the tube were 
incubated for 5 minutes at RT after which 6 mL of pre-chilled Buffer P3 was added 
and the lysate mixed by inverting. The lysate was poured into a QIAfilter cartridge 
with a cap screwed onto the outlet port and was incubated for ten minutes at RT. 
The cap was removed and, using the plunger, the lysate pushed into a HiSpeed Midi 
tip (pre-wetted with 4 mL Buffer QBT). The lysate was allowed to drain by gravity 
flow and 20 mL of Buffer QC was added and allowed to drain. DNA was eluted with 
5 mL Buffer QF into a universal tube and 3.5 mL isopropanol was added. This was 
incubated at RT for 5 minutes to precipitate the DNA. A QIAprecipitator Midi 
Module was attached to a 20 mL syringe from which the plunger had been removed 
and the isopropanol mixture poured into the syringe. The plunger was inserted and 
the liquid pushed through the cartridge. The QIAprecipitator was taken off the 
syringe and the plunger was removed. The module was placed on the syringe barrel 
and 2 mL 70% ethanol was pushed through by re-inserting the plunger into the 
syringe. The QIAprecipitator was removed from the syringe and the plunger 
removed. The QIAprecipitator and the syringe were re-assembled and air was 
pushed through at a constant pressure. The module was blotted onto absorbent 
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tissue to ensure no carry-over of ethanol. A 5 mL syringe (no plunger) was attached 
to the QIAprecipitator and 600 µL NFW added to the syringe. The plunger was 
added to push this through into a 1.5 mL microcentrifuge tube. The QIAprecipitator 
was removed from the 5 mL syringe and the plunger removed. The previous step 
was repeated to ensure maximum recovery of the DNA. The concentration of the 
eluted DNA was determined by NanoDrop 2000c analyser and stored at -20 °C. 
 
2.2.10. DNA sequencing 
DNA sequencing is the elucidation of the nucleotide sequence of a specific DNA 
molecule. Cloned PCR products were submitted for Sanger sequencing by Source 
Bioscience Ltd (Nottingham, UK). PCR products cloned into the pGEM-T vector were 
sequenced using standard M13 forward and reverse sequencing primers. Whereas, 
clones generated in pcDNA3.1His vector were sequenced using standard T7 forward 
sequencing primer and BGH reverse sequencing primer. All sequencing primers 
were supplied by Source Bioscience Ltd. The DNA sequence that was supplied by 
the facility was analysed using Chromas Lite software and compared to reference 
sequences in the NCBI database.  
 
2.3. Protein Analysis 
2.3.1. Cell lysis and protein determination 
Cell walls are disrupted to release the total protein of the cell and generate a whole 
cell lysate. The concentration of the total protein of the lysate is then determined. 
41 
 
Cell pellets were lysed in 200 µL clear lysis buffer (1% SDS (Sigma Aldrich, UK), 50 
mM Tris (Fisher Scientific, UK) (pH 6.8), 5 mM EDTA (Sigma Aldrich, UK) and 10% 
glycerol). Lysates were sonicated on ice until clear and clarified at 10000 x g, 4 °C for 
10 minutes. The protein concentration of the lysates was determined using the DC 
Protein Determination Kit (Bio-Rad). Protein standards were prepared by dissolving 
BSA (Sigma Aldrich, UK) in lysis buffer and diluting to 1.5, 1.0, 0.5 and 0.2 mg/mL. 
Each sample or standard was assayed in triplicate. Briefly, 5 µL of each sample (cell 
lysate or protein standard) was placed in one well of a 96 well plate. To each well, 
25 µL of Reagent A’ (prepared by adding 20 µL of reagent S to 1 mL of Reagent A) 
was added. Following this, 200 µL of Reagent B was then added and the plate gently 
agitated to ensure the volumes were mixed. The plate was incubated for 15 minutes 
and the absorbance read using the FLx800 Plate Reader (BioTek).  
 
2.3.2. Western Blotting 
Western blotting is a technique used to determine the presence or absence of a 
specific protein in a sample. Following separation and transfer of the proteins in the 
chosen sample, an antibody is used to detect the target. Unless otherwise stated, a 
10% resolving gel (7.05 mL water, 4.25 mL resolving buffer (Geneflow, UK), 5.7 mL 
acrylamide (Sigma Aldrich, UK), 15 µL TEMED (Sigma Aldrich, UK) and 50 µL APS 
(Sigma Aldrich, UK)) and a 4% stacking gel (4.6 mL water, 1.9 mL stacking gel 
(Geneflow, UK), 1.0 mL acrylamide (Sigma Aldrich, UK), 15 µL TEMED (Sigma Aldrich, 
UK) and 50 µL APS (Sigma Aldrich, UK)) was prepared. To the cell lysates was added 
an appropriate volume of 4x SDS loading buffer (8% w/v SDS, 40% v/v glycerol, 20% 
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v/v β-mercaptoethanol, 0.008% w/v bromophenol blue (Sigma Aldrich, UK) and 250 
mM Tris (pH 6.8) and the samples heated for 5 minutes at 95 °C. Samples were 
loaded onto the gel and run for approximately 1 hour at 30 mA per gel in 1x 
Running buffer (25 mM Tris, 190 mM glycine (Fisher Scientific, UK), 0.1% SDS). 
Separated proteins were electroblotted to Polyvinylidene fluoride (PVDF) 
membrane (pre-soaked in methanol (Sigma Aldrich, UK)) for 1 hour at 75 V in 1x 
transfer buffer (25 mM Tris, 190 mM glycine, Geneflow, UK). Membranes were 
blocked in 3% blocking solution (3% milk powder in 1x PBS-Tween (Sigma Aldrich, 
UK) (0.05%)) for 1 hour at RT with agitation. After blocking, the membrane was 
incubated in primary antibody (diluted according to the manufacturer’s instructions 
in 3% blocking solution) overnight at 4 °C with agitation. The membrane was 
washed 3 x 5 minutes in 1x PBS-Tween (0.05%) with agitation then incubated for 1 
hour with agitation with an appropriate HRP-conjugated secondary antibody which 
was diluted 1:5000 in 3% blocking solution. Following incubation, the membrane 
was washed again as described and then probed with SuperSignal West Femto 
Chemiluminescent Substrate (Thermo Scientific, UK) and visualised using the 
Luminescent Image Analyzer LAS-1000 (FujiFilm). 
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Chapter 3 : Characterisation 
of Variable LEDGF Isoform 
Expression in Primary CLL 
Cells 
 
3.1. Introduction 
CLL remains incurable with current therapies and so there remains a need to 
develop novel treatment strategies. It is suggested that antigens detected in 
patients may identify tumour markers that could be used to develop 
immunotherapeutic strategies. One method used to identify such antigens is 
‘serological identification by recombinant expression cloning’ (SEREX). Briefly, cDNA 
expression libraries are constructed from tumour tissue, transformed into E coli and 
antigens expressed are detected using autologous sera. Positive clones that are 
reactive with the sera are isolated, purified and the DNA analysed to determine the 
sequence. The sequence was used to interrogate databanks to determine the 
identity of the potential antigen. Using this technique, Krackhardt et al. identified 
14 antigens in CLL patients, 6 of which were found to be expressed exclusively in 
CLL by subsequent RT-qPCR analysis and 5 where present in CLL and other 
lymphomas59. One of these was found to have been previously described as LEDGF. 
As antibodies to this antigen have been detected in patients with other 
lymphomas59 it was suggested that this might be a tumour associated antigen 
rather than one that is specific to CLL. 
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Indeed, previous studies have identified the over expression of LEDGF in a number 
of different tumour samples and cell lines. Datasets presented in the Oncomine 
Database (www.oncomine.org) indicate that LEDGF is overexpressed, compared to 
normal cells/tissues in as many as 12 different cancers including breast and cervical 
cancer and CLL (14 datasets deposited). More specifically, in 2005, a study by 
Daniels et al. showed that 18.4% of prostate cancer patients had autoantibodies to 
the p75 isoform of LEDGF (LEDGF/p75)80. This compared to only 5.5% of normal 
matched controls. Immunohistochemistry revealed that over expression of 
LEDGF/p75 was detected in 93% of prostate tumours, but not in normal prostate 
tissue. 
In a second study, Daugaard et al. demonstrated that LEDGF/p75 mRNA levels were 
higher in primary and metastatic carcinoma compared with normal breast tissue81. 
They also present microarray data showing over expression of LEDGF/p75 in 
bladder carcinomas that had invaded muscle tissue as compared to the normal 
tissue. 
Finally, a more recent study by Basu et al. examined LEDGF/p75 mRNA expression in 
21 different human cancer tissues and compared this to the normal tissue 
counterpart using the Oncomine database82. All but bladder and uterine cancer 
showed a significant over expression of LEDGF/p75 compared to normal tissue 
counterparts. Further, the authors validated these results and used a qPCR array to 
demonstrate significant over expression of the LEDGF/p75 transcript in prostate, 
thyroid, breast and colon cancers. Using immunohistochemical methods, they were 
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able to demonstrate over expression of LEDGF protein in prostate, liver and thyroid 
tumours. 
Whilst the over expression of LEDGF has been reported in a number of tumour 
types, there is also increasing evidence that translocations between LEDGF and 
NUP98 (t(9;11)) may facilitate development of leukemia. The first reported case was 
in a patient with acute biphenotypic leukemia50, and it has since been reported that 
this t(9;11) translocation is a recurrent feature in patients with AML 51, 52, 55. It has 
also been reported in a paediatric AML case54, a patient with transformed CML53 
and in a patient with MDS56. 
Several isoforms of LEDGF have also been described in AML57. Of the isoforms 
identified, LEDGF/p75, p52 and p52b all share a common N-terminal region up to 
exon 9, but differ within the C terminal region. Three further isoforms were 
described that had varying deletions between exons 5 and 8 (Figure 3-1)57. Isoform 
LEDGF/p52bΔE6 had the complete exon 6 deleted which resulted in an altered 
reading frame within exon 7. Consequently, a premature stop codon is encoded 
which could result in the generation of a truncated protein of 167 amino acids.  
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Figure 3-1: Alternative Isoforms of LEDGF described in AML.  
In AML, four extra isoforms of LEDGF have been described, namely LEDGF/p52b, 
LEDGF/p52bΔE6, LEDGFp52Δ1 and LEDGF/p52bΔb1. The sequence of LEDGF/p52 is 
provided as a comparison. LEDGF/p52b differs from LEDGF/p52 due to its’ unique 
exon 9b whilst the other three isoforms have varying deletions. 
 
The aims of this chapter, therefore, were: 
1. Determine which of the different reported isoforms of LEDGF are expressed 
in CLL cells by using RT-PCR. 
2. Determine the relative expression levels of the different isoforms identified 
in aim 1. 
3. Determine whether there are any significant differences in the expression 
levels of the different isoforms between CLL and normal B cells 
4. Identify a suitable antibody in order to examine the protein expression of 
the different LEDGF isoforms in CLL cells 
5. Correlate LEDGF isoform expression with clinical and prognostic factors 
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3.2. Methods 
3.2.1. Sample Cohort 
CLL cDNA samples were a kind gift from Dr. G. Johnson. Normal B cell cDNA samples 
were a kind gift from Dr. A. Duckworth. These were stored at -20 °C until ready for 
use. 
The average age of the patients within the cohort was 62.7 years old and all 
patients had a white blood cell count <5x109 /L. The cohort included a variety of 
patients that covered the molecular abnormalities associated with CLL including 
deletions of chromosomes 13q, 11q and trisomy 12. A complete clinical data set for 
each patient is given in Appendix A. 
 
3.2.2. RT-PCR reaction optimisation for LEDGF/p75 and p52 
Determination of whether CLL cells expressed either of the 2 major isoforms of 
LEDGF was carried out by end point PCR using 2 sets of primers (Table 3-1). One pair 
was specific to the LEDGF/p75 isoform (LEDGFuniF and LEDGF/p75-R; amplicon size 
= 233 bp) whilst the second was specific to the LEDGF/p52 isoform (LEDGFuniF and 
LEDGF/p52-R; amplicon size = 198 bp). The primer pairs utilised a common forward 
primer that annealed in the shared N-terminal region whilst the reverse primer for 
each pair annealed to the respective unique C-terminal region. 
The location of the PCR primers with respect to the sequences for LEDGF/p75 and 
LEDGF/p52 are shown in Figure 3-2. The forward primer (LEDGFuniF) common to 
each isoform is highlighted in yellow. The reverse primer specific for LEDGF/p75 is 
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highlighted in red and the corresponding primer for LEDGF/p52 is highlighted in 
green. The unique C-terminus tail of each isoform is underlined.  
 
LEDGF isoform Primer Sequence (5’ > 3’) 
p75 LEDGFuni-F gttacttcaacctccgattc 
 LEDGFp75-R gtttctcgcttcttctccac 
p52 LEDGFuni-F gttacttcaacctccgattc 
 LEDGFp52-R gtagattacatgttgtttggtg 
 
Table 3-1: Primer sequences for the PCR primers used for the screening of CLL 
samples.  
The primers pairs are specific for either LEDGF/p75 (top) or LEDGF/p52 (bottom) 
and are for use in RT-PCR. 
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LEDGF/p75 (NM_001128217) 
ATGACTCGCGATTTCAAACCTGGAGACCTCATCTTCGCCAAGATGAAAGGTTATCCC
CATTGGCCAGCTCGAGTAGACGAAGTTCCTGATGGAGCTGTAAAGCCACCCACAAAC
AAACTACCCATTTTCTTTTTTGGAACTCATGAGACTGCTTTTTTAGGACCAAAGGAT
ATATTTCCTTACTCAGAAAATAAGGAAAAGTATGGCAAACCAAATAAAAGAAAAGGT
TTTAATGAAGGTTTATGGGAGATAGATAACAATCCAAAAGTGAAATTTTCAAGTCAA
CAGGCAGCAACTAAACAATCAAATGCATCATCTGATGTTGAAGTTGAAGAAAAGGAA
ACTAGTGTTTCAAAGGAAGATACCGACCATGAAGAAAAAGCCAGCAATGAGGATGTG
ACTAAAGCAGTTGACATAACTACTCCAAAAGCTGCCAGAAGGGGGAGAAAGAGAAAG
GCAGAAAAACAAGTAGAAACTGAGGAGGCAGGAGTAGTGACAACAGCAACAGCATCT
GTTAATCTAAAAGTGAGTCCTAAAAGAGGACGACCTGCAGCTACAGAAGTCAAGATT
CCAAAACCAAGAGGCAGACCCAAAATGGTAAAACAGCCCTGTCCTTCAGAGAGTGAC
ATCATTACTGAAGAGGACAAAAGTAAGAAAAAGGGGCAAGAGGAAAAACAACCTAAA
AAGCAGCCTAAGAAGGATGAAGAGGGCCAGAAGGAAGAAGATAAGCCAAGAAAAGAG
CCGGATAAAAAAGAGGGGAAGAAAGAAGTTGAATCAAAAAGGAAAAATTTAGCTAAA
ACAGGGGTTACTTCAACCTCCGATTCTGAAGAAGAAGGAGATGATCAAGAAGGTGAA
AAGAAGAGAAAAGGTGGGAGGAACTTTCAGACTGCTCACAGAAGGAATATGCTGAAA
GGCCAACATGAGAAAGAAGCAGCAGATCGAAAACGCAAGCAAGAGGAACAAATGGAA
ACTGAGCAGCAGAATAAAGATGAAGGAAAGAAGCCAGAAGTTAAGAAAGTGGAGAAG
AAGCGAGAAACATCAATGGATTCTCGACTTCAAAGGATACATGCTGAGATTAAAAAT
TCACTCAAAATTGATAATCTTGATGTGAACAGATGCATTGAGGCCTTGGATGAACTT
GCTTCACTTCAGGTCACAATGCAACAAGCTCAGAAACACACAGAGATGATTACTACA
CTGAAAAAAATACGGCGATTCAAAGTTAGTCAGGTAATCATGGAAAAGTCTACAATG
TTGTATAACAAGTTTAAGAACATGTTCTTGGTTGGTGAAGGAGATTCCGTGATCACC
CAAGTGCTGAATAAATCTCTTGCTGAACAAAGACAGCATGAGGAAGCGAATAAAACC
AAAGATCAAGGGAAGAAAGGGCCAAACAAAAAGCTAGAGAAGGAACAAACAGGGTCA
AAGACTCTAAATGGAGGATCTGATGCTCAAGATGGTAATCAGCCACAACATAACGGG
GAGAGCAATGAAGACAGCAAAGACAACCATGAAGCCAGCACGAAGAAAAAGCCATCC
AGTGAAGAGAGAGAGACTGAAATATCTCTGAAGGATTCTACACTAGATAACTAG 
 
LEDGF/p52 (NM_021144) 
ATGACTCGCGATTTCAAACCTGGAGACCTCATCTTCGCCAAGATGAAAGGTTATCCC
CATTGGCCAGCTCGAGTAGACGAAGTTCCTGATGGAGCTGTAAAGCCACCCACAAAC
AAACTACCCATTTTCTTTTTTGGAACTCATGAGACTGCTTTTTTAGGACCAAAGGAT
ATATTTCCTTACTCAGAAAATAAGGAAAAGTATGGCAAACCAAATAAAAGAAAAGGT
TTTAATGAAGGTTTATGGGAGATAGATAACAATCCAAAAGTGAAATTTTCAAGTCAA
CAGGCAGCAACTAAACAATCAAATGCATCATCTGATGTTGAAGTTGAAGAAAAGGAA
ACTAGTGTTTCAAAGGAAGATACCGACCATGAAGAAAAAGCCAGCAATGAGGATGTG
ACTAAAGCAGTTGACATAACTACTCCAAAAGCTGCCAGAAGGGGGAGAAAGAGAAAG
GCAGAAAAACAAGTAGAAACTGAGGAGGCAGGAGTAGTGACAACAGCAACAGCATCT
GTTAATCTAAAAGTGAGTCCTAAAAGAGGACGACCTGCAGCTACAGAAGTCAAGATT
CCAAAACCAAGAGGCAGACCCAAAATGGTAAAACAGCCCTGTCCTTCAGAGAGTGAC
ATCATTACTGAAGAGGACAAAAGTAAGAAAAAGGGGCAAGAGGAAAAACAACCTAAA
AAGCAGCCTAAGAAGGATGAAGAGGGCCAGAAGGAAGAAGATAAGCCAAGAAAAGAG
CCGGATAAAAAAGAGGGGAAGAAAGAAGTTGAATCAAAAAGGAAAAATTTAGCTAAA
ACAGGGGTTACTTCAACCTCCGATTCTGAAGAAGAAGGAGATGATCAAGAAGGTGAA
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AAGAAGAGAAAAGGTGGGAGGAACTTTCAGACTGCTCACAGAAGGAATATGCTGAAA
GGCCAACATGAGAAAGAAGCAGCAGATCGAAAACGCAAGCAAGAGGAACAAATGGAA
ACTGAGCACCAAACAACATGTAATCTACAGTAA 
 
Figure 3-2: cDNA sequence of LEDGF/p75 (above) and LEDGF/p52 (below).  
Sequences highlighted indicate the primers used in the PCR reactions whilst the 
underlined sequence identifies the unique C-terminal sequences in each of the 
isoforms. The common forward primer is highlighted in yellow, the reverse primer 
specific to LEDGF/p75 is highlighted in red and the reverse primer specific to 
LEDGF/p52 is highlighted in green. Each different exon is highlighted by a colour 
change from black to blue and vice versa. 
 
Reaction parameters were optimised as described in Chapter 2.2.3 using the 
following annealing temperature gradient: - LEDGF/p75 52 - 64 °C; LEDGF/p52 51 - 
63 °C. For all of these optimisations, cDNA from KCL22 and K562 cell lines was used 
as template. A negative control in the form of NFW was also included. Samples of 
each PCR were analysed by electrophoresis on 1% agarose gels as described in 
Chapter 2.2.4 and the chosen annealing temperature was determined by 
visualisation of the gel. 
 
3.2.3. CLL Sample screening 
CLL cDNA samples were initially screened for the presence or absence of the 2 
major isoforms of LEDGF, namely LEDGF/p75 and p52 by RT-PCR as described in 
Chapter 2.2.3 using the optimised reaction parameters described above. For each 
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reaction, a negative control containing NFW and a positive control specific for that 
primer pair (commercially purchased cDNA clones) were included. The PCR 
reactions for each of the isoforms were performed separately but analysed on the 
same agarose gel so that the presence or absence of each isoform in each sample 
could be compared. PCR products with aberrant molecular weights that were 
generated during the screening procedure were purified from agarose gels as 
described in Chapter 2.2.5. These were then cloned into the pGEM-T vector, 
transformed into in JM109 competent cells (Promega, UK) and plasmid DNA 
purified using the mini-prep procedures outlined in Chapters 2.2.6, 2.2.7 and 2.2.8. 
Cloned inserts were sequenced as described in Chapter 2.2.10.  
PCR primers that would allow specific amplification of LEDGF/p52b were designed 
to examine expression of this isoform in CLL (Table 3-2). The forward primer was 
designed in exon 6 of LEDGF as this was common to LEDGF/p75, p52 and p52b 
whilst the reverse primer was designed across the exon boundary of exon 9 and 10, 
as exon 10 is unique to LEDGF/p52b.  
 
Primer Sequence (5’ > 3’) 
P52bscreeningF gacctgcagctacagaag 
P52bscreeningR cagtaactggattaatgtgc 
 
Table 3-2: Primer sequences for PCR primers used to screen CLL cDNA cells for the 
presence of LEDGF/p52b.  
The primer pair is for use in RT-PCR. 
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The primer pair was optimised as described in Chapter 2.2.3 using a temperature 
gradient of 52 – 64 °C and KCL22 and K652 cell line cDNA as the template. PCR 
reactions were analysed by agarose gel electrophoresis. Bands were cut out of the 
gel, purified, cloned and sequences confirmed as described in Chapters 2.2.5- 2.2.8 
and 2.2.10. These conditions were then used to screen the cohort of CLL samples 
for expression of this isoform. PCR reactions were analysed by agarose gel 
electrophoresis and gels visualised to determine if the isoform was present. 
PCR primers (Table 3-3) were synthesised to screen the CLL cDNA samples for the 
other isoforms described by Huang et al. (see Figure 3-1)57. The forward primer 
(p52isoF) was designed such that it spanned the boundary of exon 4 and 5 whilst 
the reverse primer (p52isoR) was designed within exon 8. 
 
  
Primer Sequence (5’ > 3’) 
P52isoF gccagcaatgaggatgtgac 
P52isoR gaatcggaggttgaagtaaccc  
 
Table 3-3: Primer sequences for the PCR primers used to screen CLL cDNA samples 
for the presence of LEDGF isoforms as described in Huang et al.57.  
The primer pair is designed in the regions common to all of the potential isoforms 
and therefore can only be used for RT-PCR analysis. 
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The primer pair was optimised as described in Chapter 2.2.3. A gradient of 57 – 67 
°C was used with KCL22 and K652 cell line cDNA as the template. Commercially 
purchased clones of LEDGF/p75 and LEDGF/p52 were used as positive controls for 
the PCR amplification. This primer pair would amplify p75, p52 and p52b but would 
not discriminate between the 3 isoforms. The expression of other isoforms of 
LEDGF (namely p52bΔE6, p52Δ1 or p52bΔ1) as described by Huang et al.57 would be 
indicated by multiple bands when the PCR products were examined by agarose gel 
electrophoresis.  
PCR products from 5 CLL cases were analysed by 2% agarose gel electrophoresis and 
bands cut out of the gel and purified using the Wizard SV Gel and PCR Clean Up Kit 
as described in Chapter 2.2.5. Two samples were chosen and their purified products 
ligated into pGEM-T vector at a ratio of 3:1 (insert:vector) and transformed into 
JM109 competent cells by following the method in Chapters 2.2.6 and 2.2.7. 
Plasmid DNA was purified from selected clones using the mini-prep procedure 
described in Chapter 2.2.8. The sequences of the clones were verified externally at 
Source Bioscience Ltd (Chapter 2.2.10).  
 
3.2.4. Quantitative RT-PCR analysis of LEDGF isoform expression in CLL 
Quantitative RT-PCR (RT-qPCR) was performed using the HOT FIREPol EvaGreen 
qPCR Mix (Solis BioDyne) in 96 well PCR plates sealed with optical strip caps (Web 
Scientific, UK). Amplification reactions were carried out on a MX3005P qPCR 
machine and analysed using MxPro v4.1 software (Agilent Technologies, UK). 
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Four sets of primers, each designed to identify a specific LEDGF isoform, were used 
to investigate the relative levels of each of the isoforms in a cohort of CLL cDNA 
samples (including normal B cell cDNA) (Table 3-4). The primer pair specific for the 
LEDGF/p52b isoform was the same primer pair used for the end-point PCR 
screening already discussed (Table 3-2). Where possible, primers were designed 
such that each primer pair had similar annealing temperatures. The relative 
expression of each of the isoforms was determined by comparison to expression of 
a reference gene, ribosomal protein L27 (RPL27), using the ΔΔCt method. 
Individual reactions required 5 µL of 5x HOT FIREPol EvaGreen qPCR Mix, 1 µL of 
each forward and reverse primer, (stock concentration 5 µM, final concentration of 
0.2 µM each) and 16 µL of NFW. Each reaction was performed in triplicate. Thus, 
sufficient mastermix was always prepared for the required number of reactions for 
each sample. From this mastermix, 23 µL was aliquoted into the required number of 
wells on the plate and 2 µL of cDNA template (stock diluted 1:4 with NFW) was 
added to give a final volume of 25 µL. A negative control using 2 µL of NFW, instead 
of sample, was always prepared. Following completion of the reaction, the average 
Ct value for each sample was determined. 
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Target Primer name Primer sequence 
LEDGF/p75 p75qpcrF ctgagcagcagaataaagatg 
p75qpcrR gtgacctgaagtgaagcaag 
LEDGF/p52 p52qpcrF agaagagaaaaggtgggagg 
p52qpcrR gattacatgttgtttggtgctc 
LEDGF/p52b p52bscreeningF gacctgcagctacagaag 
p52bscreeningR cagtaactggattaatgtgc 
LEDGF/p52bΔE6 p52be6qpcrF gaaagagaaagctacagaag 
p52be6qpcrR cttcatccttcttaggctg 
RPL27 RPL27F caagttcatgaaacctgggaa 
RPL27R gcagtttctggaagaaccactt 
 
Table 3-4: Sequences of primers used for RT-qPCR analysis. 
Each primer pair is specific for one target (left hand column), namely one of the four 
isoforms of LEDGF that has been shown to be present in CLL cases by RT-PCR and 
RPL27, the reference gene used for the expression analysis. 
 
Cycling parameters were as follows: 
95 °C 10 minutes (x1) 
94 °C 10 seconds, annealing temperature for 15 seconds, 72 °C for 30 
seconds, 80 °C for 7 seconds (fluorescence measurement) (x40) 
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To confirm the specificity of the primers and that only a single product was 
amplified, a sample of each PCR product from the reaction was analysed by 
electrophoresis on a 2% agarose gel (Chapter 2.2.4).  
To determine if there was a correlation between the relative levels of LEDGF and 
any clinical prognostic factors, statistical analysis was performed by Dr. Fotis 
Polydoros, The Liverpool Clinical Trials Unit. One-Way Analysis of Variance (ANOVA) 
tests were performed using the STATA version 13 statistical software package. Data 
was presented in the form of boxplots. 
 
3.2.5. Analysis of protein levels of LEDGF isoforms. 
To investigate the levels of protein of each of the LEDGF isoforms present in CLL 
samples, an antibody to the N-terminal region common to all of the isoforms was 
required. To test the specificity of the antibody, a 10% resolving and 4% stacking gel 
was prepared. To the gel, 10, 20, 30 and 40 µg of 293T and Mec-1 (a CLL derived cell 
line) cell lysates where added and run as described in Chapter 2.3.1 and 2.3.2. The 
blots where probed with primary anti-PSIP1 antibody N-terminal region (Aviva, 
Rabbit polyclonal, 1.25:1000). 
 
3.3. Results 
3.3.1. Optimisation of RT-PCR conditions 
Using cDNA generated from the cell lines K562 or KCL22, the annealing temperature 
for the primer pairs LEDGFuniF plus LEDGF/p75-R and LEDGFuniF plus LEDGF/p52R 
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was determined to be 57 °C and 54 °C for p75 and p52 respectively (Figure 3-3). The 
lack of any bands in the NFW and no enzyme control lanes confirm that there was 
no contamination of the PCR reaction.  
 
 
Figure 3-3: Optimisation of RT-PCR annealing temperatures.  
RT-PCR reactions were performed using cDNA from either KCL22 or K562 cells with 
a range of annealing temperatures and a primer pair specific for LEDGF/p75 or 
LEDGF/p52. Reactions were analysed by agarose gel electrophoresis and the 
annealing temperature for the primer pairs determined visually (indicated by 
arrows). Specifically, the chosen annealing temperature for the primer pair specific 
to LEDGF/p75 was 57 °C (top) and for LEDGF/p52 was 54 °C (bottom). 
 
3.3.2. Screening CLL cases for LEDGF/p75 or p52 isoform expression 
Using the reaction conditions chosen above, cDNA samples from a cohort of 78 CLL 
cases (pre-screened for the presence of the reference gene to ensure integrity of 
NF
W 
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the template) were screened by PCR to determine whether or not they expressed 
either the p75 and/or p52 isoform of LEDGF. Each of the PCR reactions was 
performed separately and included positive controls in the form of commercially 
purchased cDNA clones for each of the isoforms. Negative controls in the form of 
NFW in place of cDNA were also included. Upon completion of the reaction, a 
sample of each PCR was analysed by agarose gel electrophoresis. In order to aid the 
analysis, PCR products for each isoform from the same sample were analysed in 
adjacent lanes. Figure 3-4 shows a representative gel for 6 of the CLL cases 
examined. Results of the entire cohort are summarised in Table 3-5. 
 
 
Figure 3-4: RT-PCR screening of CLL cases for expression of LEDGF isoforms p75 
and p52. 
cDNA from 78 CLL cases were screened by RT-PCR for expression of the p75 or p52 
isoforms of LEDGF using primer pairs specific to each isoform at the chosen 
annealing temperatures described above. PCR products were analysed by agarose 
gel electrophoresis. This shows a representative gel for 6 of the cases (1815, 2399, 
2962, 3092, 3207 and 2565). The bands representing LEDGF/p75 and LEDGF/p52 
are highlighted. 
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The results of this screening show that 68 of the 78 cases examined expressed the 
p75 isoform, whilst 67 expressed the p52 isoform. With the exception of 2 cases 
(2499 and 3071) those that did not express the p75 isoform were not the same as 
those that did not express the p52 variant and vice versa. In some of those cases 
that did express LEDGF/p75, a faint band was also observed running at 
approximately 500 bp (for example sample 2565, Figure 3-4). As the nature of this 
band is uncertain and not present in all of the samples, it was further investigated.  
 
3.3.3. Identification of a p52b isoform of LEDGF 
During the process of screening CLL cases for the expression of the p52 and p75 
isoforms of LEDGF, a band was identified on the agarose gel whose size did not 
correspond to the expected PCR products. Therefore this band was purified, cloned 
into pGEM-T and sequenced. The results from the sequencing are shown in Figure 
3-5.  
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ATTTCCAATTAGGGGGCGATTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCCG
CGGGATTGTTACTTCAACCTCCGATTCTGAAGAAGAAGGAGATGATCAAGAAGGTGA
AAAGAAGAGAAAAGGTGGGAGGAACTTTCAGACTGCTCACAGAAGGAATATGCTGAA
AGGCCAACATGAGAAAGAAGCAGCAGATCGAAAACGCAAGCAAGAGGAACAAATGGA
AACTGAGCACATTAATCCAGTTACTGAAAAGAGAATACAAGTGGAGCAAACAAGAGA
TGAAGATCTTGATACAGACTCATTGGACTGAATTTCCCCCTTCCCCCCATTGATGGA
AGAATGTTCCAGATTCTAAATTGAGGACTTCATTATTAATGGCATTACTGTGTTATG
ATTAACAAATTTCCTGTAAGGCAGAATAAAGATGAAGGAAAGAAGCCAGAAGTTAAG
AAAGTGGAGAAGAAGCGAGAAACAATCACTAGTGCGGCCGCCTGCAGGTCGACCATA
TGGGAGAGCTCCCAACGCGTTGGATG 
 
H I N P V T E K R I Q V E Q T R D E D L D T D S L D Stop I S P F P P L Met E E C S R F 
Stop I E D F I I N G I T V L Stop L T N F L Stop 
Figure 3-5: Sequence of the alternative splice form of LEDGF.  
(Top) The PCR product identified during the screening procedure was cloned into 
pGEM-T and sequenced. The primers used to generate the PCR product (LEDGFuni-F 
and LEDGF/p75-R) are highlighted in yellow. The red text signifies the inserted 
sequence identified in this study (182 nucleotides) which results in a larger product 
than LEDGF/p75 when analysed by agarose gel electrophoresis. (Bottom) The 
translate tool of Expasy was used to determine the amino acid sequence of the 
identified PCR product. The inserted sequence results in a premature stop codon. 
 
This showed that the sequence immediately downstream of the universal forward 
primer was the expected sequence from exon 9 of LEDGF common to both the p52 
and p75 isoform of LEDGF. However, the sequence then continued for 182 
nucleotides into the intron following exon 9 and then spliced back into exon 10 of 
LEDGF/p75 ie an alternative splice donor site within intron 9 was used. In order to 
determine the effects of this extra nucleotide sequence on the amino acid 
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sequence, the Translate tool of Expasy (http://web.expasy.org/translate/) was used. 
The amino acid sequence returned is also shown in Figure 3-5. 
The alternative splicing results in a disruption to the reading frame of LEDGF/p75 at 
the carboxyl region. The first His residue shown in Figure 3-5 is a result of the last 2 
nucleotides from exon 9 (bases C and A) and the first nucleotide (C) from the intron.  
Following this the reading frame encodes 25 amino acids prior to a stop codon.  
This result suggests there is a third isoform of LEDGF that is expressed in CLL that 
shares the same amino terminal sequence as LEDGF/p75 and p52, but which differs 
at the carboxy terminus. This would result in a protein that was bigger in size than 
LEDGF/p52 (351 residues compared to 333). Based on the results of the sequencing 
this isoform was subsequently identified as LEDGF/p52b, previously described by 
Huang et al. in AML57, and the result suggests this isoform is also expressed in CLL.  
 
3.3.4. Screening CLL cases for LEDGF/p52b isoform expression 
Having shown that the p52b isoform of LEDGF was expressed in CLL cells, PCR 
primers (p52bscreeningF and p52bscreeningR) specific for this isoform (Table 3-2) 
were synthesised and used to screen the entire cohort by RT-PCR. PCR conditions 
were optimised by amplifying cDNA from KCL22 and K562 cells and the annealing 
temperature was determined to be 57 °C (Figure 3-6). Sequencing of the cloned PCR 
product confirmed its specificity. 
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Figure 3-6: Optimisation of RT-PCR annealing temperature 
RT-PCR reactions were performed with KCL22 cDNA (top) and K562 cDNA (bottom) 
with a range of annealing temperatures and the primer pair specific for LEDGF/p52b 
(p52bscreeningF and R). Reactions were analysed by agarose gel electrophoresis 
and the chosen annealing temperature determined visually (indicated by arrows) 
and shown to be 57 °C.  
 
A representative gel from the screening of the CLL cohort using the PCR conditions 
optimised above is shown in Figure 3-7. The results demonstrated that this 
alternative splice form of LEDGF was expressed in 76 of the 78 samples analysed in 
the cohort (Table 3-5). 
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Figure 3-7: Representative image from the screening of CLL cDNA samples to 
examine the expression of LEDGF/p52b.  
Primers p52bscreeningF and R were used in RT-PCR reactions at the chosen 
annealing temperature of 57 °C, to screen the CLL cDNA cohort for the presence of 
LEDGF/p52b. RT-PCR products were analysed by agarose gel electrophoresis and 
the presence or absence of the isoform determined visually. The CLL samples shown 
by this representative image are detailed at the top of the gel. 
 
3.3.5. PCR screening of CLL cases for other isoforms of LEDGF 
Three further isoforms of LEDGF were described by Huang et al.57. In order to 
screen CLL patients for evidence of expression of these isoforms, PCR primers (Table 
3-3) were synthesised which would allow amplification of all three and PCR 
conditions optimised using cDNA from K562 or KCL22 as described earlier. As shown 
in Figure 3-8, the chosen annealing temperature for this primer pair was 64 °C. 
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Figure 3-8: Optimisation of RT-PCR annealing temperatures. 
RT-PCR reactions were performed on K562 (top) KCL22 (bottom) cell line cDNA with 
a range of annealing temperatures and the primer pair p52isoF and p52isoR. RT-PCR 
products were analysed by agarose gel electrophoresis and the annealing 
temperature determined visually to be 64 °C (indicated by arrows). 
 
These chosen PCR conditions were then used to screen the 78 CLL cases for 
expression of these various isoforms. Figure 3-9 shows a representative example of 
the results obtained from the screening of the CLL cDNA samples. As the primers 
used cannot distinguish between LEDGF/p75, p52 and/or p52b, the major band at 
443 bp could represent any of these isoforms. The band at approximately 350 bp 
would represent LEDGF/p52bΔE6. The lack of bands at 239 bp or 134 bp suggests 
that the 2 further isoforms described by Huang et al.57 are not expressed in CLL. 
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Figure 3-9: Representative image from RT-PCR screening of CLL cDNA to 
determine the presence of extra isoforms of LEDGF.  
The primers, p52isoF and p52isoR, were used to screen CLL cDNA by RT-PCR at the 
chosen annealing temperature of 64 °C. The products of the reactions were 
analysed by agarose gel electrophoresis to determine the presence or absence of 
extra isoforms of LEDGF. The primer pair used did not discriminate between 
LEDGF/p75, p52 and p52b (top bright band). The faster migrating band represents 
LEDGF/p52bΔE6 and shows that this isoform I present in CLL. 
 
In order to confirm the band at 350 bp was LEDGF/p52bΔE6, the PCR was repeated 
and the band was purified, cloned into pGEM-T and sequenced. The sequence 
returned confirmed this band was LEDGF/p52bΔE6. 
 
Summary  
As a summary of the PCR screening Table 3-5 shows the presence or absence of 
each isoform in the CLL samples used in this cohort.  
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Sample  p75 p52 p52b p52bΔE6 
2415 Y Y Y N 
2953 Y N Y Y 
2512 Y N Y N 
3047 Y N Y Y 
2902 Y Y Y Y 
2968 Y Y Y Y 
2950 Y Y Y Y 
2673 Y Y Y Y 
2979 Y Y Y Y 
2744 Y N Y Y 
2999 Y Y Y Y 
2248 Y N Y Y 
2565 Y Y Y Y 
2408 N Y Y Y 
1780 N Y Y Y 
2418 Y Y Y Y 
1800 Y Y Y Y 
2136 N Y Y Y 
2539 Y Y Y Y 
2533 Y Y Y Y 
1731 Y Y Y Y 
2472 Y Y Y Y 
1815 Y Y Y N 
2375 Y N Y Y 
2390 Y N Y N 
2722 Y Y Y Y 
2674 Y N Y Y 
2499 N N Y Y 
2230 Y Y Y Y 
2747 Y Y Y Y 
2399 Y Y Y Y 
2088 Y Y Y N 
2765 N Y Y Y 
2787 N Y Y Y 
2792 N Y Y Y 
2793 Y Y Y N 
2794 N Y N Y 
2809 Y Y N N 
2820 Y Y Y N 
2821 Y Y Y Y 
2843 Y Y Y Y 
2844 N Y Y Y 
2867 Y Y Y Y 
2874 Y Y Y Y 
2877 Y Y Y Y 
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2909 Y Y Y Y 
2920 Y Y Y Y 
2924 Y Y Y Y 
2930 Y Y Y Y 
2937 Y Y Y Y 
2938 Y Y Y Y 
2949 Y Y Y Y 
2962 Y Y Y Y 
2967 Y Y Y Y 
2985 Y Y Y Y 
3016 Y Y Y Y 
3018 Y Y Y Y 
3035 Y Y Y Y 
3037 Y Y Y Y 
3038 Y N Y Y 
3068 Y Y Y Y 
3069 Y Y Y N 
3071 N N Y Y 
3076 Y Y Y Y 
3078 Y Y Y Y 
3089 Y Y Y Y 
3091 Y Y Y Y 
3092 Y Y Y N 
3139 Y Y Y N 
3151 Y Y Y N 
3144 Y Y Y N 
3187 Y Y Y Y 
3192 Y Y Y Y 
3160 Y Y Y Y 
3162 Y Y Y Y 
3193 Y Y Y Y 
3207 Y Y Y Y 
3210 Y Y Y Y 
 
Table 3-5: Summary of the RT-PCR screening results showing LEDGF isoform 
expression In CLL.  
78 CLL samples were screened by RT-PCR for the expression of different isoforms of 
LEDGF. The sample numbers are detailed in the first column followed by separate 
columns specific for each isoform of LEDGF/p75, p52, p52b and p52bΔE6. Presence 
or absence of an isoform is indicated by “Y” or “N” respectively. 
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3.3.6. Quantitative RT-PCR analysis of LEDGF expression in CLL 
Having identified which of the isoforms of LEDGF are expressed in CLL by RT-PCR, it 
was felt that it was important to determine their relative levels of expression. 
Therefore, RT-qPCR was performed on the same cohort of CLL samples using primer 
pairs that were specific to each of the identified isoforms.  
 
3.3.7. Optimisation of RT-qPCR conditions 
Using cDNA generated from HEK293 and Raji cell lines, the annealing temperature 
for the primer pairs specific for LEDGF/p75 and LEDGF/p52bΔE6 was determined 
using a standard PCR machine and shown to be 57 °C for LEDGF/p75 and 53 °C for 
LEDGF/p52bΔE6 (Figure 3-10). The lack of bands in the NFW control lanes confirms 
there was no contamination of the PCR reaction. 
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Figure 3-10: Optimisation of RT-qPCR annealing temperature 
PCR reactions were performed using cDNA from either KCL22 or K562 cell lines with 
a range of annealing temperatures and primer pairs specific for LEDGF/p75 and 
LEDGF/p52bΔE6. PCR products for LEDGF/p75 (upper panel) and LEDGF/p52ΔE6 
(lower panel) were analysed by agarose gel electrophoresis and the chosen 
annealing temperatures determined to be 57 °C and 54 °C respectively (indicated by 
arrows).  
 
Using the chosen annealing temperature for the primer pair specific to LEDGF/p75, 
and with the knowledge that the annealing temperature for the primer pair specific 
for LEDGF/p52b is 57 °C (Figure 3-6), PCR reactions were performed on a qPCR 
machine in order to determine the optimal temperature at which to read the 
fluorescence signal. Figure 3-11 shows the melt curve obtained using PCR primers 
specific for LEDGF/p52 and p52b which were used to amplify cDNA from HEK293 
and Raji cells. The cycling parameters were: 
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95 °C 10 minutes (x1) 
94 °C 10 seconds, 57 °C 15 seconds, 72 °C for 30 seconds, 78 °C for 7 seconds 
(fluorescence measurement) (x40) 
 
 
Figure 3-11: Melt curve analysis of LEDGF/p52 and p52b amplicons in cell line 
cDNA. 
RT-qPCR reactions were performed with primers pairs specific to LEDGF/p52 and 
p52b and cell line cDNA as template. Following the amplification phase, the melt 
curve was produced and shown above. The yellow and red peaks indicate 
fluorescence obtained using Raji cDNA and primers specific for LEDGF/p52 or 
LEDGF/p52b respectively, whilst grey and blue peaks indicate fluorescence using the 
same primer pairs with HEK293 cDNA. 
 
Analysis of the melt curve indicated that the read temperature could be increased 
to 80 °C and this was used in subsequent reactions. 
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3.3.8. RT-qPCR screening of CLL cases for the relative expression levels of 
the LEDGF isoforms and comparison to normal B cells 
These optimised RT-qPCR conditions were then used to determine the expression 
levels of the various isoforms of LEDGF in CLL cells. Due to limited sample 
availability only a proportion (46) of the 78 cases already examined by RT-PCR, plus 
three normal B cell controls were used. The relative level of each isoform was 
determined by comparison to the level of expression of a reference gene, RPL27. On 
each separate RT-qPCR plate, a sample of HEK293 cell line cDNA was included. In 
addition to acting as a positive control, this allowed the normalisation of Ct values 
across the plates so they could be compared across the cohort. Figure 3-12 shows a 
representative example of the PCR products obtained from the analysis of the RT-
qPCR performed on these cases.  
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Figure 3-12: Representative image from the RT-qPCR screening of CLL cDNA 
samples. 
CLL cDNA samples were examined for the expression of the four isoforms of LEDGF 
by RT-qPCR. Products were analysed by agarose gel electrophoresis to ensure a 
single product is amplified by each primer pair. The products amplified using primer 
specific for LEDGF/p75 are shown at the top, followed by those for LEDGF/p52, then 
LEDGF/p52b and finally LEDGF/p52bΔE6. The sample numbers (CLL samples and 
normal B (NB)) that had been analysed for the particular isoform are shown. 
 
To determine the relative expression level of each isoform compared to the 
reference gene RPL27, the average Ct value of the three replicates was calculated. 
The ΔCt value was then calculated by subtracting the average Ct value of the 
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reference gene (RPL27), from the average Ct value of the gene of interest (isoform 
of LEDGF). The ΔCt values were calculated for all of the cDNA samples including the 
HEK293 cell line cDNA control.  
 
ΔCt(isoform X) in sample Y=Ct(LEDGF isoform) –Ct(reference gene) 
The ΔΔCt value for each of the isoforms in each CLL sample was then calculated 
using the formula: 
ΔΔCt(isoform X) in sample Y= ΔCt(sample) - ΔCt(HEK293) 
Relative expression of isoform X in sample Y=2(-ΔΔCt) 
 
An example of the results obtained for the LEDGF/p75 isoform is shown in Table 
3-6.  
 
 
 
 
 
 
 
74 
 
Sample Gene Ct RPL27 Ct ΔCt Relative expression 
HEK293 cDNA 22.47 19.2 3.27   
2408 24.76 19.84 4.92 0.3186 
2539 26.96 20.4 6.56 0.1022 
2472 25.08 19.54 5.54 0.2073 
2744 25.48 20.38 5.1 0.2813 
 
Table 3-6: Representative example of the calculation of ΔCt and relative 
expression values.  
Using data from analysis of the expression of LEDGF/p75 in CLL cDNA samples and 
HEK293 cell line cDNA, the ΔCt value (column 4) is calculated by subtracting the Ct 
of the value of the RPL27 (reference gene, column 3) from the Ct value of the 
LEDGF/p75 (column 2). The relative expression (final column) is then determined by 
ΔΔCt(isoform X) in sample Y= ΔCt(sample) - ΔCt(HEK293) and Y=2
(-ΔΔCt). The relative expression 
of LEDGF/p75 was calculated for CLL samples detailed in column 1. 
 
The ΔΔCt values for each isoform were then organised into ascending order and 
presented in a graphical form (Figure 3-13 - Figure 3-16). 
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CLL case 
Levels of p75 relative to RPL27 
Figure 3-13: The expression levels of LEDGF/p75 in CLL cases and three normal B cell (NB) controls.  
The relative expression of LEDGF/p75 in the cases was determined by RT-qPCR and is relative to the expression of the reference gene RPL27. 
The expression is presented in increasing order. 
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CLL case 
Levels of p52 relative to RPL27 
 
Figure 3-14: The expression levels of LEDGF/p52 in CLL cases and three normal B cell (NB) controls.  
The relative expression of LEDGF/p52 in the cases was determined by RT-qPCR and is relative to the expression of the reference gene RPL27. 
The expression is presented in increasing order. 
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CLL case 
Levels of p52b relative to RPL27  
 
  
Figure 3-15: The expression levels of LEDGF/p52b in CLL cases and three normal B cell (NB) controls.  
The relative expression of LEDGF/p52b in the cases was determined by RT-qPCR and is relative to the expression of the reference gene RPL27. 
The expression is presented in increasing order. 
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CLL case 
Levels of p52bΔE6 relative to RPL27 
Figure 3-16: The expression levels of LEDGF/p52bΔE6 in CLL cases and three normal B cell controls.  
The relative expression of LEDGF/p52bΔE6 in the cases was determined by RT-qPCR and is relative to the expression of the reference gene 
RPL27. The expression is presented in increasing order. 
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The results show that the range of the normalised ΔΔCt values for each isoform is 
variable. Thus, whilst the values for LEDGF/p75 show the narrowest range (0.028 to 
1.101), the largest range comes from p52 at 0.0254 to 23.263. LEDGF/p52bΔE6 and 
LEDGF/p52b show intermediate ranges of expression (0.018 to 5.351 and 0.018 to 
7.568 respectively). 
The levels of each LEDGF isoform in the CLL cDNA cases were then compared to the 
levels in ‘normal’ B cells (3292, 3293 and 3294) using SPSS Statistics 20 software. 
The results obtained using a Non-parametric Mann-Whitney U Test are shown in 
Table 3-7. 
Isoform P-value Significance 
LEDGF/p75 0.000 Significant 
LEDGF/p52 0.511 Not-significant 
LEDGF/p52b 0.069 Not-significant 
LEDGF/p52bΔE6 0.008 Significant 
 Confidence interval level=95%, α=0.05. 
Table 3-7: Comparison of the differential expression of the various LEDGF isoforms 
between CLL and normal B cells.  
Two of the four isoforms of LEDGF appear to be significantly differentially expressed 
between CLL cases and normal B cells. Specifically, LEDGF/p75 is significantly over 
expressed in CLL cases whilst LEDGF/p52bΔE6 is significantly under expressed in CLL 
cells compared to normal B cells. 
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The results show that the expression levels of the LEDGF isoforms differ between 
CLL and normal B cells. LEDGF/p75 appears to be the lowest expressed isoform in 
normal B cells (Figure 3-13), closely followed by LEDGF/p52b (Figure 3-15) then 
LEDGF/p52 (Figure 3-14). The highest expressed isoform in normal B cells was found 
to be LEDGF/p52bΔE6 (Figure 3-16).  
When analysing the levels of the isoforms in CLL cells compared to their levels in the 
normal B cells, LEDGF/p75 is significantly over expressed in CLL cells compared to 
normal B cells and LEDGF/p52bΔE6 is significantly under expressed in CLL cells 
compared to normal B cells (Table 3-7). Although the difference between 
LEDGF/p52b expression in normal B cells and CLL cells isn’t statistically significant 
(Table 3-7), there is a trend which suggests that this isoform is expressed at greater 
levels in CLL cases compared to normal B cells (Figure 3-15). In contrast, the results 
show that the level of expression of LEDGF/p52 observed in normal B cells is 
randomly distributed within the range seen in CLL cells (Figure 3-14). 
 
3.3.9. Analysis of protein levels of LEDGF isoforms. 
Having determined that LEDGF is differentially expressed at the mRNA level, it was 
felt that it was important to confirm protein translation of the different isoforms. 
Therefore, a western blot was performed on cell line lysates which was probed with 
an antibody that recognises residues 85 to 136 which is common to all of the 
isoforms discussed.  
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Figure 3-17: Western blot analysis of cell line lysates to examine the 
presence/absence of the four LEDGF isoforms.  
Varying amounts (10-40 μg) of whole cell lysates from 293T and Mec-1 cells were 
run on a 10% resolving, 4% stacking gel. The proteins were transferred to PVDF 
membrane and the membrane probed using α-PSIP1 antibody (Aviva, Rabbit 
polyclonal, 1.25:1000). The levels at which a band of 75 kDa was expected, is 
highlighted. 
  
As shown in Figure 3-17, a band of 75 kDa which would correspond to LEDGF/p75 
was not detected, even when large amounts of lysates were analysed. In order to 
verify the presence of LEDGF protein, 10 µg of the same 293T lysate plus that from 
HeLa cells was analysed by western blotting and probed using an alternative 
antibody (α-LEDGF, BD Biosciences, Mouse monoclonal, 1:4000) that should detect 
LEDGF/p75. The result shows that LEDGF protein is present in these lysates (Figure 
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3-18) and suggests that the first antibody, which should detect all four isoforms of 
LEDGF, is not suitable for this study. 
 
 
Figure 3-18: Western blot analysis of cell line lysates to examine the 
presence/absence of LEDGF isoforms. 
10 μg of whole cell lysates from 293T and HeLa cells were run on a 10% resolving, 
4% stacking gel. The proteins were transferred to PVDF membrane and the 
membrane probed using α-LEDGF antibody (BD Biosciences, mouse monoclonal, 
1:4000). The bands in both lanes represent LEDGF/p75. 
 
3.3.10. Correlation between the expression levels of the LEDGF isoforms   
and clinical and prognostic factors. 
To help understand if there was a clinical significance to the different expression of 
the isoforms of LEDGF in CLL cells, the relationship between the expression of the 
isoforms and other clinical and prognostic factors was assessed (see Appendix B). 
Preliminary analysis suggested a possible link between the expression of LEDGF 
isoforms and the degree of CD38 expression. CLL cells are classed as CD38+ if over 
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30% of the total B-cells are CD38+, and negative if less than 30% are CD38+83. 
Therefore, the data relating to the expression of CD38 (a variable data set) was 
modified to be a categorical data set and samples were denoted positive or 
negative for CD38 expression. With this modification to the data, the relationship 
was re-evaluated and the results are shown in Figure 3-19. 
 
 
Figure 3-19: Correlation between the levels of expression of the LEDGF isoforms 
and CD38 expression.  
ANOVA tests were employed to determine the correlation between the expression 
levels of the isoforms of LEDGF and CD38 expression. 
 
The results show that in patients whose CLL cells are CD38 positive, although not 
significant, levels of mRNA for all LEDGF isoforms are generally higher compared to 
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those whose cells are CD38 negative (LEDGF/p75 (p=0.07), LEDGF/p52 p=0.06, 
LEDGF/p52b p=0.13 and LEDGF/p52bΔE6 p=0.40).  
 
3.4. Discussion 
With current treatment strategies, CLL remains incurable. Thus, there remains the 
need to identify potential new drug targets. One proposed target is LEDGF, of which 
several isoforms have been described. The aims of this chapter were five fold. 
Firstly, I set out to identify which of the reported isoforms of LEDGF are expressed 
in CLL cells using end point PCR. Secondly, having identified which of the isoforms 
are expressed, I used quantitative RT-qPCR to determine the relative levels of each 
isoform compared to the reference gene RPL27. Thirdly, the levels of the LEDGF 
isoforms expressed in CLL were compared to normal B cells. I then attempted to 
identify a suitable antibody that could be used to determine the protein levels for 
the different isoforms expressed in CLL. Finally, I analysed the data to see if there 
was any correlation between the expression of the different isoforms in CLL and any 
of the prognostic factors used in CLL.  
The results demonstrated that of the 6 isoforms of LEDGF described by Huang et 
al.57, only 4 were detected in CLL cells. Thus, LEDGF/p75, p52, p52b and p52bΔE6 
were detected by RT-PCR. However, not all isoforms were detected in all of the CLL 
cases examined. Of the 78 samples included in the study using end-point PCR, 10 
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did not appear to express p75, 11 did not express p52, p52b was not detected in 2 
cases whilst the p52Δe6 isoform was not detected in 13 cases (Table 3-5).  
Whilst RT-PCR can determine the presence or absence of a particular LEDGF 
isoform, it does not provide a relative level of expression of one isoform compared 
to another or the level of expression of a particular isoform in different samples. 
Therefore, a quantitative PCR approach was employed. Results from this analysis 
showed that LEDGF/p75 has the smallest range of expression between the CLL cases 
examined (Figure 3-13). This is in contrast to LEDGF/p52 which had a wide range of 
expression levels (Figure 3-14). Using the NB4 AML cell line, Huang et al. suggested 
that the LEDGF/p52b isoform of LEDGF is more highly expressed than the 
LEDGF/p52bΔE6 isoform57. However, analysis of these 2 isoforms in CLL does not 
fully support this hypothesis. In CLL, the level of expression of LEDGF/p52b is more 
variable than seen for p52bΔE6, and is not simply expressed at a higher level. 
The expression levels of the 4 different isoforms of LEDGF identified in CLL cells 
were also examined in normal B cells. Levels of the LEDGF/p75 isoform were very 
consistent and were lower than the levels seen in CLL cells, and this difference was 
statistically significant (p=0.000) (Figure 3-13, Table 3-7). As was seen for 
LEDGF/p75, the levels of LEDGF/p52b were fairly consistent between samples 
(Figure 3-15), unlike LEDGF/p52 which showed a wide variation in expression 
between the different samples (Figure 3-14). Within each normal B sample, levels of 
both LEDGF/p52 and p52b were higher than that seen for LEDGF/p75, although 
levels of LEDGF/p52b were lower than LEDGF/p52. However, this was not the case 
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for the CLL samples, as there was no correlation observed as regards levels of 
expression of each of the isoforms. Interestingly, LEDGF/p52bΔE6, which was 
reported by Huang et al. to have the lowest level of expression in AML57, actually 
had the highest average level of expression amongst the normal B cell samples 
(Figure 3-16). 
Analysis of the RT-qPCR results using SPSS Statistics 20 software showed that of the 
four isoforms, LEDGF/p75 was significantly over expressed in CLL cases compared to 
Normal B cells (p=0.000), whilst LEDGF/p52bΔE6 was significantly under expressed 
in CLL cases compared to Normal B cells (p=0.008) (Table 3-7). Even though the 
expression of LEDGF/p52b isn’t significantly different between CLL and normal B 
cells, the general trend is that the levels are higher in CLL (Figure 3-15). In contrast 
to these isoforms, the expression level of LEDGF/p52 was shown to be highly 
variable in both normal B and CLL cells and there doesn’t appear to be any 
trend/pattern associated with the levels of expression of this variant (Figure 3-14). 
These results are in agreement with the conclusion of both Basu et al. and Daugaard 
et al. that over expression of LEDGF/p75 mRNA may be a general feature of 
cancer81, 82. 
Even though the significant over expression of LEDGF/p75 in CLL is in accordance 
with the literature, specifically, that this isoform is over expressed in many cancers, 
caution should be employed with this study due to the low number of normal B cell 
control samples (n=3) included. The normal B cell control samples are obtained 
from healthy volunteers and are therefore in limited supply. However, it should be 
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noted that the normal B cell samples used within this study were all processed in 
the same way, as where the cohort of the CLL samples (a departmental standard 
operating procedure governs the processing of all blood samples). As there was not 
one single or group of samples who all exhibited the same pattern in isoform 
expression a batch effect is not considered a major variable.  
Due to the exploratory nature of this study, no formal a-priopi power analysis was 
performed to determine the appropriate sample size; essential information such as 
population variance estimates and effect size could not be determined prior to the 
study. Instead, a sample cohort of convenience was used due to their availability. A 
retrospective or observed power analysis was not performed due to 
inappropriateness; post-hoc power procedures incorporate improper calculations of 
a probability and do not add to the interpretation of the results since the observed 
power is completely determined by the observed p-value.  
Over expression of the p52bΔE6 isoform in HEK293 cells has been shown to 
increase apoptosis, whilst in contrast, over expression of the p52b variant in the 
same cells appeared to increase viability57. It would therefore appear that deletion 
of exon 6 imparts a pro-apoptotic phenotype on LEDGF. As the results presented in 
this thesis have shown that the expression levels of LEDGF/p52bΔE6 are generally 
lower in CLL compared to normal B cells, this would suggest that the pro-apoptotic 
function of this LEDGF variant is reduced in CLL cells, and hence provide CLL cells a 
mechanism to evade cell death. 
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LEDGF/p75 has been suggested to be a cancer associated protein. As discussed, it is 
involved in translocations involving the NUP98 protein and has an increased mRNA 
and protein expression in a variety of cancers. It is also part of the MLL complex 
(reviewed in chapter 1 and 5) that targets the complex to chromatin to regulate 
expression of HOX genes. The data presented in this thesis further supports the 
theory that LEDGF is a cancer associated protein. 
Recent evidence indicates that augmented states of cellular oxidative stress 
contribute to the development of cancers82, 84. LEDGF/p75 is a known stress-
response protein that binds to STRE and HSE and activates expression of a number 
of stress response genes, thus protecting mammalian cells against oxidative and 
environmental stressors and promoting cell survival. Thus, it has been shown 
LEDGF/p75 over expression protects cells against serum starvation85 as well as 
thermal and oxidative stress1. The data presented by Singh et al. suggests that this 
resistance could be caused by the LEDGF/p75 dependent over expression of heat 
shock proteins, namely Hsp27 and αβ-crystallin1. An increased expression level of 
LEDGF/p75 mRNA has been demonstrated in murine lens epithelial cells and Cos7 
cells following heat and oxidative stress86. Concomitant to this was an increase in 
the levels of LEDGF/p75 protein but not LEDGF/p52. LEDGF/p75 has also been 
shown to have a protective role in human retinal pigment epithelial cells exposed to 
UVB radiation via the up-regulation of Hsp27 expression87. Recent evidence 
suggests that CLL cells are under oxidative stress88. Given that it has been shown 
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that low/absent levels of LEDGF/p75 result in cell death85 the data suggests that an 
over expression of p75 would provide an anti-apoptotic function to CLL cells. 
Three of the isoforms of LEDGF that were identified as being expressed in CLL share 
a common amino terminal sequence. Thus, LEDGF/p75, p52 and p52b are identical 
up to and including exon 9. The C-terminal tails of both LEDGF/p52 and p52b are 
derived from within an intron of the LEDGF/p75 isoform. The predicted molecular 
mass of p75 is 60 kDa, whilst for p52b and p52 it is 40 and 38 kDa respectively. 
However, western blot analysis shows that LEDGF/p75 and LEDGF/p52 run with 
apparent molecular weights of 75 and 52 kDa28. This anomaly suggests the proteins 
are significantly modified post translationally.  
The fourth isoform detected in CLL was the LEDGF/p52bΔE6. As this isoform has a 
complete deletion of exon 6, it alters the reading frame of the mRNA sequence and 
results in a premature stop codon after residue 167. The resulting truncated protein 
would have a predicted molecular mass of 19 kDa. The deletion of exon 6 and 
subsequent alteration of the reading frame disrupts the end of the NLS and 
abolishes the AT hooks and CR2 and 3 that is common to the other isoforms 
(including LEDGF/p52b). If this isoform undergoes significant post translational 
modification, it is difficult to predict what the apparent molecular weight of the 
protein would be on a western blot. 
An attempt was made to analyse the expression of the 4 isoforms of LEDGF in CLL 
cells by western blot, but this proved unsuccessful. Western blot of LEDGF isoform 
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expression in CLL would be predicted to show a ‘ladder’ effect if each of the 
isoforms was present in the particular sample being analysed. LEDGF/p75 would be 
the largest isoform so would be the top of the lane, followed by p52b, then p52 
and, finally, p52bΔE6 as this has the lowest molecular weight. The antibody used in 
this investigation was raised against an immunogen of residues 1-51 which was 
common to LEDGF/p75, p52, p52b and p52bΔE6. To confirm the specificity of the 
antibody, a western blot was performed using a lysate from 293T cells as 
LEDGF/p75 had been shown to be present in this cell line29. However, the western 
blot (Figure 3-17) failed to show the presence of a band at 75 kDa in either of the 
cell lysates tested, even when high levels of protein were loaded. A subsequent blot 
(Figure 3-18) using the same 293T lysate (plus an additional lysate from HeLa cells) 
that was probed with a different antibody (immunogen of  residues 85-188) that 
would detect the p75 isoform (as well as LEDGF/p52 and p52b), showed the 
presence of a band that would represent LEDGF/p75 in these cell lines.  
As a positive band at 75 kDa could not be identified in the 293T lysate using the 
antibody predicted to detect the four isoforms I have described in CLL, the double 
bands present in the 293T cell lysates at 37 and ~45 kDa cannot be assigned to any 
of the isoforms with any certainty (Figure 3-17). 
There has been a flow cytometry and indirect intracellular staining method 
developed by Mous and colleagues to examine the expression levels of LEDGF89. 
However, the antibody used for the assay has an immunogen common to both 
LEDGF/p75 and p52 (and in theory p52b). Thus, in this assay it would be difficult to 
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distinguish between the level of expression of each individual isoform and indeed, 
analysis of cell lysates showed the presence of several bands on western blot89. 
Therefore, these methods would not be suitable to analyse the protein levels of 
each isoform in CLL cells due to their ability to detect at least two of the main 
isoforms of LEDGF.  
It has been shown in this chapter that the levels of the LEDGF/p75 and p52bΔE6 are 
differentially expressed between CLL cells and normal B cells. Thus, CLL cells over 
express LEDGF/p75, whilst under expressing p52bΔE6, and although not significant, 
there is a trend to suggest that LEDGF/p52b is also over expressed in CLL cells. In 
addition to this, I have shown that there is a trend for patients who are CD38 
positive to have a higher level of expression of each of the isoforms of LEDGF 
(Figure 3-19).  
LEDGF/p75 has been shown to be over expressed in chemotherapy resistant and 
relapsed AML patients, and its effect on chemotherapy resistance was 
demonstrated by exogenous over expression in HEK293 cells which led to a 
reduction in daunorubicin induced apoptosis57. The report showed that expression 
of LEDGF/p52b also had a similar effect. Whilst this report demonstrated that 
expression of LEDGF/p52ΔE6 leads to an increase in spontaneous apoptosis, this 
effect was shown to be negated by co-expression of LEDGF/p75. The authors 
concluded that expression of LEDGF/p75 and p52b protects AML cells against 
spontaneous and drug induced cell death in vitro, and suggest that over expression 
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of these LEDGF isoforms in primary AML cells that are resistant to therapy is not 
coincidental. 
The results from this thesis showing that CD38 positive CLL cells tend to have 
increased levels of all LEDGF isoforms support this suggestion. CD38 is a receptor 
that has been shown to cause an induction of proliferation and increased cell 
survival in CLL90, and expression of this receptor has been associated with the 
aggressive form of CLL, a poor response to chemotherapy and a shorter survival 
time90, 91. Thus, those cases of CLL that are more likely to be resistant to 
chemotherapy are those that express the higher levels of LEDGF. 
 
Future work 
Even though differences in expression of two of the isoforms of LEDGF have been 
shown to be statistically significant between normal B cells and CLL cells (namely 
LEDGF/p75 and LEDGF/p52bΔE6), this was not the case for LEDGF/p52b. However, 
there is a definite trend in the data suggesting that LEDGF/p52b is over expressed in 
CLL (Figure 3-15). In order to see if this trend is true and does become significant, a 
greater number of normal and CLL cases could be screened. 
It will be necessary to confirm whether the differences in the level of expression of 
the isoforms identified by RT-qPCR are mirrored by the levels protein expression. 
However, a suitable antibody that is capable of detecting all of the isoforms by 
western blot, or several antibodies capable of distinguishing each of the isoforms by 
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flow cytometry would be required. Suitable positive controls would also be 
required, although this issue could be overcome for western blotting through the 
use of purified over expressed recombinant proteins.  
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Chapter 4 : Mutational 
Analysis of SF3B1 and 
Correlation with LEDGF 
Isoform Expression 
 
4.1. Introduction 
In 2012, Quesada and colleagues published results of a study in which they 
performed whole-exome sequencing on matched tumour and normal samples from 
105 CLL cases70. Of these, 60 were IGHV mutated cases whilst the remaining 45 
were unmutated cases. They identified 78 genes that had mutations that could 
potentially lead to functional alterations which were present in more than one 
sample. One of the genes shown to be recurrently mutated in CLL is SF3B1, which 
forms part of the catalytic core of the splicing machinery. 
Two further published reports confirmed that SF3B1 is recurrently mutated in CLL 
cells. Furthermore, it was demonstrated that SF3B1 mutations were frequently 
encountered in patients refractory to treatment with fludarabine or those with 
progressive disease71, or in patients with deletions of 11q, who generally have a 
poor prognosis63. 
These mutations of SF3B1 in CLL patients are clustered within the HEAT repeats 
located within the C-terminal region of the protein63, 70. One very interesting point 
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from these reports was the link between the mutational status of SF3B1 with the 
splicing pattern of other mRNAs within the cell.  
One of the genes predicted to be alternatively spliced between SF3B1 mutated and 
unmutated cases is LEDGF/p75 (NM_033222) (p= 0.0001)70. Having demonstrated 
that CLL cells express different isoforms of LEDGF, and that these were differentially 
expressed between CLL cases (see Chapter 3 for results), it was felt pertinent to 
examine the mutational status of the SF3B1 gene in the same cohort of patient 
samples. 
The aims of this chapter, therefore, were: 
1. Using RT-PCR and Sanger sequencing, determine the mutational status of 
the HEAT repeat region of SF3B1, in the cohort of CLL samples that were 
examined for LEDGF expression in Chapter 3. 
2. To determine if there is any correlation between the mutational status of 
SF3B1 and the differential expression of the LEDGF isoforms identified in 
chapter 3. 
3. To investigate the potential clinical implications of the mutational profiles in 
CLL. 
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4.2. Methods 
4.2.1. Primer design 
Given that the PCR products were going to be sequenced and the limitations with 
this method for long amplicons, it was deemed necessary that the region of interest 
be amplified as two separate products. Using this approach, the main recurring 
mutational hotspots that have been previously reported (namely nucleotides 
around residues 625 and 666, and 70065) would be in the centre of the regions to be 
sequenced allowing for greater confidence in the results. Therefore, 2 sets of PCR 
primers (Table 4-1) were designed around the HEAT regions based on the sequence 
NM_012433.2 (NCBI reference). The mRNA sequence for exons 11-17, which 
contains the HEAT repeat regions is shown below (Figure 4-1). This region contains 
the most commonly reported mutations. 
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Primer name Primer sequence 
SF3B1pcr507-693F caccaccaatgagaaaggctg 
SF3B1pcr507-693R gctcatccacaagaccatgttc 
SF3B1pcr600-823F gcaaaggctgctggtctgg 
SF3B1pcr600-823R catcctgtgctgccagaagtg 
 
Table 4-1: Sequences of RT-PCR primers used to screen the SF3B1 gene.  
Both primer pairs are designed to the HEAT repeat region of the gene. Specifically, 
the top primer pair will amplify the region from amino acid 507 to 693 and the 
bottom pair will amplify the region from amino acid 600 to 823. The primers will be 
used in separate reactions. 
 
 
 
 
 
 
 
 
98 
 
GTTGATGTTGATGAATCAACACTTAGTCCAGAAGAGCAAAAAGAGAGAAAAATAATGAAGTTGCTTTT
AAAAATTAAGAATGGAACACCACCAATGAGAAAGGCTGCATTGCGTCAGATTACTGATAAAGCTCGTG
AATTTGGAGCTGGTCCTTTGTTTAATCAGATTCTTCCTCTGCTGATGTCTCCTACACTTGAGGATCAA
GAGCGTCATTTACTTGTGAAAGTTATTGATAGGATACTGTACAAACTTGATGACTTAGTTCGTCCATA
TGTGCATAAGATCCTCGTGGTCATTGAACCGCTATTGATTGATGAAGATTACTATGCTAGAGTGGAAG
GCCGAGAGATCATTTCTAATTTGGCAAAGGCTGCTGGTCTGGCTACTATGATCTCTACCATGAGACCT
GATATAGATAACATGGATGAGTATGTCCGTAACACAACAGCTAGAGCTTTTGCTGTTGTAGCCTCTGC
CCTGGGCATTCCTTCTTTATTGCCCTTCTTAAAAGCTGTGTGCAAAAGCAAGAAGTCCTGGCAAGCGA
GACACACTGGTATTAAGATTGTACAACAGATAGCTATTCTTATGGGCTGTGCCATCTTGCCACATCTT
AGAAGTTTAGTTGAAATCATTGAACATGGTCTTGTGGATGAGCAGCAGAAAGTTCGGACCATCAGTGC
TTTGGCCATTGCTGCCTTGGCTGAAGCAGCAACTCCTTATGGTATCGAATCTTTTGATTCTGTGTTAA
AGCCTTTATGGAAGGGTATCCGCCAACACAGAGGAAAGGGTTTGGCTGCTTTCTTGAAGGCTATTGGG
TATCTTATTCCTCTTATGGATGCAGAATATGCCAACTACTATACTAGAGAAGTGATGTTAATCCTTAT
TCGAGAATTCCAGTCTCCTGATGAGGAAATGAAAAAAATTGTGCTGAAGGTGGTAAAACAGTGTTGTG
GGACAGATGGTGTAGAAGCAAACTACATTAAAACAGAGATTCTTCCTCCCTTTTTTAAACACTTCTGG
CAGCACAGGATGGCTTTGGATAGAAGAAATTACCGACAG 
 
Figure 4-1: mRNA sequence of SF3B1 exons 11-17.  
The mRNA sequence is to the SF3B1 gene, NM_012433.2 (NCBI reference) and is 
part of the HEAT repeat region. Each exon is highlighted by a colour change (blue to 
black). Primers pair are highlighted in yellow (SF3B1pcr507-693F and R) or red 
(SF3B1pcr600-823F and R). The mutational hotspots at amino acids 625, 666 and 
700, are underlined. 
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4.2.2. Optimisation of PCR reaction conditions 
Reaction parameters where optimised as described in Chapter 2.2.3 using an 
annealing temperature gradient of 57 – 67 °C. For these optimisations, cDNA from 
HEK293 cells was used as template and a negative control in the form of NFW was 
included. PCR products were analysed by electrophoresis on 2% agarose gels as 
described in Chapter 2.2.4 and the annealing temperature determined by 
visualisation of the gel. A sample of the PCR product amplified at the chosen 
annealing temperature for each primer pair was purified from the agarose gel as 
described in Chapter 2.2.5 and sequenced as described in 2.2.10.  
 
4.2.3. Analysis of the mutation status of the HEAT repeats of the SF3B1 
gene 
CLL cDNA samples that had been analysed for the presence or absence of the LEDGF 
isoforms (see Chapter 3) were screened to determine the mutational status of the 
HEAT repeats of the SF3B1 gene.  
To determine if there was a correlation between the relative levels of LEDGF and 
the mutational status of the SF3B1 gene, statistical analysis was performed by Dr 
Fotis Polydoros. ANOVA tests were performed using the STATA version 13 statistical 
software package. Data was presented in the form of boxplots. In addition, the 
relationship between the mutational status of the SF3B1 gene and other clinical 
factors (for example age) was also investigated. 
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4.3. Results 
4.3.1. Optimisation of RT-PCR conditions 
Using cDNA generated from HEK293 cell line, the annealing temperatures for the 
primer pairs SF3B1pcr507-693F and SF3B1pcr507-693R; and SF3B1pcr600-823F and 
SF3B1pcr600-823R (Table 4-1) were determined and shown to be 64 °C and 67 °C 
respectively (Figure 4-2).  
 
 
Figure 4-2: Optimisation of PCR annealing temperature. 
PCR reactions were performed using cDNA from HEK293 cells with a range of 
annealing temperatures with primer pairs SF3B1pcr507-693F and SF3B1pcr507-
693R (upper panel) and SF3B1pcr600-823F and SF3B1pcr600-823R (lower panel). 
Reactions were analysed by agarose gel electrophoresis and the annealing 
temperature determined visually (indicated by arrows). Specifically, the annealing 
temperature chosen for primer pair SF3B1pcr507-693F and SF3B1pcr507-693R was 
64 °C and for SF3B1pcr600-823F and SF3B1pcr600-823R was 68 °C. 
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4.3.2. Determination of the mutational status of SF3B1  
Utilising the chosen reaction conditions described above, the HEAT repeat region of 
interest of SF3B1 was amplified by PCR using cDNA samples from the same cohort 
of CLL cases used in Chapter 3. Figure 4-3 shows a representative gel of PCR 
products amplified with each primer set. 
 
 
Figure 4-3: Representative image of the PCR amplification of the HEAT region of 
the SF3B1 gene in CLL cells. 
Primer pairs SF3B1pcr507-693F and SF3B1pcr507-693R (upper panel) and 
SF3B1pcr600-823F and SF3B1pcr600-823R (lower panel) were used to amplify the 
HEAT repeat region from the SF3B1 gene in a cohort of CLL cDNA samples 
(numbered). RT-PCR reactions were analysed by agarose gel electrophoresis and 
bands purified and sequenced as described.  
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The sequences of the PCR products were analysed using Chromas Lite software and 
compared against the published sequence of the SF3B1 gene (Figure 4-1). Chromas 
traces for those samples in which mutations were identified are shown in Figure 
4-4. The results identified SF3B1 gene mutations in 13 of the 75 CLL samples 
analysed (17%) which is a similar incidence as has been previously reported65. With 
the exception of one case, all of the mutations identified were missense mutations, 
with the most common resulting in changes to amino acids 663 (n=2), 636 (n=2), 
666 (n=2), 684 (n=2) and 700 (n=2). In four patients within this cohort, two 
concurrent mutations within the HEAT repeat region of SF3B1 were identified 
(Figure 4-4 and Table 4-2). Unlike previous reports, deletion mutations were not 
identified92. In sample 2230, a nonsense mutation (Q659stop) was identified (Figure 
4-4, Table 4-2). This mutation is a novel finding and has not been previously 
described. This mutation, if translated, would result in a truncated SF3B1 protein 
lacking 646 amino acids from the carboxy terminus. 
A summary of the amino acid changes that would occur as a result of the mutations 
identified in this study is given in Table 4-2. 
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CLL case Mutation status Nucleotide change 
2408 T663I c.1988C>T 
2358 T663A c.1987A>G 
2472 R630K, A636S c.1889G>A, c.1906G>T 
2230 Q659Stop, R661I c.1975C>T, c.1982G>T 
2789 N533Y, A660V c.1597A>T, c.1979C>T 
2793 K666N c.1998G>T 
2843 R684T c.2051G>C 
2877 R684I c.2051G>T 
3160 K666E c.1996A>G 
2999 K700E c.2098A>G 
3071 K700E c.2098A>G 
2674 A636T/P, P642S c.1906G>C/A, c.1924C>T 
2539 G742D c.2225G>A 
 
Table 4-2: Summary of the inferred amino acid change in the SF3B1 gene.  
The CLL case shown to have the mutation in their SF3B1 gene is in the left hand 
column. The second column details the amino acid that is subject to the change and 
what the change is. More specifically, column three details the nucleotide that is 
changed that causes the change in amino acid. 
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Figure 4-4: Chromas traces of the SF3B1 gene sequences that contain point 
mutations. 
In each trace, the amino acid sequence that is mutated is highlighted by a red box. If 
the peaks are a mixture of two, ie, the mutation is heterozygous, an ‘N’ is used. If 
there is one single peak representing one nucleotide, that peak is described 
specifically.  
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4.3.3. Analysis of the potential truncated protein 
One of the SF3B1 mutations identified in this study was a previously unreported 
nonsense mutation that introduced a premature stop codon at nucleotide 1975. 
Translation of the mRNA containing this mutation would result in the expression of 
a truncated SF3B1 protein. To determine if this was the case, a western blot was 
performed (Chapter 2.3.1 and 2.3.2) using whole cell lysate of this sample, along 
with that from a CLL case shown to have wild type SF3B1 gene and a positive 
control (Jurkat cell lysate). The full length SF3B1 protein is 1304 amino acids long 
and runs with an apparent molecular weight of 155 kDa. The predicted truncated 
protein produced would be 658 amino acids and would therefore be predicted to 
have an apparent molecular weight of ~75 kDa. The results are given in Figure 4-5. 
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Figure 4-5: Western blot analysis of whole cell protein lysates of CLL cases 2230 
and 2418 and the Jurkat cell line.  
10 μg of whole cell lysate from two CLL cases (one with the potential nonsense 
mutation in the SF3B1 gene (2230) and one with wild type SF3B1 gene (2418)) and a 
jurkat cell line (positive for SF3B1) was run on a 10% resolving and 4% stacking gel. 
Proteins where transferred to PVDF membrane. The membrane was probed with 
anti-SF3B1 antibody (Abcam, Mouse monoclonal, 1:2500) (top). The highlighted 
area where the putative truncated protein is expected to run is shown in the 
enlargement (bottom). A band with the predicted molecular weight is highlighted 
by an arrow. 
 
107 
 
In all three cell lysates, there is a band at 155 kDa which represents the wild type 
SF3B1 protein (upper panel, Figure 4-5) showing that the western blot has worked 
successfully. The area around the 75 kDa mark has been enlarged for the two CLL 
cases (lower panel, Figure 4-5). The predicted molecular weight of the truncated 
protein would be approximately 75 kDa. There is a weak band (indicated by the 
arrow) running at this molecular weight that is present in sample 2230 (mutated 
SF3B1) that is much less apparent in sample 2418 (wild type SF3B1). This difference 
is not likely due to uneven loading of the sample, as the blot for β-actin indicates 
protein loading for each sample was similar. However, as can be seen in the upper 
blot, bands of a similar molecular weight are also seen in lysate from Jurkat cells, 
although due to the level of reactivity, visualisation of a discrete band is difficult. 
Therefore, it is difficult to confirm with any degree of certainty that a truncated 
SF3B1 protein is expressed in this CLL sample.  
 
4.3.4. Correlation between SF3B1 mutation and LEDGF isoform 
expression 
It has previously been suggested that mutations within the SF3B1 gene could affect 
splicing of the LEDGF pre-mRNA70. In Chapter 3, it was shown that CLL cells express 
different isoforms of LEDGF, and the results from Chapter 3 demonstrate that some 
of these same cases of CLL have mutations within the SF3B1 gene. The relationship 
between the presence of these mutations and the LEDGF isoform expression was 
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therefore investigated. In addition, the relationship between the mutation status of 
the SF3B1 gene and clinical factors (for example age) was also investigated. 
The results show that samples with unmutated SF3B1 generally have higher levels 
of all isoforms of LEDGF (Figure 4-6). However, the differences did not reach 
statistical significance. 
 
Figure 4-6: Correlation analysis of SF3B1 mutational status and LEDGF isoform 
expression. 
ANOVA tests were employed to determine the correlation between the relative 
expression of the isoforms of LEDGF and the mutation status of the SF3B1 gene. 
Data was presented in the form of box plots. The correlation between CD38 
expression and the relative expression of each isoform is considered individually. 
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The results, although not significant, suggest that mutations of SF3B1 do affect the 
expression of LEDGF. However, this effect is not specific to one isoform, as the 
levels of all isoforms are reduced in mutated SF3B1 samples. There remained the 
possibility that samples with extreme relative expression values for LEDGF/p52 and 
p52b (see Chapter 3.3.8) were skewing the result and should be considered. There 
was no relationship between the mutation status of the SF3B1 gene and clinical 
factors (Appendix C). 
 
4.4. Discussion  
SF3B1 forms part of the splicing machinery, a complex that is involved in the 
catalytic removal of introns from pre-mRNA. Recent studies have demonstrated 
that SF3B1 is frequently mutated in CLL63, 70, 71, 93. Moreover, alterations in pre-
mRNA splicing in other genes has been suggested and identified in CLL cases 
harbouring SF3B1 mutations63, 70. One of the genes predicted to be affected by 
mutation of SF3B1 is LEDGF70. In the previous chapter, I showed that CLL cells 
differentially express four isoforms of LEDGF, including two novel isoforms not 
previously reported in CLL. It was therefore hypothesised that mutation of SF3B1 in 
CLL will affect the splicing, and hence isoform expression, of LEDGF in these cells. 
Therefore, cDNA samples that were used to examine the expression levels of the 
four isoforms of LEDGF (see Chapter 3) were screened for the mutational status of 
the HEAT repeats of SF3B1. The frequency of SF3B1 gene mutations within our 
cohort (17.3%) is in-line with published reports65.  
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The most commonly reported mutation is K700E (50% of reported mutations), with 
additional common mutations occurring at G742 (19%) and K666 (12%)94. That 
mutations at these sites are also identified in the cohort examined in this study 
(Figure 4-4 and Table 4-2) instils confidence in the results. In addition, four patients 
in this cohort had two concurrent mutations in their SF3B1 gene, and this 
phenomenon has previously been described in CLL64.  
Given that the aim of this work was to determine whether mutation of the SF3B1 
gene correlated with the isoform expression of LEDGF, it was sufficient to use RT-
PCR amplification and Sanger Sequencing to determine the presence of mutations 
in the SF3B1 gene. Sanger Sequencing has been shown to have a detectable 
mutation load of 5-10% (confirmed by concurrent analysis with Next Generation 
Sequencing)64. However, there is some variability in the mutation load detectability 
based on the actual platform used95. Next generation sequencing is known to be 
more sensitive (~3% depending on the read count) but as the work did not require 
the detection of novel mutations (although some have been found), analysis by this 
method would have been costly both in expense and time, was and hence was not 
pursued. 
It is expected that mutations within SF3B1 would impact on its normal function. In 
this study, it was found that threonine (a polar residue that can potentially be 
phosphorylated) at position 663 was changed to the hydrophobic residue isoleucine 
(sample 2408) or alanine (sample 2358). Thus, these mutations would not only 
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remove a potential phosphorylation site, but also alter the biochemical properties 
of the protein as a polar residue is replaced with a hydrophobic residue.  
In case 2472, two mutations were identified. The first is an arginine to a lysine 
change and the second an alanine to a serine alteration. Arginine and lysine are 
both positively charged amino acids, and hence the mutation is conservative. Both 
of these amino acids are likely involved in interactions with negatively charged 
ligands, but as lysine is slightly smaller than arginine, the size difference brought 
about by the change may have a functional effect. The alanine to serine change, 
however, is likely more significant. As discussed above, alanine is a small 
hydrophobic residue, whereas serine is polar and has a hydroxyl group as part of its 
chain. This mutation not only alters the biochemical characteristics of the protein 
but also introduces a potential phosphorylation site. Sample 2674 also has two 
mutations. Firstly alanine is mutated to either a threonine or a proline at residue 
636, whilst at residue 642 proline is mutated to a serine. The potential effects of a 
threonine/alanine alteration have already been discussed. Like alanine, proline is 
non-polar, and thus such a change will have no effect on charge. However, due to 
its ring like structure, proline can prevent some secondary structures (for example 
α-helices) from forming. Therefore, a mutation from alanine to proline will almost 
certainly have an effect on the tertiary structure of SF3B1. The second mutation in 
sample 2674 is the loss of a proline in favour of a serine at residue 642. Compared 
to proline, serine is polar, it is smaller and more flexible in its ability to interact with 
other residues and it also gives rise to an extra potential phosphorlyation site. 
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Like cases 2472 and 2674, case 2789 also has two mutations. At residue 533, an 
asparagine is replaced by a tyrosine. Asparagine and tyrosine are both polar. 
However, tyrosine is a bigger residue and contains an aromatic side chain with a 
joined hydroxyl group that is reactive. The change of asparagine to tyrosine would 
result in the loss of a potential site for N-linked glycosylation and introduce a 
potential phosphorylation site. The second mutation is at residue 660 and results in 
the change of an alanine to a valine. Valine is similar to alanine in that both are 
relatively small, have simple hydrocarbon side chains and are aliphatic and non-
polar. However, of the two, valine is slightly larger.  
The mutation described in cases 2793 and 3160 is a well-documented change. At 
residue 666, a lysine is substituted for asparagine or glutamic acid respectively. 
Samples 2999 and 3071 also have the same mutation (lysine is changed to a 
glutamic acid) but this is at residue 700. Lysine has a positively charged long, flexible 
side chain, whereas asparagine is a polar amino acid that has the potential to be 
modified by glycosylation. Glutamic acid, like lysine, does have a flexible side chain 
however it does carry a negative charge in comparison to lysine which is positive. 
Such mutations are likely to impact on both the structure and function of the 
protein.  
In cases 2843 and 2877, an arginine at residue 684 is mutated to a threonine or 
isoleucine respectively. As discussed above, arginine is a positive amino acid with a 
long side chain capped by a unique guanidinium group. It is the most basic of the 
amino acids and is readily involved in interactions with negatively charged DNA. A 
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change from this to a polar residue like threonine, that also has the potential to be 
phosphorylated, would affect the function of the protein. Isoleucine is a large 
residue with a complex hydrophobic side chain and this mutation may have an 
impact on the tertiary structure of the protein.  
In sample 2539 a glycine residue at 742 is mutated to an aspartic acid. Glycine and 
aspartic acid both have relatively simple side chains. Whilst glycine is a non-polar 
amino acid, aspartic acid is, in contrast, negatively charged. Thus, whilst such a 
mutation may not significantly affect the structure of the SF3B1 protein, it may 
affect its ability to interact with ligands. 
Case 2230 is potentially interesting as this would be the first reported nonsense 
mutation in SF3B1. If translated, this sequence would result in the production of a 
truncated protein. This sample also contains a second mutation. However, this 
occurs downstream of the stop codon, and thus is unlikely to be translated. 
To determine if this truncated protein is expressed in CLL, a Western blot was 
performed using whole cell lysate from this sample (Figure 4-5). However, there 
was no discernible band at the predicted molecular weight that could be confidently 
assigned to the truncated SF3B1 protein. The premature stop codon in the SF3B1 
mRNA may be recognised and degraded by the nonsense mediated decay (NMD) 
pathway96 such that the mRNA is not translated into a protein. If the species wasn’t 
degraded by this process and the truncated protein was indeed translated, it raises 
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the possibility that it may have been degraded in the proteosome following its 
tagging with ubiquitin97.  
Determining the allele burden of the SF3B1 mutation isn’t possible in this 
investigation as analysis is by end-point PCR and Sanger Sequencing of one PCR 
reaction. However, as the sequence traces show, the peaks relating to the mutated 
nucleotide are mixed. It can therefore be inferred that there is a mixture of wild-
type and mutated mRNA species present. This is likely a result of a mixture of CLL 
cells expressing either wild type or mutated SF3B1 ie a heterozygous mutation. This 
observation is in-line with previous studies98, 99.  
Results presented in the previous chapter demonstrated that CLL cells express four 
different isoforms of LEDGF. In this chapter, I have shown that some of these CLL 
cases have mutations within the SF3B1 gene (Table 4-2). To determine if a 
correlation exists between the presence of these mutations and the levels of 
expression of LEDGF isoforms in CLL, normalised levels of LEDGF expression were 
compared between mutated and unmutated SF3B1 samples (Figure 4-6). Whilst the 
results suggest that unmutated samples generally have higher levels of expression 
of all LEDGF isoforms, the number of cases analysed meant that these differences 
did not reach significance. Although the cohort investigated for the mutational 
status of the SF3B1 gene contained 75 CLL cases, there was not sufficient material 
to allow the expression level of all isoforms to be determined in every sample by 
RT-qPCR.  
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Failure to correctly splice pre-mRNA would likely result in mRNA with an altered 
open reading frame, such that it would contain aberrant stop codons. As discussed 
earlier, such mRNA species may be degraded by the NMD pathway. Such an 
outcome would lead to down regulation of all LEDGF isoforms at the mRNA level. 
Indeed, the results presented in this thesis demonstrate a trend for CLL cases in the 
cohort with mutated SF3B1 to have lower levels of all four isoforms of LEDGF as 
compared to those with wild type SF3B1. The results presented in this thesis, 
although not significant, suggest that the mutations within SF3B1 identified in this 
study may impact on the ability of SF3B1 to correctly splice mRNA molecules such 
as LEDGF, leading to their degradation. However, to confirm this theory, further 
investigations with an increased cohort of samples will need to be investigated. 
As yet, the functional significance of any of the mutations in SF3B1 has not been 
demonstrated65. However, it is thought that with the majority of them clustering in 
exons 14 – 16 of the protein99, they may be involved in modifying the functional 
role of SF3B1100, and the data presented in this thesis supports this notion. 
 
Future Work 
1. Extend the cohort of CLL patients for the study of SF3B1 mutational status. 
2. Determine the expression levels of LEDGF isoforms in these patient samples. 
3. Repeat the statistical analysis including this new data. 
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Chapter 5 : Cloning and 
Purification of LEDGF 
Isoforms 
 
5.1. Introduction 
Whilst purifying positive co-factor 4 (PC4), Ge et al. identified a co-purifying ~75 kDa 
protein which correspond to the full-length isoform of LEDGF28, 101. Using 
degenerate oligonucleotides, and a HeLa cDNA library, they identified an additional 
shorter p52 isoform. By virtue of differences in the C-terminii of these two known 
isoforms, LEDGF is likely to exhibit diverse protein interactions and participate in 
alternate complexes. The differences in protein complexes that LEDGF/p75 and p52 
assemble are likely important for specialisation of function and transcriptional 
outcomes.  
Cherepanov et al. demonstrated that LEDGF/p75 is a critical component of an HIV 
integrase complex102, and subsequently showed that this requires the presence of 
residues 339 – 442 (the IBD)103. A number of other proteins have since been shown 
to interact with LEDGF/p75 through its’ IBD motif. Maertens et al. demonstrated 
that the nuclear localisation of the Myc interacting protein JPO2 was dependent on 
its binding to residues 347-429 of the LEDGF/p75 IBD104. This interaction was 
subsequently confirmed in 2007 by Bartholomeeusen et al. who demonstrated that 
LEDGF/p75 also interacts with pogo transposable element-derived protein with zinc 
117 
 
finger (PogZ)105, 106. Cell division cycle 7-activator of S-phase kinase (Cdc7-ASK) also 
interacts with the IBD domain of LEDGF/p75107. Critically, this interaction requires 
the auto-phosphorylation of the kinase, and following such binding, LEDGF becomes 
primarily phosphorylated on Ser-206.  
The role of LEDGF/p75 over expression in CLL, and translocations involving NUP98 
in a variety of leukemias has been discussed (Chapters 1 and 3). Importance of its 
role in haematopoietic development and cancer is further inferred by its 
participation in the MLL/menin complex36. Within the complex, menin is required to 
directly link LEDGF/p75 to MLL and subsequently direct the complex to chromatin36  
and specifically to histone H3K36me3 24. More recently, Mereau et al. have 
confirmed that LEDGF/p75 is a critical component of menin/MLL complex108. 
With regards LEDGF/p52, this isoform is shown to specifically interact with SRSF1, 
an essential splicing factor27. Pradeepa et al. published a list of potential protein-
partners of LEDGF/p5224. Of the proteins identified, ~95% have a role in pre-mRNA 
processing and the rest are involved in transcription. One of these proteins is 
indeed SRSF1 thus confirming the findings of Ge et al. Furthermore, the PWWP 
domain of LEDGF was not required for this interaction further validating the 
specificity of the interaction with LEDGF/p52.  
To date, only one protein, MeCP2, has been shown to interact with both LEDGF/p75 
and p52, via a shared amino acid sequence109. Importantly, the region of LEDGF/p75 
and p52 responsible for the interaction with MeCP2 is preserved in the LEDGF/p52b 
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and p52bΔE6 isoforms, suggesting preservation of interaction. Given that 
LEDGF/p75 and p52 have unique and yet disparate interacting protein partners, and 
that two further isoforms (namely LEDGF/p52b and p52bΔE6) are now described, 
the pursuit of differences in the composition of each of the LEDGF isoform 
complexes was deemed worthwhile. Identification of the proteins that bind to the 
two newly described isoforms may also allow us to dissect their functional roles. In 
addition to this, the differences in complexes between the two well-known 
isoforms, LEDGF/p75 and p52 and their respective ΔPWWP domain mutants, may 
provide additional insights into the role of the PWWP domain, not only in the 
context of LEDGF, but also in terms of its role in binding modified histone or non-
histone proteins and for chromatin localisation. 
 
The aims of this chapter, therefore, were: 
1. To prepare mammalian-expression plasmid constructs of all four (full length) 
isoforms of LEDGF and additionally ΔPWWP domain mutants of the two 
main isoforms LEDGF/p75 and p52. 
2. To establish stable HEK293 cell lines each expressing a unique tagged 
protein. 
3. To optimise methods for the future purification of the core-complex of each 
expressed isoform. 
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5.2. Methods 
5.2.1. Construction of LEDGF Expression Plasmids 
cDNA constructs for LEDGF/ p75 (cloned into pDNR-DUAL) and p52 (cloned into 
pCMV-Sport6) were purchased from OriGene Technologies and Open Biosystems 
respectively, and transformed into competent E.coli DH5α cells (Life Technologies, 
UK); and plasmid DNA prepared from 6 clones using the mini-prep procedure 
outlined in Chapters 2.2.7 and 2.2.8. The integrity of each isoform was confirmed by 
restriction-enzyme digestion of 200 ng of plasmid with NotI and SalI (pCMV-Sport6-
LEDGF/p52) or SalI and HindIII (pDNR-DUAL-LEDGF/p75) (all restriction enzymes 
from New England Biolabs, UK). Digested plasmid was analysed by agarose gel 
electrophoresis as described in chapter 2.2.4, and the sequences of positive clones 
verified (see chapter 2.2.10). 
In order to generate tagged cDNA clones for all isoforms identified in this study, PCR 
primers were designed to amplify the complete mRNA sequence of each variant 
isoform. In each case, the forward primer incorporated (from 5´ to 3´) an EcoRI 
restriction site, the sequence for a FLAG, HA or Myc tag and then specific sequence 
for each isoform whilst the reverse primers, in all cases, contained an XbaI 
restriction site (Figure 5-1). A stop codon was not included in the reverse primer. 
Primer sequences are shown in Table 5-1. 
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Figure 5-1: Organisation of primer sequences used to generate tagged cDNA 
clones of each isoform.  
The forward primer is composed of an EcoRI restriction site, a tag then the 
sequence specific to the N-terminus of the isoform that is to be amplified. The 
reverse primer is composed of a 5’ XbaI restriction site and the 3’ end of the 
sequence of the isoform that is to be amplified. 
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Primer Primer sequence (5’ > 3’) 
p75ecoRIHAtag 
cctggaattctgtacccctacgacgtg 
cccgactacgccatgactcgcgatttcaaacctggag 
p75ecoRIFLAGtag 
cctggaattctggactacaaggac 
gacgacgacaagatgactcgcgatttcaaacctggag 
p75notagXbaI cctctagacgttatctagtgtagaatcc 
p52notagXbaI-new cctctagacctgtagattacatgttgtttggtgc 
p52bc-mycF 
cctggaattctggaacaaaaacttatttctgaa 
gaagatctgatgactcgcgatttcaaacctggag 
p52bLinkerPrimerNEW 
gaggaacaaatggaaactgagcacat 
taatccagttactgaaaagag 
p52bmiddleR tgctcagtttccatttgttcctcttgc 
p52bRXbaI gcctctagacgtccaatgagtctgtatcaagatc 
p52bE6R cctctagacccattttgggtctgcctcttgg 
PWWPmutEcoMYC 
cctggaattctggaacaaaaacttatttctgaagaagatctgatgag
tcaacaggcagcaactaaacaatc 
 
Table 5-1: Primer sequences used to generate tagged cDNA clones of each 
isoform.  
All forward primers incorporate an EcoRI restriction site, a tag and then the specific 
isoform sequence. All reverse primes incorporate the sequence specific to that 
isoform and an XbaI restriction site.  
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5.2.2. Generation of pcDNA3.1His-HA-LEDGF/p75 and pcDNA3.1His-FLAG-
LEDGF/p75 
Plasmids, pcDNA3.1His-HA-LEDGF/p75 (pcDNA3.1His mammalian expression vector 
+ tag + isoform of LEDGF) and pcDNA3.1His-FLAG-LEDGF/p75, were generated by 
PCR amplification using pDNR-DUAL-LEDGF/p75 as template and primer pairs 
p75ecoRIFLAGtag/p75notagXbaI and p75ecoRIHAtag/p75notagXbaI (Table 5-1) 
(annealing temperature gradients of 66-68 °C and 59-69 °C respectively). Each PCR 
reaction contained 5 µL of 10x Expand High Fidelity buffer (Roche, UK), 1 µL PCR 
grade nucleotide mix (Roche, UK), 0.3 µM of each primer, 0.1 ng template and 0.75 
µL Expand High Fidelity enzyme mix (Roche, UK), in a total reaction volume of 50 µL. 
Cycling parameters were as follows:  
 
94 °C 2 minutes (x1) 
94 °C 15 seconds, annealing temperature for 30 seconds, 72 °C for 1 minute (x10) 
94°C 15 seconds, annealing temperature for 30 seconds, 72 °C for 2 minutes 
(x20) 
72 °C for 7 minutes (x1) 
Hold at 4 °C 
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Products generated at the chosen annealing temperature were excised from the gel 
and further purified using the Wizard SV Gel and PCR Clean-Up Kit, ligated into 
pGEM-T and transformed into competent JM109 cells as described in Chapters 
2.2.4- 2.2.7. Plasmid DNA was purified from selected clones using the mini-prep 
procedure described in Chapter 2.2.8 and clone sequences verified (Chapter 2.2.10).  
Tagged cDNA inserts were released by digesting two micrograms of purified plasmid 
(pGEMT-HA-LEDGF/p75 or pGEMT-FLAG-LEDGF/p75) with XbaI and EcoRI (New 
England Biolabs, UK). Empty Plasmid pcDNA3.1HisA was digested in the same 
manner and then dephosphorylated by treatment with 1 µL calf intestinal alkaline 
phosphatase (CIP) (Promega, UK) for 15 minutes at 37 °C. Digested DNA was 
separated by agarose gel electrophoresis (Chapter 2.2.4). Bands corresponding to 
the empty pcDNA3.1HisA (Life Technologies, UK), or tagged p75 PCR products were 
purified using the Wizard SV gel and PCR Clean Up Kit (Chapter 2.2.5). Purified 
products were ligated into linearised pcDNA3.1HisA at a vector to insert ratio of 1:5 
using the Rapid Ligation Kit (Roche, UK). Briefly, the volume of vector plus insert 
was made up to 10 µL with 1x DNA dilution buffer. To this, 10 µL T4 DNA ligation 
buffer and 1 µL T4 DNA ligase were added. After vortexing the reaction was 
incubated for 30 minutes at RT. Ligations were transformed using Max Efficiency 
DH5α cells as described in Chapter 2.2.7. 
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5.2.3. Generation of pcDNA3.1His-FLAG-LEDGF/p52 and pcDNA3.1His-HA-
LEDGF/p52 
To avoid additional rounds of PCR amplification, HA and FLAG tagged constructs of 
LEDGF/p52 were generated by replacing the C-terminii of pcDNA3.1His-HA-
LEDGF/p75 and pcDNA3.1His-FLAG-LEDGF/p75 with the C-terminus of p52. Two 
micrograms of plasmids pcDNA3.1His-HA-LEDGF/p75 and pcDNA3.1His-FLAG-
LEDGF/p75 were digested with XbaI and XhoI (New England Biolabs, UK) then 
dephosphorylated by incubating with 1 µL CIP at 37 °C for 15 minutes. pCMV-
SPORT-LEDGF/p52 was digested in the same manner but was not 
dephosphorylated. Digested DNA was separated by agarose gel electrophoresis 
(Chapter 2.2.4) and bands corresponding to the C-terminal XhoI-XbaI fragment of 
LEDGF/p52, pcDNA3.1His-FLAG-LEDGF/p75-XhoI-XbaI and pcDNA3.1His-HA-
LEDGF/p75-XhoI-XbaI were excised and purified using the Wizard SV Gel and PCR 
Clean up Kit as detailed in (Chapter 2.2.5). 
Two separate ligation reactions were performed as described in Chapter 5.2.2 
which contained the C-terminal XhoI-XbaI fragment of LEDGF/p52 together with 
either pcDNA3.1His-FLAG-LEDGF/p75-XhoI-XbaI or pcDNA3.1His-HA-LEDGF/p75-
XhoI-XbaI. Ligation products were transformed into Max Efficiency DH5α cells as 
described in Chapter 2.2.7. 
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5.2.4. Generation of pcDNA3.1His-MYC-LEDGF/p75ΔPWWP and 
pcDNA3.1His-MYC-LEDGF/p52ΔPWWP 
Plasmids pcDNA3.1His-FLAG-LEDGF/p75 and pcDNA3.1His-FLAG-LEDGF/p52 were 
used as templates in a PCR reaction using primer pairs 
PWWPmutEcoMYC/p75notagXbaI and PWWPmutEcoMYC/p52notagXbaI-new 
(Table 5-1). Resulting amplicons were analysed by agarose gel electrophoresis 
(Chapter 2.2.4) and bands of interest purified using the Wizard SV Gel and PCR 
Clean Up Kit as described in Chapter 2.2.5. PCR products were ligated into pGEM-T 
vector to give pGEM-T-MYC-LEDGF/p75ΔPWWP and pGEM-T-MYC-
LEDGF/p52ΔPWWP and transformed into JM109 competent cells (see sections 2.2.6 
and 2.2.7). Plasmid DNA was purified using the mini-prep procedure and sequences 
verified externally at Source Bioscience Ltd (Chapter 2.2.10).  
The resulting plasmids were digested with XbaI and EcoRI and separated by agarose 
gel electrophoresis. Bands of interest were purified (Chapter 2.2.5), ligated into 
pcDNA3.1HisA using the Rapid DNA Ligation Kit and transformed into Max Efficiency 
DH5α cells as described (Chapter 2.2.7). 
 
5.2.5. Generation of pcDNA3.1His-MYC-LEDGF/p52b 
Dual tagged LEDGF/p52b was generated by PCR amplification of the N- and C-
terminal regions as 2 separate fragments which had complementary 3’ and 5’ 
sequences respectively, which were then joined together (Figure 5-2). Thus, the N-
terminal region of LEDGF (amino acids 1-325) was generated by PCR amplification of 
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pDNR-DUAL-LEDGF/p75 using primer pair p52bc-mycF and p52bmiddleR (Table 5-1) 
whilst the C-terminal region of LEDGF/p52b was amplified with primer pair 
p52bLinkerPrimerNEW and p52bRXbaI (Table 5-1) using pcDNA3.1His-HA-
LEDGF/p52 as template. PCR reactions were analysed by agarose gel 
electrophoresis (Chapter 2.2.4) and the bands of interest purified as described 
(Chapter 2.2.5).  
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Figure 5-2: Diagram to show the amplification strategy used to generate cDNA for 
LEDGF/p52b.  
Two separate PCR products (LEDGF N-terminus and p52b C-terminus) were joined 
together to give the full length tagged LEDGF/p52b isoform. The method first 
involved amplification in the absence of primers and then a standard RT-PCR 
amplification cycle. 
 
The two products were then joined together to generate full length LEDGF/p52b by 
use of a “primer-less” PCR reaction (Figure 5-2). Thus, 5 µL each PCR product, 4 µL 
10x Expand High Fidelity buffer, 1 µL nucleotide mix and 0.75 µL Expand High 
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Fidelity Enzyme mix were added to a tube and the volume made up to 40 µL with 
NFW. This reaction mix was subject to 5 cycles using the following parameters: 
 
  94 °C 2 minutes (x1) 
  94 °C 15 seconds, 40 °C 30 seconds, 72 °C 1 minute (x5) 
 
Following this, 2.5 µL each of primers p52bc-mycF and p52bRXbaI (Table 5-1) (stock 
concentration 6 µM), 1 µL 10x Expand High Fidelity buffer and 4 µL NFW were 
added to the tube and the reaction mix amplified using the following PCR 
parameters: 
 
94 °C 1 minute (x1) 
94 °C 15 seconds, 40 °C 30 seconds, 72 °C 1 minute (x10) 
94 °C 15 seconds, 45 °C 30 seconds, 72 °C 2 minutes 40 seconds (x20) 
72 °C 7 minutes (x1) 
 
Resulting amplicons were analysed by agarose gel electrophoresis and bands of 
interest purified and ligated into pGEM-T vector (Chapters 2.2.4-2.2.6) to give 
pGEM-T-MYC-LEDGF/p52b. The insert was released by digestion with XbaI and 
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EcoRI and separated by agarose gel electrophoresis (Chapter 2.2.4) and purified 
(Chapter 2.2.5). The purified band was ligated into pcDNA3.1HisA (enzyme digested 
and CIP prepared as described previously) using the Rapid DNA Ligation Kit. 
Ligations were transformed into Max Efficiency DH5α cells according to Chapter 
2.2.7. 
 
5.2.6. Generation of pcDNA3.1His-MYC-LEDGF/p52bΔE6 
Primers p52bc-mycF and p52bE6R (Table 5-1) were used in a PCR reaction with an 
annealing temperature gradient as previously described using HEK293 cDNA as 
template. PCR products were purified by agarose gel electrophoresis, ligated into 
pGEM-T and transformed into E.coli as described previously (Chapters’ 2.2.4-2.2.7) 
to generate pGEM-T-MYC-LEDGF/p52bΔE6. The resulting plasmid was digested with 
XbaI and EcoRI and separated by agarose gel electrophoresis (Chapter 2.2.4). Bands 
of interest were purified, ligated into linearised pcDNA3.1-HisA and transformed 
into Max Efficiency DH5α cells as described earlier. 
 
5.2.7. Optimisation of transfection conditions 
The optimum conditions for transfection were determined using the plasmid 
pcDNA3.1His-HA-LEDGF/p75 and 293T cells using a matrix (Figure 5-3) and the 
protocol outlined below.  
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Adequate plasmid DNA was obtained using a midi-prep kit as described in Chapter 
2.2.9. Adherent 293T cells were passaged and plated as described in Chapter 2.1.3. 
Twenty four hours prior to transfection, two 6-well plates were seeded with 293T 
cells at the required densities shown in Figure 5-3 in 2 mL complete DMEM per well 
and incubated overnight at 37 °C and 5% CO2 in a humidified incubator. The next 
day, for each transfection, 10 µL Lipofectin (Life Technologies, UK) was mixed with 
90 µL serum-free DMEM media in a sterile microfuge tube and incubated at RT for 
30-45 minutes. 
 
 
 
 
 
Figure 5-3: Matrix of different conditions to be used to determine the optimum 
viable cell density and amount of DNA for transfection using Lipofectin.  
For the investigation, two 6-well plates were plated with 293T cells at the density 
stated in each well. Nine wells were then transfected with pcDNA3.1His-HA-
LEDGF/p75 at the concentration detailed on the left of each row. Two other wells 
were transfected with either empty vector or the Lipofectin, the transfection 
reagent. The final well was a wild type control. The cells were incubated for a total 
of 48 hours. 
1 x 105 v.c/well 1.5 x 105 v.c/well 2 x 105 v.c/well 
1 x 105 v.c/well 1.5 x 105 v.c/well 2 x 105 v.c/well 
1 x 105 v.c/well 1.5 x 105 v.c/well 2 x 105 v.c/well 
2 x 105 v.c/well, 
pcDNA3.1His 
2 x 105 v.c/well 
Lipofectin only 
2 x 105 v.c/well 
Wild type 
1 µg 
1.5 µg 
2 µg 
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The relevant amount of plasmid (according to Figure 5-3) was added and the 
volume made up to 100 µL with serum-free DMEM media. The DNA was mixed with 
the Lipofectin/DMEM and incubated for 15 minutes at RT. Media was removed 
from the cells and the adherent cells washed with 2 mL serum free DMEM. This was 
discarded, replaced with 800 µL of serum free DMEM media per well and the 
appropriate lipofectin/DNA mixture added (according to Figure 5-3). The plates 
were gently rocked to ensure the cell monolayer was evenly covered and 
transferred overnight to a humidified incubator (37 °C and 5% CO2). The following 
morning the media was discarded and 2 mL complete DMEM media was added. The 
plate was returned to the incubator for a further 24 hours.  
Forty-eight hours post-transfection, the adherent cells were harvested by Trypsin-
EDTA digestion. Cell suspensions were collected and pelleted for 5 minutes at 500 x 
g, RT. Supernatant was discarded and the pellet washed in 1 mL PBS. Cells pellets 
were resuspended in 0.5 mL lysis buffer (50 mM NaH2PO4 (Sigma Aldrich, UK), 300 
mM NaCl (Fisher Scientific, UK), 10 mM imidazole (Sigma Aldrich, UK), 0.05% Tween 
20, pH 8) and 5 µL protease inhibitor cocktail (Merck Millipore, UK) and stored 
overnight at -80 °C. The following day, the cells were lysed by freeze/thawing (-80 
°C/RT) three times followed by sonication on ice (continued until clear) and clarified 
by centrifugation at 10000 x g, 4 °C for 10 minutes. The supernatant was transferred 
to a fresh 1.5 mL microcentrifuge tube and stored at -20 °C until required.  
The protein concentration of the lysates was determined using the RC DC Protein 
Determination Kit (Bio-Rad). Protein standards were prepared by dissolving BSA in 
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lysis buffer to yield 1.5, 1.0, 0.5 and 0.2 mg/mL. Briefly, 25 µL of each sample (cell 
lysate or protein standard) was placed in a 1.5 mL microcentrifuge tube and mixed 
with 125 µL Reagent I. The tubes were incubated at RT for 1 minute, and then 125 
µL Reagent II added to each and mixed. After centrifugation for 3 minutes at 15000 
x g at RT the supernatant was discarded. One hundred and twenty seven microliters 
of Reagent A’ (prepared by adding 5 µL Reagent S to 250 µl Reagent A) was added 
to each tube and contents vortexed. The tubes were incubated for 5 minutes at RT 
before the addition of 1 mL Reagent B. Samples were then incubated for 15 minutes 
at RT and the absorbance at 750 nm determined using the NanoDrop 2000c. 
Five microgram of protein from each transfection was analysed by Western Blotting 
with an anti-HA antibody (Covance, Mouse monoclonal, 1:1000) followed by a Goat-
anti-mouse IgG-HRP (Santa Cruz, 1:5000) as described in Chapter 2.3.2. To assess 
equal loading, the membrane was probed with anti-β-actin antibody (Sigma Aldrich, 
Mouse monoclonal, 1:10000). Following visual capture of the gel, the blots were 
treated with 10 mL stripping buffer (1x TBS (Sigma Aldrich, UK), 2% SDS, 0.1 M β-
mercaptoethanol) for 10 minutes at 55 °C. Membranes were washed 3 x 5 minutes 
in 1x PBS-Tween (0.05%) then probed with an anti-LEDGF primary antibody (BD 
Biosciences, Mouse monoclonal, 1:4000) followed by Goat-anti-mouse IgG-HRP 
secondary (Santa Cruz, 1:5000). 
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5.2.8. Generation of cell lines stably expressing different isoforms of 
LEDGF 
Using optimal transfection conditions determined above (Chapter 5.2.7), stable 
HEK293 cell lines expressing the described LEDGF isoforms were generated. Forty-
eight hours post-transfection, cells were selected with geneticin. The media in the 
wells was discarded and replaced with 2 mL of selective media (complete DMEM 
containing 400 µg/mL G418 (Merck Millipore, UK)) and the plates returned to the 
incubator. Every 2-3 days, selective media was removed and replaced with fresh 
selective media with antibiotic. When at a suitable density, the persistent cells were 
transferred to a T-25 cm2 vented tissue culture flask and passaged (see Chapter 
2.1.3) until there were sufficient cells to yield 5 vials for storage at -150 °C as 
detailed in Chapter 2.1.4. 
 
5.2.9. Small scale purification of His tagged protein 
A total of 1x107 viable cells were lysed, sonicated and clarified as described in 
section 5.2.7. Thirty microlitres of Ni-NTA magnetic agarose beads (Qiagen, UK) 
were added to each tube and incubated overnight at 4 °C on a rotator. The 
following morning the tubes were centrifuged to ensure that the beads were at the 
bottom of the tube and then placed on a magnetic separator for one minute. The 
supernatant was discarded and after 3 further washes beads were suspended in 
wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 0.05% Tween 20, 
pH 8) and the tubes placed on the magnetic separator. Following a final wash, 
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bound His-tagged protein was eluted by incubating the beads with 50 µL elution 
buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 0.05% Tween 20, pH 8) 
for two minutes. The tubes were then placed on a magnetic separator for one 
minute and the elution transferred to a fresh tube and stored at -20 °C.  
 
5.2.10. Large scale purification of His tagged proteins 
Cell pellets (equivalent to 1x108 viable cells) were resuspended in 0.5 mL lysis buffer 
(50 mM NaHPO4, 300 mM NaCl, 10 mM imidazole, 0.05% Tween 20, pH 7.4), lysed, 
sonicated and clarified as described in Chapter 5.2.7. Supernatants from specific 
isoforms were pooled and transferred to a 25 mL universal tube and stored on wet 
ice. A small aliquot was sequestered to serve as non-purified control. Sample 
loading, washing and elution was continually monitored at 280 nm.  
A 1 mL HisTrap HP column (GE Healthcare, UK) (connected to a peristaltic pump (P-
1, Pharmacia LKB, Sweden) and UV monitor (Econosystem, Bio-Rad, UK)) was 
washed at 2 mL/min with elution buffer (50 mM NaHPO4, 300 mM NaCl, 250 mM 
imidazole, 0.05% Tween 20, pH 7.4). The column was then equilibrated in lysis 
buffer until UV traces returned to baseline and stabilised, after which clarified lysate 
was loaded at a flow rate of 0.2 mL/min and the flow-through collected in a 25 mL 
universal tube held on ice. The column was washed with lysis buffer at a flow rate of 
1 mL/min until UV traces returned to baseline. This was followed by a further wash 
(50 mM NaHPO4, 300 mM NaCl, 50 mM imidazole, 0.05% Tween 20, pH 7.4) at a 
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flow rate of 0.5 mL/min. Wash buffer elutions were collected (2 mL for the first 
fraction and 1 mL for subsequent fractions) until UV traces returned to baseline. 
Bound proteins were then released by applying elution buffer (250 mM NaHPO4, 
300 mM NaCl, 250 mM imidazole, 0.05% Tween 20, pH 7.4) at a rate of 0.5 mL/min 
and 2 mL fractions were collected until UV traces returned to baseline. All samples 
were immediately transferred to -20 °C. 
 
5.2.11. Immunoprecipitation of Nickel purified protein 
To 250 µL of sample, 250 µL no-salt 1% Triton-X100 buffer (20 mM Tris-HCl pH 7.4, 
1% Triton-X100, (Sigma Aldrich, UK)) plus 5 µL protease inhibitor cocktail, was 
added. Immunoprecipitation was carried out using anti-FLAG M2 Magnetic beads 
(Sigma Aldrich, UK). One hundred microlitres of the bead suspension (50 µL packed 
gel volume) was transferred to a 1.5 mL microfuge tube. The tube was placed on a 
magnetic separator for 1 minute and the supernatant removed and discarded. The 
beads were washed twice with 500 µL 1x TBS. To the washed beads, 500 µL of 
clarified lysate was added. To one set of beads, 500 µL Triton-X 100 buffer 
(supplemented with NaCl to give 150 mM) was added which acted as a ‘beads only’ 
negative control. The tubes were incubated overnight at 4 °C on a rotator. Following 
incubation, the tubes were placed on a magnetic separator for one minute. The 
supernatant was discarded and the beads washed three times with 1 mL 1x TBS. 
After the final wash, 40 µL 2x SDS loading buffer (125 mM Tris HCl pH 6.8, 4% SDS, 
20% (v/v) glycerol and bromophenol blue) was added to each tube and the tubes 
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boiled for 3 minutes at 95 °C. After this, the tubes were placed on a magnetic 
separator for one minute and the supernatant transferred to a clean 1.5 mL 
centrifuge tube. 
 
5.2.12. Coomassie Blue staining of acrylamide gels 
Following electrophoresis, the gel was transferred to a clean plastic container. 100 
mL of Coomassie Blue stain (0.25% CBB R250 (Sigma Aldrich, UK), 40% methanol 
and 10% glacial acetic acid (Fisher Scientific, UK)) was added and the gel incubated 
for one hour with gentle agitation at RT. The stain was then discarded and the gel 
incubated in de-stain buffer (30% methanol and 10% glacial acetic acid) with gentle 
agitation. The buffer was changed regularly until the bands reached a suitable 
intensity after which the gel was stored in ultrapure water. 
 
5.2.13. Silver staining of acrylamide gels 
Following electrophoresis, the gel was rinsed in ultrapure water then stained using 
the SilverQuest Silver Staining Kit (Life Technologies, UK). The water was discarded 
and the gel incubated in 100 mL fixative (40% ethanol, 10% acetic acid made with 
ultrapure water) for 1 hour followed by washing with 100 mL of 30% ethanol for 10 
minutes with gentle agitation. The gel was then incubated for 10 minutes in 100 mL 
Sensitizing solution (10% sensitizer solution, 30% ethanol, in ultrapure water). The 
Sensitizer solution was discarded and the gel incubated in 100 mL 30% ethanol for 
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10 minutes followed by 10 minutes incubation in 100 mL ultrapure water. The 
water was discarded and replaced with 100 mL Staining Solution (1% Staining 
solution made up with ultrapure water). Following a 15 minute incubation the 
solution was decanted and the gel washed again with ultrapure water for 20-60 
seconds. The gel was then incubated in 100 mL developing solution until the bands 
reached an acceptable intensity, at which point 10 mL Stopper solution was added 
and incubated for 10 minutes. Following this, the solution was discarded and the gel 
washed in 100 mL ultrapure water for 10 minutes. The gel was stored in fresh 
ultrapure water. 
A summary of the experimental work performed in this chapter is detailed in Figure 
5-4. 
 
 
 
 
Figure 5-4: Summary of work described in this chapter.  
The workflow summarises the steps taken to purify out the protein complex around 
each of the tagged isoforms of LEDGF.  
 
 
Generation of tagged 
LEDGF expression plasmids 
in pcDNA3.1His vector 
(Invitrogen). 
Generation of stable 
HEK293 cells exogenously 
expressing the tagged 
LEDGF isoforms. 
Development of method 
for the purification of the 
exogenously expressed 
isoforms of LEDGF. 
Implementation of method 
to purify exogenously 
expressed isoforms of 
LEDGF and their associated 
protein complexes. 
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5.3. Results 
5.3.1. Verification of LEDGF Expression Plasmids 
The integrity of commercially purchased clones of LEDGF/p52 and p75 was 
confirmed by restriction digestion and agarose gel electrophoresis. Briefly, pCMV-
SPORT6-LEDGF/p52 was digested with NotI and SalI, whilst pDNR-DUAL-LEDGF/p75 
was digested with SalI and HindIII. As seen in Figure 5-5, bands of 1593 bp and 1842 
bp , corresponding to the p75 and p52 inserts were released by digestion, verifying 
the identity of the clones. Sanger sequencing confirmed clone integrity (data not 
shown). 
 
Figure 5-5: Restriction enzyme digestion of pDNR-DUAL-LEDGF/p75 and pCMV-
SPORT6-LEDGF/p52.  
200 ng pDNR-DUAL-LEDGF/p75 (left) or pCMV-SPORT6-LEDGF/p52 (right) was 
digested with either SalI/HindIII or NotI/SalI respectively. Resulting digests were 
analysed by agarose gel electrophoresis. Lane 1: molecular weight markers; Lane 2: 
undigested plasmid; Lane 3: digested plasmid. Arrows indicate the relevant inserts 
released following the double digestion. 
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5.3.2. Construction of tagged LEDGF cDNA expression clones 
Using pDNR-DUAL-LEDGF/p75 as template, a PCR reaction was performed using 
primer pairs p75ecoRIHAtag/p75notagXbaI and p75ecoRIFLAGtag/ p75notagXbaI 
(Table 5-1) at different annealing temperatures. PCR reactions were analysed by 
agarose gel electrophoresis, and products at the chosen annealing temperature 
(determined to be 68 °C and 64 °C respectively; Figure 5-6) were purified.  
 
 
Figure 5-6: PCR amplification of the 75 kDa isoform of LEDGF.  
PCR reactions were performed using pDNR-DUAL-LEDGF/p75 and primer pairs 
p75ecoRIHAtag and p75notagXbaI (upper panel) or p75ecoRIFLAGtag and 
p75notagXbaI (lower panel) with a range of annealing temperatures. The products 
were analysed by agarose gel electrophoresis and the annealing temperature 
determined visually (indicated by arrows). 
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The purified PCR products were cloned into pGEM-T to generate pGEM-T-HA-
LEDGF/p75 and pGEM-T-FLAG-LEDGF/p75. Positive clones were subsequently 
digested with XbaI and EcoRI and the insert transferred into linearised 
pcDNA3.1HisA (digested with the same enzymes) to yield pcDNA3.1His-HA-
LEDGF/p75 and pcDNA3.1His-FLAG-LEDGF/p75. 
Expression constructs for LEDGF/p52 were generated by replacing the C-terminus of 
LEDGF in plasmids pcDNA3.1His-HA-LEDGF/p75 and pcDNA3.1His-FLAG-LEDGF/p75 
with that of p52 (from plasmid pCMV-SPORT6-LEDGF/p52 as described in Chapter 
5.2.3). Restriction digests were analysed by agarose gel electrophoresis (Figure 5-7).  
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Figure 5-7: Restriction enzyme digestion of pcDNA3.1His-HA-LEDGF/p75, 
pcDNA3.1His-FLAG-LEDGF/p75 and pCMV-SPORT6-LEDGF/p52.  
The plasmids were digested with XbaI and then XhoI in sequential reactions. At each 
stage, a sample was retained. Digests were analysed by agarose gel electrophoresis 
to follow the digestion and release of inserts. The plasmids digested are detailed at 
the top of the image. For each plasmid there is an undigested sample (lanes 1, 6 and 
11), a single digested with XbaI (lanes 2, 4, 7, 9, 12 and 14) and a double digested 
with XbaI and XhoI (lanes 3, 5, 8, 10, 13 and 15) from constructs. Highlighted bands 
were excised from the gel.  
 
Each digestion was performed in duplicate to ensure that sufficient vector and 
insert was recovered. For each construct that was double digested, the release of 
the insert and change in mobility of the larger band suggested the digestion was 
successful. Relevant bands were purified, and the LEDGF/p52 XhoI/XbaI fragment 
was ligated into the pcDNA3.1His-FLAG-LEDGF/p75-XhoI and pcDNA3.1His-HA-
LEDGF/p75-XhoI vector backbones separately as described (Chapter 5.2.3) to form 
pcDNA3.1His-HA-LEDGF/p52 and pcDNA3.1His-FLAG-LEDGF/p52 respectively. 
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In order to study the role of the PWWP domain of LEDGF, expression constructs for 
the LEDGF/p75 and p52 isoforms were generated in which the PWWP domain was 
deleted. PCR primers that would introduce the deletion were synthesised (Table 5-
1) and used in amplification reactions using pcDNA3.1His-FLAG-LEDGF/p75 and 
pcDNA3.1His-FLAG-LEDGF/p52 as templates. Reactions were performed using a 
range of annealing temperatures and the resulting amplicons analysed by agarose 
gel electrophoresis (Figure 5-8).  
 
 
Figure 5-8: PCR amplifications of MYC-LEDGF/p75ΔPWWP (left panel) and MYC-
LEDGF/p52ΔPWWP (right panel).  
PCR reactions were performed using pcDNA3.1His-FLAG-LEDGF/p75 and 
pcDNA3.1His-FLAG-LEDGF/p52 and primers PWWPmutEcoMYC and p75notagXbaI 
and PWWPmutEcoMYC and p52notagXbaI-new with a range of annealing 
temperatures. PCR products were analysed by agarose gel electrophoresis and the 
chosen annealing temperature determined visually and indicated by the arrows.  
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Products generated at the chosen annealing temperature (determined to be 70 °C 
for primers PWWPmutEcoMYC/p52notagXbaI-new and 65 °C for 
PWWPmutEcoMYC/p75notagXbaI; Figure 5-8) were excised from the gel and 
purified. The PCR products were first cloned into pGEM-T as described in Chapter 
5.2.4 and subsequently transferred to pcDNA3.1HisA to generate pcDNA3.1His- 
MYC-LEDGF/p75ΔPWWP and pcDNA3.1His-MYC-LEDGF/p52ΔPWWP. 
To prepare pcDNA3.1His-MYC-LEDGF/p52b, a three-step PCR method was used. 
Using pDNR-DUAL-LEDGF/p75 as template, the N-terminal region of LEDGF 
corresponding to amino acids 1-325 was amplified in a PCR reaction using primers 
p52bc-mycF and p52bmiddleR (Table 5-1). Resulting amplicons were analysed and 
the band at the chosen annealing temperature (shown to be 70 °C; Figure 5-9) was 
purified. 
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Figure 5-9: Optimisation of PCR annealing temperature. 
PCR reactions were performed using p52bc-mycF and p52bmiddleR with a range of 
annealing temperatures. PCR products were analysed by agarose gel 
electrophoresis and the chosen annealing temperature determined visually and 
indicated by arrows. Specifically, the annealing temperature chosen was 70 °C. 
  
The C-terminal region of LEDGF/p52b was amplified in a separate reaction with 
primers p52bLinkerPrimerNEW and p52bRXbaI (Table 5-1) using plasmid 
pcDNA3.1His-HA-LEDGF/p52 as template. The resulting amplicon was purified from 
an agarose gel (data not shown). The 2 amplicons have complementary 5´ and 3´ 
regions, such that following a denaturation step, they can anneal together. The 
annealed amplicons were allowed to extend in a “primerless” PCR (see Figure 5-2) 
which enriched for the full length cDNA for LEDGF/p52b. Following this, primers 
p52bc-mycF and p52bRXbaI (Table 5-1) were added and a normal PCR reaction was 
performed. Figure 5-10 shows the result of this PCR. The band corresponding to 
myc-tagged LEDGF/p52b was purified, cloned into pGEM-T then transferred to 
pcDNA3.1HisA to generate pcDNA3.1His-MYC-LEDGF/p52b.  
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Figure 5-10: PCR amplification of full length MYC-tagged LEDGF/p52b. 
The full length tagged isoform of LEDGF/p52b was generated by joining two 
separate PCR products representing the N-terminus and C-terminus of the isoform. 
The first step involved amplification in the absence of primers then the addition of 
primers and amplification as in a standard RT-PCR reaction.  
 
The full length myc-tagged LEDGF/p52b was generated by the joining of the two 
separate N and C-terminal products using primers p52bc-mycF and p52bRXbaI. The 
product was run on a gel, excised and purified. 
Expression plasmids for the LEDGF/p52b isoform lacking exon 6 were generated by 
PCR amplification of HEK293 cDNA using the primer pair p52bc-mycF and p52bE6R 
(Table 5-1). The optimal annealing temperature was determined to be 69 °C (Figure 
5-11).  
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Figure 5-11: Optimisation of RT-PCR amplification of LEDGF/52bΔE6.  
RT-PCR reactions were performed using p52bc-mycF and p52bE6R with a range of 
annealing temperatures. Products were analysed by agarose gel electrophoresis 
and the annealing temperature determined visually (indicated by arrows). 
Specifically, the chosen annealing temperature was 69 °C. 
 
The band generated at 69 °C, the chosen annealing temperature, was excised from 
the gel and, by following the method described in Chapter 5.2.6, pGEM-T-MYC-
LEDGF/p52bΔE6 was prepared and subsequently pcDNA3.1His-MYC-
LEDGF/p52bΔE6 generated. 
Plasmid maps for the constructs generated in pcDNA3.1HisA vector are shown in 
Appendix D. 
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5.3.3. Optimisation of transfection conditions 
Having generated cDNA expression constructs for the 4 isoforms of LEDGF 
expressed in CLL, and the PWWP domain deletion mutants, the optimal transfection 
conditions that would yield the highest protein expression were determined using a 
transfection matrix (Figure 5-3) that comprised different cell numbers and amounts 
of DNA. Whole cell lysates were generated from transfected cells and analysed by 
western blotting. Results are shown in Figure 5-12.  
 
 
Figure 5-12: Western Blot analysis of whole cell lysates from the transfection of 
293T cells at a range of viable cell densities and different DNA inputs.  
Different cell densities of 293T cells were transfected with varying amounts of 
plasmid as per Figure 5-3. Cells were harvested 48 hours post-transfection and 
whole cell lysates analysed by western blotting using anti-HA (top), anti-LEDGF 
(middle) and anti-β-actin (bottom) antibodies. WT = wild type cells; Lip = cells 
treated with lipofectin but no plasmid; pcDNA3.1HisA = cells transfected with empty 
plasmid. 
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The first 9 lanes contain lysates of 293T cells all transfected with the pcDNA3.1His-
HA-LEDGF/p75 plasmid whilst the last three depict controls. The presence of bands 
in the transfected lanes but not control lanes with anti-HA antibody demonstrates 
successful transfection. The blot probed with an anti-LEDGF antibody reveals 
endogenous LEDGF/p75 protein. In the lanes containing lysates from the cells 
transfected with the plasmid, there is evidence of a second slower migrating band 
indicating HA tagged exogenous LEDGF. The third blot was probed with anti-β-actin 
antibody to assess protein loading. It was deemed that a viable cell density of 1x105 
and 1.5 µg DNA would be most suitable for future transfections. 
 
5.3.4. Verification of stable HEK293 cells expressing LEDGF isoforms 
Having determined the optimal conditions, stable cell lines expressing each of the 
tagged LEDGF isoforms were generated by transfecting the relevant cDNA 
constructs into HEK293 cells and geneticin selection. Once stable lines were 
established, whole cell lysates were prepared from each and protein expression 
analysed by Western blotting. 
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Figure 5-13: Western blot analysis of whole cell lysates of HEK293 cells stably 
expressing the tagged LEDGF isoforms. 
10 μg of whole cell lysate from each stable cell line and wild type cells were 
analysed by western blotting and the membrane probed using antibodies to the 
tags. Namely, anti-HA (top), anti-flag (second panel) and anti-myc (third and fourth 
panel). Anti-β-actin was also included to show equal loading.   
 
Equal amounts of protein from whole cell lysates were analysed using antibodies to 
the FLAG, Myc or HA tags (Figure 5-13). The result shows that the stable cell lines 
express the tagged isoforms of LEDGF. The anti-Myc antibody does identify 
endogenous c-Myc protein. The Myc tagged LEDGF/p52b is predicted to run at 
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approximately 54 kDa, and thus would run slightly faster than endogenous c-Myc. A 
doublet can be observed in the lane containing lysate from the HEK293 cells stably 
transfected with this isoform, corresponding to endogenous c-Myc (upper band) 
and the Myc-LEDGF/p52b (lower band). Visualisation of a band corresponding to 
Myc tagged LEDGF/p52bΔE6 required long exposure of the blot, and hence this 
portion of the blot is shown separately. In the lanes containing lysates of the 
ΔPWWP domain mutants, bands are seen at the predicted molecular weights.  
 
5.3.5. Small scale purification of His-tagged LEDGF protein 
Each of the exogenous LEDGF isoforms contains a plasmid encoded 6xHis tag that 
enables the protein to be purified using Nickel beads. Initially, this was carried out 
on a small-scale as detailed in Chapter 5.2.9 using lysate from cells transiently 
transfected with pcDNA3.1His-HA-LEDGF/p75 in preparation for a large-scale 
purification.  
In the initial experiments, exogenous His-tagged protein was purified using bead 
manufacturer’s instruction. Briefly, 500 µL lysate was incubated with 10 µL beads 
for 2 hours at 4 °C, and the beads washed and eluted as described in Chapter 5.2.9. 
However, results from the Western blot show that when the purified protein is 
compared to the input sample (10% of the crude lysate), only a small amount of 
protein was recovered (Figure 5-14).  
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Figure 5-14: Western blot analysis of lysates from 293T cells transiently 
transfected with empty vector (pcDNA3.1HisA) or pcDNA3.1His-HA-LEDGF/p75 
and purified with Ni-NTA beads.  
Lysates from wild type (WT) cells and cells treated with Lipofectin only (Lip) served 
as controls. In each case, whole cell lysate (wcl) was loaded alongside the Ni-NTA 
beads purified material (P). The material was purified according to the 
manufacturers’ instructions. The blot was probed with anti-HA antibody (Covance, 
Mouse monoclonal, 1:1000). 
 
In an effort to maximise the amount of protein purified, the effects of increasing the 
volume of beads to 20 µL and incubating the beads with the lysate overnight was 
assessed. Cell pellets from HEK293 cells stably expressing the exogenous tagged 
LEDGF isoform or wild type cells were utilised. For comparison, lysates were 
purified with either 10 or 20 µL beads, and incubated with nickel beads for either 2 
hours or overnight. Following incubation, beads were isolated by magnetic 
separation and the unbound lysate transferred to a clean tube. To determine if 
protein is lost in the washes, the first wash was retained and labelled “WE” (wash 
end), and the final elution from this purification was labelled “E1” (elution 1). 
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Proteins that remained bound to the beads were eluted by incubating the beads at 
95 °C for 5 minutes in 20 µL of 2x SDS loading buffer and then placed on the 
magnet. The supernatant was transferred to a clean tube and labelled “beads”.  
The unbound fraction, following overnight incubation, was incubated for a second 
time with fresh beads for 2 hours and the purification procedure repeated. The 
resultant elution was labelled “E2”(elution 2). The unbound fraction from this 
purification was incubated a third time with fresh beads and the elution labelled 
“E3”(elution 3). The unbound fraction at this stage was retained and labelled “End”. 
Aliquots of all fractions were then analysed by Western blotting and probed with an 
anti-FLAG antibody (Sigma Aldrich, Mouse monoclonal, 1:1000) and anti-β-actin 
antibody (Sigma Aldrich, Mouse monoclonal, 1:10000) (Figure 5-15). 
As expected, there are no bands in the western blot of lysates from WT cells probed 
with the anti-FLAG antibody. Probing the blots for B-actin showed that the protein 
was only present in the whole cell lysate and “End” sample. 
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Figure 5-15: Western blot analysis of eluates from each step of the small scale 
purification of His-tagged FLAG-LEDGF/p75 using Ni-NTA beads depending on the 
volume of beads added (10 or 20 µL) and the incubation time (2 hour or overnight 
(o/n)). 
Eluates collected at each step where analysed by western blotting and the 
membranes probed with anti-flag antibody. Membranes were also probed with 
anti-β-actin antibody as a control. WCL: whole cell lysate, E: elution from beads, 
WE: wash elution. 
 
As for the transfected samples, there were no specific bands in the wash lane 
(“WE”) showing that the over expressed protein is not eluted away during the wash 
procedure. Compared to the standard protocol when 10 µL beads are incubated for 
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2 hours with 500 µL lysate, increasing the volume of beads and/or increasing the 
initial incubation time resulted in a greater recovery of tagged protein (“E1”). 
However, this also resulted in an increased amount of protein that remained bound 
to the beads (“Beads”). This was particularly noticeable for overnight incubations. 
Furthermore, despite increasing the volume of beads, tagged protein was still 
present in the “End” sample. 
Therefore, the method was further modified in two ways. Firstly, the length of time 
the beads were incubated in the elution buffer was increased, and secondly, 
following the initial magnetic isolation of the beads, the elution step was repeated a 
further two times (method summarised in Figure 5-16). Thus, wild type HEK293 and 
HEK293-FLAG-LEDGF/p75 cell lysates were incubated with 10 µL and 30 µL Ni-NTA 
Magnetic Agarose beads overnight at 4 °C on a rotator. The samples were then 
purified according to the method in section 5.2.9. Beads were isolated by magnetic 
separation and the unbound fraction transferred to a new tube. In addition, the first 
wash was collected and labelled “W”(wash). Bound protein was eluted from the 
beads and labelled E1 (1) (elution). Second and third elutions were labelled E1 (2) 
and E1 (3) respectively. Protein remaining bound to the beads was eluted by 
incubating at 95 °C for 5 minutes in 2x SDS buffer followed by magnetic separation. 
This elution was labelled E1BB. The unbound fraction that remained following the 
overnight incubation and the wash buffer supernatant (“W”) was re-incubated with 
10 or 30 µL beads (depending on the amount in the first overnight incubation) and 
incubated for 2 hours on a rotator at 4 °C. The beads were isolated from the 
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unbound fraction by magnetic separation and incubated in elution buffer to give 
fractions “E2” and “WE” respectively. Protein remaining bound to the beads was 
eluted by incubating at 95 °C for 5 minutes in 2x SDS buffer followed by magnetic 
separation to give fractions “E2BB” and “WEBB” respectively. Unbound proteins 
from the second incubation with beads was incubated for a third time with 10 or 30 
µL beads for 2 hours on a rotator at 4 °C, and eluted protein labelled “E3”. The 
beads were incubated in 2x SDS buffer to elute remaining bound protein (“E3BB”). 
The remaining unbound fraction was labelled ‘End’. Aliquots of each sample were 
analysed by western blot and anti-FLAG antibody (Sigma Aldrich, Mouse 
monoclonal, 1:1000).  
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Figure 5-16: Summary of method to improve the recovery of the His-tagged 
protein during the small scale purification using the Ni-NTA beads.  
A box indicates each sample taken to be analysed by western blotting. 
 
As shown in Figure 5-17, and as with the previous experiment (Figure 5-15), 
increasing the volume of beads results in a greater yield of tagged protein (compare 
lanes E1 (1) between 10 and 30 µL bead volumes). However, even when the number 
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of elutions and the elution time was increased, tagged protein remained on the 
beads (lanes BB, E2BB and E3BB). This was more apparent when 30 µL of beads 
were used for the purification. Further, uneluted protein remained in the final 
supernatant following all of the isolations (lane “End”). 
 
 
Figure 5-17: Analysis of eluates from each step of the small scale purification of 
His-tagged proteins using different volumes of Ni-NTA beads. 
Eluates at each step of the small scale purification was collected and analysed by 
western blotting. Membranes were probed with α-flag antibody. Whole cell lysates 
(WCL) from wild type HEK293 cells and HEK293 cell exogenously expressing FLAG-
LEDGF/p75 were incubated with 10 or 30 μL of Ni-NTA beads and purified as 
described. E: elution, BB: boiled beads, WE: wash elution. 
 
Elutions E1-E3 from both HEK293 and HEK293-FLAG-LEDGF/p75 were separated by 
SDS-PAGE and the gel stained using the SilverQuest Silver Staining Kit. As seen in 
Figure 5-18, a band is present in elutions from the transfected cells corresponding 
HEK293-FLAG-LEDGF/p75 HEK293 
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to FLAG-LEDGF/p75 which is not present in elutions from wild type HEK293 cells.  As 
expected, the intensity of the band decreases with each subsequent elution. 
 
 
Figure 5-18: Silver staining of sequential elutions of FLAG-LEDGF/p75 from Ni-NTA 
beads.  
Elutes collected from their elution from Ni-NTA beads during small scale purification 
of whole cell lysates from wild type HEK293 cells and HEK293-FLAG-LEDGF/p75 cells 
where separated by SDS-PAGE. The gel was silver stained. The arrow indicates the 
presence of a band in the transfected HEK293 cells that is not present in wild type 
HEK293, and which would correspond to purified FLAG-LEDGF/p75. 
 
As well as a 6xHis tag, each of the different LEDGF constructs encoded a second tag 
viz. FLAG or Myc that would allow for double purification. Therefore, nickel bead 
purified protein samples from HEK293 and HEK293-FLAG-LEDGF/p75 cells were 
immunoprecipitated with magnetic anti-FLAG beads overnight according to the 
method described Chapter 5.2.11. Unbound protein was transferred to a clean tube 
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and labelled as IP waste. Aliquots of nickel bead purified, nickel bead plus 
immunoprecipitated sample (IP) (double purified), and IP waste samples were 
separated by SDS-PAGE and visualised using the SilverQuest Silver Stain Kit.  
As shown in Figure 5-19, in lanes containing protein purified from HEK293-FLAG-
LEDGF/p75 cells by either Nickel beads alone or double purified with Nickel beads 
and immunoprecipitation, there is a band that corresponds to FLAG-LEDGF/p75 
which is absent in HEK293WT and beads-only lanes. This confirms that the double 
purification procedure was successful. The band (although very weak) is, however, 
present in the IP waste lane suggesting that not all of the protein is bound to the 
beads during the IP step. However, it should be noted that there are fewer bands 
present in the IP lane suggesting that this extra step removes non-specific proteins 
(for example, those that have bound to the Nickel beads via a naturally occurring 
run of His residues in their protein sequence). 
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Figure 5-19: Silver staining of cell lysates from HEK293 and HEK293-FLAG-
LEDGF/p75 cells purified by Ni-NTA beads alone or immunoprecipitated with FLAG 
beads following purification by Ni-NTA beads.  
Eluates purified with Ni-NTA beads were subject to immunoprecipitation with anti-
flag beads. Eluates from this (IP) were analysed alongside the respective Ni-NTA 
purified sample (Ni lysate). The remaining supernatant was also analysed (IP waste). 
The enlarged lanes show the region of the gel containing a band representing FLAG-
LEDGF/p75 (indicated by the arrow).  
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5.3.6. Large scale purification of His-tagged LEDGF 
The results so far demonstrate that the exogenous tagged LEDGF/p75 isoform can 
be purified on a small scale. However, the results also highlighted a number of 
limitations using this method (i.e. not all material binds to or elutes from the 
beads). It was therefore decided to use a larger scale purification system based on a 
low pressure chromatography system where the material was pumped through a 1 
mL column containing the nickel beads in order to allow efficient binding (Chapter 
5.2.10). Lysate from HEK293 cells stably expressing FLAG-LEDGF/p75 or 
pcDNA3.1HisA was re-cycled through the column five times to allow maximal 
binding. All washes and final elutions were collected and run on a 10% resolving gel, 
4% stacking gel and stained with Coomassie Blue.  
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Figure 5-20: Analysis of wash and elution fractions collected from the purification 
of HEK293-pcDNA3.1HisA and HEK293-FLAG-LEDGF/p75.  
A sample of the eluates collected from the washing of the column (wash buffer) and 
from the elution off the column in the elution buffer, were separated by SDS-PAGE. 
The gels were stained with Coomassie Blue. The top image is analysis of eluates 
from the purification of HEK293-pcDNA3.1HisA and the bottom is analysis of eluates 
from the purification of HEK293-FLAG-LEDGF/p75. 
 
Elution 3, in each case, shows the most amount of relevant protein (Figure 5-20). To 
enable direct comparison between purified protein from wild type and transfected 
HEK293 cells, aliquots of elution 3 from both cell types were analysed next to each 
other on a polyacrylamide gel, stained with Coomassie Blue and examined for 
presence of LEDGF/p75. However, it was difficult to distinguish a band at 75 kDa 
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that would represent FLAG-LEDGF/p75 specifically in the transfected cell sample 
(Figure 5-21).  
 
Figure 5-21: Analysis of the elution samples from the purification of HEK293 cells 
transfected with pcDNA3.1HisA empty vector and pcDNA3.1His-FLAG-LEDGF/p75.  
Corresponding elutes in elution buffer from the column purification of HEK293-
pcDNA3.1HisA and HEK293-FLAG-LEDGF/p75 were separated by SDS-PAGE and the 
gels stained with Coomassie Blue.  
 
To confirm that FLAG-LEDGF/p75 protein was purified, an aliquot (and dilutions of) 
of elution 3 from each cell line was separated by SDS-PAGE and probed by western 
blot using anti-FLAG antibody (Sigma Aldrich, Mouse monoclonal, 1:1000). 
As shown in Figure 5-22, a band corresponding to FLAG-LEDGF/p75 is present in 
purified lysate from the transfected cells but not in wild type cells. This result 
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indicates that the purification procedure does work, and that FLAG-LEDGF/p75 
protein can be purified using this method. 
 
 
Figure 5-22: Western blot analysis of the purification of pcDNA3.1HisA and FLAG-
LEDGF/p75.  
Whole cell lysates from wild type and FLAG-LEDGF/p75 transfected HEK293 cells 
were purified using the low pressure chromatography system. Eluates in elution 
buffer were analysed by western blot using an anti-FLAG antibody. Samples were 
loaded neat, diluted 1:5 and 1:10. 
 
Having demonstrated successful purification of FLAG-LEDGF/p75, it was important 
to show that proteins known to co-associate with LEDGF/p75 were also co-purified. 
One such protein is MeCP2109. To this end, an immunoprecipitation was performed 
using elution 3 (Figure 5-20) and anti-Flag magnetic beads. Equal volumes of 
precipitated proteins were separated on two SDS-PAGE gels and analysed by 
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western blot using anti-MeCP2 (Diagenode, Polyclonal, 1:1000) and α-FLAG 
antibodies. Results are illustrated in Figure 5-23. 
 
 
Figure 5-23: Western blot analysis of stable HEK293 whole cell lysates purified 
with nickel beads and then immunoprecipitation.  
Samples of nickel purified lysates from HEK293 cells stably transfected with 
pcDNA3.1HisA or pcDNA3.1His-FLAG-LEDGF/p75 were subject to 
immunoprecipitation with anti-Flag beads. The precipitated proteins (IP) were 
analysed by Western blot alongside nickel purified input samples (Ni bead) as 
control. Blots were probed with anti-MeCP2 and anti-FLAG antibodies (upper and 
lower panel respectively). 
 
MeCP2 protein contains a sequential run of 7 histidine residues which can bind to 
the nickel beads used in the purification. This is demonstrated by the presence of a 
band in the nickel purified sample from cells transfected with both the empty 
plasmid and FLAG-LEDGF/p75 (Figure 5-23, upper panel). However, following 
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immunoprecipitation with FLAG beads, this band is only present in the lane 
corresponding to cells transfected with the LEDGF construct. The results 
demonstrate the presence of MeCP2 in the purified tagged-LEDGF/p75 complex.  
To further confirm the presence of FLAG-LEDGF/p75 in the immunoprecipitated 
complex, samples were analysed by Western blot and probed with an anti-FLAG 
antibody (Figure 5-23, lower panel). The presence of a band corresponding to FLAG-
LEDGF/p75 in the IP lane confirms that the procedure was successful. 
Western blot of elutions from either a nickel bead column or immunoprecipitated 
samples demonstrates that the method successfully purifies the LEDGF complex but 
sufficient material is not purified to allow visualisation by Coomassie Blue or Silver 
staining. There seem to be additional proteins that are common to the elution and 
control lanes (ie cells transfected with empty plasmid). It was therefore decided to 
add an extra wash step using 50 mM imidazole in the wash buffer in an effort to 
reduce the number of non-specifically purified proteins. This would mean the 
column was subjected to two washes with different concentrations of imidazole (20 
and 50 mM) before elution at 250 mM imidazole. The column purification was 
repeated and all elutions collected. A sample of each eluate was analysed by 
western blot and anti-FLAG antibody (Sigma Aldrich, Mouse monoclonal, 1:1000). 
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Figure 5-24: Western Blot analysis of nickel purified lysates from HEK293 cells 
transfected with FLAG-LEDGF/p75.  
Whole cell lysates of HEK293-FLAG-LEDGF/p75 stable cells were purified using the 
low pressure chromatography system attached to a nickel column. Samples from all 
wash (50 mM wash) and elution (250 mM elution) steps were analysed by Western 
blot using an anti-FLAG antibody. As controls, samples of whole cell lysate (wcl) and 
flow through (F/T) were included. 
 
A band representing FLAG-LEDGF/p75 was present in the unpurified whole cell 
lysate and elution 2 (Figure 5-24). There were no bands samples from cells 
transfected with empty plasmid (data not shown). To confirm that an LEDGF 
complex was purified, an immunoprecipitation was performed as described earlier 
using elution 2 (Figure 5-24) and anti-Flag beads and the gels probed with anti-FLAG 
and MeCP2 antibodies previously described. 
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Figure 5-25: Western blot analysis of transfected HEK293 cell lysates purified with 
nickel beads and immunoprecipitation.  
Samples of nickel purified lysates from HEK293 cells stably transfected with 
pcDNA3.1HisA or pcDNA3.1His-FLAG-LEDGF/p75 were subject to 
immunoprecipitation with anti-Flag beads. The precipitated proteins (IP) were 
analysed by Western blot alongside nickel purified input samples (Nickel bead) as a 
control. Blots were probed with an anti-FLAG antibody (upper panel) or an anti-
MeCP2 antibody (lower panel). 
 
As shown in Figure 5-25, there is a band in the lanes containing the 
immunoprecipitated sample on the blots probed with both the anti-FLAG and 
MeCP2 antibodies showing that the immunoprecipitation (and hence double 
purification) worked. Therefore, samples of elution 2 from both pcDNA3.1HisA and 
FLAG-LEDGF/p75 transfected HEK293 cells were run on a gel and probed using the 
SilverQuest Silver Staining Kit. To enable a direct comparison between each of the 
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transfections, the immunoprecipitated samples were loaded alongside each other 
on the gel. Figure 5-26 shows that there were no discernible bands specific to the 
lane containing immunoprecipitated sample from the FLAG-LEDGF/p75 transfected 
cells. As the previous result (Figure 5-25) had demonstrated the presence of FLAG-
LEDGF/p75 in the immunoprecipitated sample, this result suggests that the amount 
of purified protein is below the detection limit of silver staining. 
 
 
Figure 5-26: Analysis of nickel bead column and immunoprecipitated samples by 
silver staining.  
Samples analysed by western blotting (Figure 5-25) were separated by SDS-PAGE 
and the gel visualised by silver staining. The immunoprecipitated samples (IP) from 
each of the samples were run adjacent to each other to allow for direct comparison. 
The respective column purified material (Nickel bead) was run alongside the IP 
samples. 
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As the results suggest that there is insufficient protein being purified to be visible by 
Coomassie Blue or silver staining, the amount of starting crude lysate was 
increased. Thus, lysate from 1x108 total cells was applied to the nickel column and 
purified as previously described. Aliquots from all elution steps were analysed by 
Western blot with an anti-FLAG antibody (Sigma Aldrich, Mouse monoclonal, 
1:1000) (Figure 5-27).  
 
 
Figure 5-27: Western Blot analysis of eluates of the column purification of 
HEK293-FLAG-LEDGF/p75.  
Whole cell lysates of HEK293-FLAG-LEDGF/p75 cells were subject to purification 
using the nickel column attached to the low pressure chromatography system. Each 
eluate in elution buffer was analysed by western blotting and the membranes 
probed with anti-flag antibody. 
 
As expected, there were no bands present in any of the wash steps or elutions of 
lysate from cells transfected with empty plasmid nor were there any bands in 
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samples of the wash steps from cells transfected with FLAG-LEDGF/p75 (data not 
shown). The result also suggested that the purified protein was eluted from the 
column in the first four elutions (ie within 4 mL). It is therefore surmised that the 
final protocol should consist of the following steps:  
1) Binding of the crude lysate to the column should be performed by passing the 
lysate through the column once at a very low flow rate.  
2) Washes should be performed with 50 mM imidazole.  
3) Purified protein should be recovered from the column with 2 x 2 mL elutions in 
250 mM imidazole.  
To this end, lysates from 1x108 cells stably transfected with each of the LEDGF 
isoforms were purified and samples of the wash and final elutions were analysed by 
Western blot probed with either an anti-FLAG or anti-Myc antibody. 
As can be seen in Figure 5-28, each of the isoforms was successfully purified. 
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Figure 5-28: Western blot analysis of purified LEDGF isoforms.  
Lysates from 1x108 stably transfected HEK293 cells expressing each of the six 
isoforms of LEDGF were subject to nickel column purification as described. Samples 
of whole cell lysate (wcl), flow through (F/T), 50 mM wash and 250 mM elutions 
were analysed by western blot and the membranes probed with antibodies to the 
tags. Specifically anti-flag (top) and anti-myc (middle and bottom). 
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Samples of each of the elutions were run alongside on the same gel and silver 
stained as described in section 5.2.13. The result is shown in Figure 5-29.  
 
Figure 5-29: Analysis of eluates in elution buffer from the large scale purification 
of each of the tagged isoforms of LEDGF.  
Whole cell lysates of each of the cell lines exogenously expressing a tagged isoform 
of LEDGF, were subject to purification on a nickel column attached to a low 
pressure chromatography system. Eluates in elution buffer were separated on a 
resolving gel and visualised by silver staining. 
 
As in previous results, whilst the western blot clearly shows that the purification 
was successful, silver staining again failed to identify bands that are unique for each 
isoform. 
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5.4. Discussion 
The aim of this chapter was to develop a method that could be used to examine 
how alternative splicing affects the ability of the different isoforms of LEDGF to 
participate in unique and distinct complexes, rather than in a disease-specific 
setting. A pitfall of such an investigation is the possibility of identifying proteins that 
are non-specifically bound to the molecule under investigation. In order to minimise 
this in my study, cDNA constructs of the different isoforms of LEDGF, identified in 
CLL cases, were generated to contain 2 unique tags. This would therefore allow 
LEDGF containing complexes to undergo 2 rounds of serial purification methods. 
Thus, constructs were cloned in to the pcDNA3.1HisA vector, such that recombinant 
proteins when expressed in cells would contain a 6xHis tag at the amino terminus. 
This would allow the complexes to be initially purified under native conditions. 
Secondly, the PCR primers used to generate the cDNA incorporated either a Myc, 
HA or FLAG tag which allowed for further enrichment by immunoprecipitation using 
antibodies specific for the tag. 
The precise method used to generate the tagged constructs varied depending on 
the nature of the constructs. The cDNA molecules (with the exception of 
LEDGF/p52) that were generated were initially cloned into the pGEM-T cloning 
vector. This enabled the cDNA to be sequenced to ensure its integrity, and also 
allowed for easier digestion with the restriction enzymes (EcoRI and XbaI) used to 
generate the final pcDNA3.1HisA clones. 
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A modified technique was used to generate pcDNA3.1His-HA-LEDGF/p52 and 
pcDNA3.1His-FLAG-LEDGF/p52. A “cut and paste” approach was used that exploited 
the unique XhoI restriction site present within the N-terminus common to both the 
LEDGF/p75 and p52 isoforms, which obviated the use of a further PCR reaction and 
cloning into pGEM-T. 
Due to the nature of the p52b isoform, a modified PCR technique was employed to 
generate pcDNA3.1His-MYC-LEDGF/p52b (Figure 5-2). This isoform is thought to 
arise from either the retention of part of the intron of LEDGF/p75 or the 3’-UTR of 
LEDGF/p52. If a reverse primer is designed to anneal to the end of the LEDGF/p52b 
C-terminal sequences, there is the potential to amplify the correct sequence at the 
very C-terminus, but then to diverge into the LEDGF/p52 sequence. Therefore, the 
N-terminus (amino acids 1 – 325) was amplified from the verified clone of pDNR-
DUAL-LEDGF/p75. This ensured the sequence was the same in all constructs. A 
second “Touchdown” PCR reaction was used to allow specific amplification of the C-
terminal region of LEDGF/p52b using the primers p52bLinkerPrimerNEW and 
p52bRXbaI (Table 5-1) and pcDNA3.1His-HA-LEDGF/p52 as template. After 
purification, the two resulting amplicons (N-terminus and C-terminus) were added 
to a 10-cycle primer-less PCR reaction. This allowed the two overlapping ends of the 
amplicons with complimentary sequences to anneal and be extended by the 
polymerase in the PCR reaction. Thus, at each cycle, the number of LEDGF/p52b 
full-length amplicons increased in a linear fashion. Following these 10 cycles, the 
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primers p52bc-mycF and p52bRXbaI were added which allowed for amplification of 
the full length LEDGF/p52b and also for the incorporation of the Myc tag. 
Finally, PWWP domain mutants of both LEDGF/p75 and p52 were generated. The 
PWWP domain is found in members of the “royal superfamily” of proteins which 
have a role, amongst other functions, in epigenetic regulation as the domains 
recognise methylated lysine or arginine residues110. However, little else is known 
about the PWWP domain in the context of LEDGF, and thus generating deletion 
mutants would help dissect the molecular functions of proteins that contain the 
domain. 
Initial studies to optimise the transfection conditions in order to obtain the 
maximum levels of expression were performed using pcDNA3.1His-HA-LEDGF/p75 
and the 293T cell line. This cell line was chosen as it is highly receptive to 
transfection. Transfected cells were lysed in the buffer that would be used for nickel 
purification (Ni-purification was not carried out at this initial stage), and lysates 
examined by western blot using an anti-HA antibody (Figure 5-12). The results 
clearly demonstrate that the level of HA-LEDGF/p75 was similar in each of the 
conditions used. Bands were not detected in control transfection lanes (cells 
transfected with empty plasmid), confirming that the bands present in the positive 
transfection lysates were indeed the transfected protein. To further support this, 
when the blots were probed with an antibody against LEDGF bands were present in 
both the control transfection and transfected cell lanes that corresponds to 
endogenous LEDGF. In the lanes containing lysates from transfected cells, a second, 
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slower migrating band was observed that corresponds to the tagged LEDGF. Whilst 
the results suggested transfecting 2x105 cells with 2 µg plasmid yielded slightly 
more protein, the increased numbers of cells and amount of plasmid required, 
especially if the transfection was to be scaled up, meant future transfections would 
be performed with 1x105 viable cells with 1.5 µg plasmid. 
Having established optimal transfection parameters, the integrity of each of the 
constructs was verified by western blot using whole cell lysates (Figure 5-13). Use of 
a β-actin antibody as a control meant it was possible to confirm protein had been 
loaded in the lanes containing whole cell lysate as bands were not visible using 
antibodies to the tags. As expected, bands were not detected in lanes containing 
lysates from mock or control transfected cells confirming the specificity of the 
antibodies that recognise the tags. 
When the blots were probed with an anti-Myc antibody, a band of 60 kDa 
corresponding to endogenous C-myc protein acted as an internal positive control in 
the whole cell lysate lanes as well as a negative control in the lanes that contained 
purified protein that wasn’t Myc-tagged. In the lane containing whole cell lysate 
from HEK293 cells over expressing MYC-LEDGF/p52bΔE6, a very faint band was 
visualised after longer exposure suggesting that the expression of this isoform in the 
HEK293 cells was low. When whole cell lysates from cells transfected with the 
ΔPWWP constructs were analysed, a number of bands with lower molecular 
weights were seen and not observed in lanes containing lysate from control 
transfections or purified protein. Deletion of the PWWP domain may result protein 
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instability, and hence these bands may represent breakdown products that are not 
purified with the Ni beads. 
In order to examine the components of isoform specific LEDGF complexes, it was 
decided to establish stable cell lines expressing each of the splice forms. Several 
previous reports investigating the general role of LEDGF have used transiently 
transfected 293T cells36, 102, 104, 107. The 293T cell line is a variant of the HEK293 cell 
line which has been transformed to stably express the SV40 large T antigen. 
However, it is also highly resistant to neomycin and therefore stable cell lines 
cannot be established using G418. Therefore, stable cell lines were established 
using the parental HEK293 line. 
There remained the possibility that the different isoforms of LEDGF could hetero- or 
homo-dimerise. This would confound the results if the over expressed protein 
dimerised with endogenous LEDGF. Thus, any binding partners identified in 
subsequent analyses would be specific for the isoform in question. 
Previous studies that have identified binding partners associated with LEDGF have 
restricted the analysis to just one part of the protein. For example, it has been 
shown that the C-terminal region of LEDGF/p75 interacts with the HIV-1 IN, JPO2 
and pogZ 102, 105, 106 and the Cdc7-ASK107. Other studies have restricted the analysis 
to a set of proteins with a specific function. Leoh et al. used transcription factor 
protein arrays to identify MeCP2 as a binding partner of LEDGF109. Martaens et al. 
did use a full length HA tagged LEDGF/p75 when they described JPO2 as an 
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interactor with the C-terminus of LEDGF104. However, very strict screening criteria 
were employed such that identified proteins were only considered if the peptides 
identified by mass spectrometry were present only in 293T-HAp75 samples and 
were completely absent from 293T samples, plus the proteins were identified by at 
least 2 unambiguous peptides. Using such an approach, several dozen potential 
interacting proteins were disregarded. It is interesting to note that Cdc7-ASK, 
MeCP2, PogZ and menin/MLL were all identified as binding partners of LEDGF/p75 
following publication of this work36, 106, 107, 109. My work to identify the binding 
partners of LEDGF isoforms utilised full-length proteins. The ΔPWWP domain 
mutants of the two well documented LEDGF isoforms were also included in the 
protein complex investigation, as it is of interest to highlight any proteins that may 
solely bind to this important region. 
The initial experiments to purify the constructs using Ni-NTA beads were carried out 
using the protocol described by the manufacturer. However, analysis of the elutions 
by western blot suggested the yields were not optimal. Therefore, it was necessary 
to optimise the amount of beads as well as incubation times. Whilst this led to an 
increase in amount of protein purified (Figure 5-15 and Figure 5-17), it gave rise to 
the problem that a lot of protein remained bound to the beads. Even when the 
number of elutions was increased, not all of the tagged protein was eluted from the 
beads (Figure 5-17). However, silver staining did show that as the number of 
elutions increased, the protein concentration in each elution decreased (Figure 
5-18). As multiple elution sample analysis isn’t practical; it would be better if 
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complexes could be purified in the lowest possible number of elutions. Even though 
it was very encouraging to visualise the over expressed protein on a gel that was 
silver stained, on closer inspection, it was noted that in the lanes containing 
“purified” wild type HEK293 lysates, there are multiple bands that would represent 
endogenous proteins in the cells that bind non-specifically to the nickel beads. 
These bands are also present in the lanes of the purified FLAG-LEDGF/p75 and it is 
therefore very difficult to highlight any bands that are present only in the purified 
over expressed protein lane and not in the wild type lane that may correspond to a 
unique protein that is part of a complex assembled around LEDGF/p75. This 
suggests that washing of the beads isn’t efficient and/or the concentration of 
imidazole in the wash buffer should be increased from 20 mM. Furthermore, it 
should be noted that proteins with a natural run of histidine residues will non-
specifically bind to the nickel beads.  
As was described earlier, from the outset of this project, it was decided that the 
constructs should contain two different tags. As the results have so far 
demonstrated, a single purification using just nickel beads resulted in elution of 
proteins that were non-specifically purified from control cell lysates. Therefore, 
following nickel purification, an additional immunoprecipitation step was 
performed exploiting the FLAG tag in the protein to improve the purity of the 
proteins. This second step did purify the FLAG tagged LEDGF/p75 and reduced the 
number of the non-specific proteins (Figure 5-19) thus confirming the benefits of 
the extra purification strategy.  
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In order to perform mass spectrophotometric analysis, large amounts of starting 
material are required to purify the protein/complex of interest. As such, the small 
scale purification of the nickel tagged proteins using the Ni-NTA agarose beads isn’t 
practical due to time, labour, amount of starting material required and 
inconsistencies in recovery and washing. To overcome this, a large scale purification 
method was developed using a low pressure chromatography system connected to 
a HisTrap HP column to achieve the maximum recovery of the tagged protein. 
HEK293 cells transfected with the empty pcDNA3.1His vector would allow for 
determination of proteins eluted in a non-specific manner.  
Initially, the whole cell lysate was passed through the HisTrap HP column five times 
to give the over expressed protein maximum opportunity to bind. Eluates from each 
of the wash and elution steps were analysed by SDS-PAGE and Coomassie blue 
staining (Figure 5-20). Coomassie Blue staining was chosen as it was felt that if the 
over expressed protein purified by small-scale nickel beads could be visualised by 
silver staining, then the amounts of protein from a large-scale purification should be 
visible by this method.  
The results demonstrated that the majority of the protein was eluted in the third 
elution with 250 mM imidazole. However, there were no bands apparent that were 
specifically found in the lane containing purified lysate from cells transfected with 
pcDNA3.1His-FLAG-LEDGF/p75. However, a subsequent western blot of the elutions 
demonstrated that the over expressed protein was present (Figure 5-22) and that 
the purification strategy was successful. Furthermore, an immunoprecipitation of 
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these same elutions with anti-FLAG magnetic beads and analysis by western blot 
illustrated that a known binding partner of LEDGF/p75, namely MeCP2109 was 
purified using this method (Figure 5-23). Therefore, it would appear that this 
method was successful in purifying FLAG tagged LEDGF/p75 and at least one of the 
known interacting proteins. However, further optimisation was required to ensure 
maximum recovery of the tagged protein and the associated complex. 
To this end, the first aspect to be considered was to improve the 
efficiency/stringency of the wash step. A second wash step was included with an 
increased imidazole concentration of 50 mM. Western blot analysis showed that 
this increase in imidazole did not result in any of the FLAG-LEDGF/p75 being 
displaced from the column (Figure 5-24). This extra wash step did not have any 
adverse effect on the subsequent immunoprecipitation following elution of bound 
proteins with 250 mM imidazole (Figure 5-25). Although it was anticipated that this 
extra wash step would aid in identifying bound proteins by silver staining, this was 
found not to be the case (Figure 5-26). 
Therefore, the purification was repeated, but this time the lysate from ten times the 
number of cells was applied to the column. The method was once again successful 
as the release of the tagged protein could be tracked by western blot (Figure 5-27).  
This method, however, was used to purify all of the tagged proteins with minor 
modifications. Firstly, the lysate was applied to the column just once, but with a low 
flow rate to allow as much of the tagged protein to bind. Secondly, the 20 mM wash 
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step was excluded, and washing was instead performed with 50 mM imidazole as it 
had been demonstrated that this concentration had no impact on the recovery of 
the tagged protein. Finally, the volumes of the 250 mM imidazole eluates collected 
were increased so as to reduce the number of fractions collected. The success of 
the purification was tracked by western blot (Figure 5-28) and the 250 mM eluate 
fractions analysed by silver staining (Figure 5-29). 
 
Future work 
As the large-scale purification method is now complete and material from the 
HisTrap HP column successfully purified and stored at -20 °C, the next steps are to 
investigate the options available to analyse the elutions to determine unique 
binding partners of the different isoforms of LEDGF.  
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Chapter 6 : Conclusions and 
Future Work 
 
The novel findings resulting from this thesis are: 
1. Both CLL and normal B cells express four isoforms of LEDGF, namely 
LEDGF/p75, LEDGF/p52, LEDGF/p52b and LEDGF/p52bΔE6.  
2. These four isoforms of LEDGF are differentially expressed in CLL. More 
specifically, LEDGF/p75 is significantly over expressed in CLL and 
LEDGF/p52bΔE6 is significantly under expressed compared to normal B cells. 
3. Mutations of the SF3B1 gene result in lower levels of expression of LEDGF. 
4. The identification of a novel nonsense mutation in SF3B1. 
5. Development of a method that allows for over expression of tagged LEDGF 
isoforms identified in CLL and normal B cells, and the subsequent 
purification of protein complexes involving these isoforms. This should allow 
for the determination of the components within the complexes associated 
with each of the LEDGF isoforms. 
 
In this thesis, I have demonstrated that both normal B cells and B cells isolated from 
CLL patients express four isoforms of LEDGF. Given the sequence similarities 
between these isoforms, it is likely they all arise from alternative splicing of the 
PSIP1 gene. The amino acid sequences of, LEDGF/p75, LEDGF/p52 and LEDGF/p52b 
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are identical up to residue 325 but then diverge into unique C-terminal sequences. 
The primary sequence of LEDGF/p52bΔE6 is identical to the three other isoforms up 
until residue 152. The whole of exon 6 is then deleted which leads to an altered 
open reading frame resulting in a premature stop codon. Ultimately, like the other 
isoforms, this isoform possesses a unique C-terminal tail57. It has been shown that 
LEDGF/p75 and LEDGF/p52 are associated with different protein complexes based 
on the ability of the unique C-terminal domains to bind to different proteins. 
Therefore, it is predicted that LEDGF/p52b and LEDGF/p52bΔE6 will also be 
associated with complexes that are unique to each isoform. It should be noted that 
there is one protein, namely MeCP2, which has been shown to bind to both 
LEDGF/p75 and p52 in their common N-terminal region109. Therefore, based on this 
knowledge, it is likely that each isoform may also share some common components 
within their respective complexes.  
It would be of interest to determine the nuclear localisation of LEDGF/p52b and 
LEDGF/p52bΔE6 shown to be expressed in CLL and Normal B cells. Deletion of exon 
6 in LEDGF/p52bΔE6 disrupts the end of the NLS and abolishes the AT hooks, 
although the critical lysine150 residue, essential for localisation within the nucleus 
(discussed in Chapter 1) is retained. It could be predicted, therefore, that this 
isoform may be localised within the nucleus but it may not bind to the DNA as the 
AT hooks are absent.  
By using RT-qPCR, it is shown that each of the four isoforms of LEDGF is 
differentially expressed in CLL compared to normal B cells. In particular, the data 
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shows that LEDGF/p75 is significantly over expressed in CLL cells whereas 
LEDGF/p52bΔE6 is significantly under expressed. The fact that LEDGF/p75 is over 
expressed in CLL is consistent with previous reports showing that this isoform is 
over expressed in a variety of other cancers81, 82 and that it can be considered a 
cancer associated protein. The over expression of LEDGF/p75, which has been 
shown to protect cells from spontaneous apoptosis coupled with the under 
expression of pro-apoptotic LEDGF/p52bΔE657, may provide CLL cells with a 
mechanism to avoid programmed cell death. The opposing function of these two 
isoforms implies that one gene can undergo alternative splicing and yield separate 
protein products that have contrasting effects in the cell.  
Statistical examination of the data generated from the RT-qPCR studies provides 
evidence for a relationship between the degree of CD38 positivity in CLL and the 
level of expression of LEDGF. Thus it was shown that those patients who are 
classified as CD38 positive have higher levels of each of the LEDGF isoforms. 
Expression of CD38 in CLL cells is associated with a poor prognosis and poor 
response to chemotherapy90, 91, and it has been shown that high levels of 
expression of LEDGF/p75 renders AML cells resistant to daunorubicin induced cell 
death57. Taken together with the fact that LEDGF/p75 protects cells from apoptosis, 
it is not difficult to surmise that those patients with high levels of expression of 
LEDGF/p75 are more likely to be those with a poorer prognosis.  
Given that LEDGF/p75 has been shown to be significantly over expressed in CLL and 
that a trend between CD38 expression and isoform expression has been suggested, 
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it may be possible to investigate LEDGF/p75 as a potential biomarker in CLL. 
Detection of LEDGF/p75 overexpression would imply a poor prognosis in individual 
cases. Hence, LEDGF/p75 could be explored as a therapeutic target in CLL. Previous 
data have suggested that low/absent levels of LEDGF/p75 results in cell death and 
thus over-expression could provide cells with an anti-apoptotic advantage 
(discussed in chapter 3). Therefore, targeting this isoform for degradation in CLL 
may tilt the balance to apoptosis in the cell. Feng et al., showed that BCL-2 
regulates the transcriptional activity of a panel of proteins, including LEDGF111. BH3 
mimetics are a class of drugs that target the BH3 domain in BCL-2 (and other family 
members) and inhibit its’ activity thus affecting the pro-survival function of the 
protein112. Therefore, administration of this class of drugs to CLL patients would 
have a negative effect on the role of BCL-2, in-turn affecting the transcription of 
LEDGF/p75. Reduced levels of LEDGF/p75 could result in cell death.   
There is growing interest in the role splicing factors play in the pathobiology of 
haematological malignancies, including CLL, after it was shown that SF3B1, a 
prominent member of the major U2 and minor U12 spliceosome complexes67, is 
recurrently mutated in these diseases63, 70. These mutations were predicted to, and 
subsequently shown to, alter the function of SF3B1 by affecting the splicing patterns 
of other mRNA species within the cell63, 70, 72. Although the data did not reach 
statistical significance, in CLL patients with a mutated SF3B1 gene, there are lower 
levels of all four LEDGF isoforms as compared with the levels in patients with wild 
type SF3B1. This would suggest that the mutated SF3B1 gene does have an effect 
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on the expression and splicing of LEDGF. As with previous reports, the mutations 
are all clustered in the HEAT repeats. Mutations in this region are predicted to alter 
the function of SF3B1100 and result in incorrect splicing. 
All of the mutations within SF3B1 that have been described to date have been 
missense, silent or deletions. One of the novel findings of this thesis is the 
identification of a nonsense mutation. Although we have shown this mutation is 
present at the mRNA, we have not been able to say with conviction that this results 
in the expression of a truncated protein. Two explanations for this could be due to 
the mRNA being degraded by NMD or the protein itself is degraded following 
ubiquitination. Either way, this would prevent detection of the truncated protein by 
western blot. However, this result does raise the possibilities that nonsense 
mutations do occur in SF3B1.  
As it has been shown that LEDGF/p75 and LEDGF/p52 are involved in different 
complexes by virtue of their divergent C-terminal domains, it is postulated that 
complexes involving LEDGF/p52b and LEDGF/p52bΔE6 will also be different. To 
determine the components of protein complexes formed around each isoform, 
mammalian expression constructs were generated that contained two different 
tags. This would allow for purification of LEDGF containing complexes by sequential 
methods, thus ensuring a high degree of purification and reliability of results. These 
constructs were transfected into HEK293 cells, and stable cell lines expressing each 
of the isoforms were established. Further, stable cell lines were established that 
express LEDGF/p75 and LEDGF/p52 with the PWWP domain deleted. A protocol was 
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developed that involves a double purification of each of the exogenously expressed 
isoforms, such that components of the associated complexes can be identified 
through mass spectrometry. Identification of these components may give an 
indication of the roles of the different LEDGF isoforms in the cell. 
In conclusion, I aimed to provide further evidence that alternative splicing is a 
mechanism of epigenetics. An epigenetic mechanism is one in which there is change 
in phenotype that isn’t caused by an alteration of DNA sequence. The PSIP1 gene is 
known to be alternatively spliced into two well characterised isoforms: LEDGF/p75 
and LEDGF/p522. These are known to have differing nuclear localisations26 as well as 
differing roles in the cell. Thus, whilst, LEDGF/p52 has been postulated to have a 
role in alternative splicing via modulating the inclusion and exclusion of exons24, 27, 
LEDGF/p75 has several roles as a molecular tether36, 102, involvement in the stress 
response46 and a role in transcription28. The ability to perform these roles is 
dependent on the different complexes these isoforms are associated with. Thus, 
one gene gives rise to two proteins with different functions, which in turn is 
dependent on the complexes they form. Thus, the proteins are phenotypically 
different but are expressed from the same genetic sequence. Therefore, although 
not investigated to exhaustion, there is evidence to support that alternative splicing 
is a form of epigenetic regulation. 
In order to carry this work forward, it will be important to determine the cellular 
localisation of LEDGF/p52b and LEDGF/p52bΔE6. As discussed, the cellular location 
of LEDGF/p75 and LEDGF/p52 is unique to each isoform and is specific to their 
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respective roles in the cell. The localisation of LEDGF/p52bΔE6 would be most 
interesting as the end of the NLS is disrupted in this isoform but the critical lysine150 
residue is still present. For such a systematic study it is essential that specific 
antibodies that each recognises the endogenous variant proteins are generated for 
the data to be meaningful. The generation of specific antibodies to each of the 
isoforms would involve them being raised against the respective unique C-terminus. 
As discussed, the C-terminal tails of LEDGF/p75, p52 and p52b all differ after residue 
325. In the case of LEDGF/p52bΔE6, deletion of exon 6 yields a unique tail from 
residue 152 to 167. However, the unique part of the immunogen used to generate 
the antibodies for LEDGF/p52 and LEDGF/p52bΔE6 is relatively small and this should 
be noted when analysing the specificity of the antibody.  
It is also important to determine the composition of the protein complexes 
associated with each isoform, as it has been shown that the complexes generated 
with LEDGF/p75 and LEDGF/p52 are unique to the specific roles of each of these 
isoforms. For example, Pradeepa et al. have shown that ~95% of proteins that bind 
to LEDGF/p52 have a role in alternative splicing24. To this end, it will be necessary to 
perform mass spectrophotometric analysis of the purified LEDGF isoform 
complexes, obtained from the stable cell lines. 
Finally, by use of the PWWP domain mutants that were generated as part of these 
studies, the proteins that specifically bind to the PWWP domain should be 
determined. As discussed, this domain is an important reader of histone 
modifications. As it is present in each of the LEDGF isoforms that are products of 
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alternative splicing, it highlights this domain may be important, both structurally 
and mechanistically.  
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Appendix A:  
 
 
 
 
 
 
 
 
Clinical data of all CLL patients used within this study to examine the expression level of each isoform of LEDGF and the mutation status of 
their SF3B1 gene. 
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Appendix A-Table 1: Clinical data of CLL cases used within this thesis.  
The CLL case number is given in column 1 followed by the white blood cell count (wbc), the Rai and Binet stage, the status of the Ig gene 
(mutated or unmutated, m or u), CD38 expression, the Ig isotype, VH segment useage, the p53 status, karyotype data, the age at diagnosis, 
treatment prior to sampling, if the patient was treated at any time, the time between diagnosis and sampling (T(Δ-S)), time to first treatment 
(TFT), overall survival (OS), status of the patient (dead or alive) and the mutational status of the SF3B1 gene. 
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Sample Normalised p75 Normalised p52 Normalised p52b Normalised p52bΔE6
2953 . . . .
2512 . . . 0.1134
3047 . . . 1.3472
2902 0.1756 0.0928 0.0317 0.0842
2968 . . . .
2950 . . . .
2673 . . . .
2979 . . . .
2744 0.2813 0.2912 0.0878 1.4340
2999 0.3209 0.1207 0.0854 0.1321
2248 . . . .
2565 0.2045 0.0461 0.1216 .
2408 0.3186 0.0600 0.0621 0.0860
2418 0.6736 0.0988 0.0748 0.2912
1800 0.3950 0.1856 0.0552 0.1476
2136 0.5434 0.1096 0.2192 0.8827
2539 0.1022 0.0313 0.0448 0.0748
2533 0.0579 0.0254 0.0548 .
1731 0.7371 23.2636 0.1207 0.8467
2472 0.2073 0.1560 0.1571 0.1507
2573 0.3099 17.0299 0.0409 0.3511
1815 0.4175 0.0884 0.0409 0.0182
2722 0.7474 14.3204 0.1684 0.8467
2674 0.2952 0.0522 0.0177 0.1127
2230 0.3299 0.0349 0.0361 0.1550
2358 . . . 1.0210
2747 0.4118 1.0425 0.1127 0.3253
2399 0.2832 0.4965 0.0670 0.5322
2088 0.6329 1.7901 0.0791 0.1487
2765 0.1397 0.0802 0.0451 0.1127
2787 . . . .
2789 . . . .
2792 . . . .
2793 0.1882 0.2774 0.0638 0.1895
2794 . . . .
2804 . . . .
2809 . . . .
2820 . . . .
2821 . . . .
2843 0.2146 0.1672 0.0718 0.1191
2844 0.2872 0.2661 0.0693 0.3487
2855 0.1487 0.0621 0.1250 .
2867 . . . .
2874 . . . .
2876 . . . .
2877 0.8467 0.4414 0.0643 0.0836
2920 0.2912 0.1358 0.0652 0.2755
2924 0.2698 0.1321 0.1119 1.1408
2930 0.3415 0.2161 0.0769 0.5864
2937 0.3896 0.1487 4.5948 0.7526
2938 . . . .
2949 0.2912 0.1008 5.0281 0.3585
2962 0.6462 0.4118 5.9381 2.6759
2967 0.2102 0.1487 5.0982 0.3923
2985 0.2449 0.0941 4.6268 0.1627
3016 . . . .
3018 0.2432 0.1627 7.5685 1.0353
3035 0.8351 0.4323 0.1183 0.3035
3037 1.1019 0.4506 0.1051 0.8645
3068 0.9138 0.6417 0.2161 0.4475
3069 0.5070 0.1436 0.0643 0.1975
3071 0.4090 0.1768 0.0934 0.5000
3076 . . . .
3078 . . . .
3089 0.2973 0.1908 0.1276 0.2973
3091 . . . .
3092 0.3463 0.1349 0.1207 0.1743
3125 . . . .
3139 . . . .
3151 0.3415 0.0415 0.0830 0.1792
3144 . . . .
3187 0.6113 0.3950 0.2365 0.4118
3190 0.4175 0.0759 0.0819 0.3057
3192 . . . .
3160 0.3660 0.1081 0.0364 1.0644
Expression data of each isoform of LEDGF in each CLL sample. 
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Sample Normalised p75 Normalised p52 Normalised p52b Normalised p52bΔE6
2953 . . . .
2512 . . . 0.1134
3047 . . . 1.3472
2902 0.1756 0.0928 0.0317 0.0842
2968 . . . .
2950 . . . .
2673 . . . .
2979 . . . .
2744 0.2813 0.2912 0.0878 1.4340
2999 0.3209 0.1207 0.0854 0.1321
2248 . . . .
2565 0.2045 0.0461 0.1216 .
2408 0.3186 0.0600 0.0621 0.0860
2418 0.6736 0.0988 0.0748 0.2912
1800 0.3950 0.1856 0.0552 0.1476
2136 0.5434 0.1096 0.2192 0.8827
2539 0.1022 0.0313 0.0448 0.0748
2533 0.0579 0.0254 0.0548 .
1731 0.7371 23.2636 0.1207 0.8467
2472 0.2073 0.1560 0.1571 0.1507
2573 0.3099 17.0299 0.0409 0.3511
1815 0.4175 0.0884 0.0409 0.0182
2722 0.7474 14.3204 0.1684 0.8467
2674 0.2952 0.0522 0.0177 0.1127
2230 0.3299 0.0349 0.0361 0.1550
2358 . . . 1.0210
2747 0.4118 1.0425 0.1127 0.3253
2399 0.2832 0.4965 0.0670 0.5322
2088 0.6329 1.7901 0.0791 0.1487
2765 0.1397 0.0802 0.0451 0.1127
2787 . . . .
2789 . . . .
2792 . . . .
2793 0.1882 0.2774 0.0638 0.1895
2794 . . . .
2804 . . . .
2809 . . . .
2820 . . . .
2821 . . . .
2843 0.2146 0.1672 0.0718 0.1191
2844 0.2872 0.2661 0.0693 0.3487
2855 0.1487 0.0621 0.1250 .
2867 . . . .
2874 . . . .
2876 . . . .
2877 0.8467 0.4414 0.0643 0.0836
2920 0.2912 0.1358 0.0652 0.2755
2924 0.2698 0.1321 0.1119 1.1408
2930 0.3415 0.2161 0.0769 0.5864
2937 0.3896 0.1487 4.5948 0.7526
2938 . . . .
2949 0.2912 0.1008 5.0281 0.3585
2962 0.6462 0.4118 5.9381 2.6759
2967 0.2102 0.1487 5.0982 0.3923
2985 0.2449 0.0941 4.6268 0.1627
3016 . . . .
3018 0.2432 0.1627 7.5685 1.0353
3035 0.8351 0.4323 0.1183 0.3035
3037 1.1019 0.4506 0.1051 0.8645
3068 0.9138 0.6417 0.2161 0.4475
3069 0.5070 0.1436 0.0643 0.1975
3071 0.4090 0.1768 0.0934 0.5000
3076 . . . .
3078 . . . .
3089 0.2973 0.1908 0.1276 0.2973
3091 . . . .
3092 0.3463 0.1349 0.1207 0.1743
3125 . . . .
3139 . . . .
3151 0.3415 0.0415 0.0830 0.1792
3144 . . . .
3187 0.6113 0.3950 0.2365 0.4118
3190 0.4175 0.0759 0.0819 0.3057
3192 . . . .
3160 0.3660 0.1081 0.0364 1.0644
Appendix A-Table 2: The expression of each isoform of LEDGF in each CLL 
sample.  
The expression level relative to RPL27 reference gene is given for each CLL 
patient. 
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Appendix B 
 
Exploratory analysis of potential relationships between the expression levels of 
each of the LEDGF isoforms in CLL samples and clinical factors associated with CLL. 
Clinical factors used for this investigation were white blood cell count (wbc), CD38 
expression, age at diagnosis, time between diagnosis and sampling (T(D-S)), time-to-
first-treatment (TFT), overall survival (OS), Rai and Binet status, IGHV gene status 
(unmutated or mutated, u or m), Ig isotype (iso A, G, M), p53 status (A, B, C or wild-
type), treated prior to sampling (treat_prior), treated while alive (treat),  status of 
patient (dead or alive, 1 or 0) and SF3B1 status (unmutated or mutated). 
1. Relationship between LEDGF/p75 expression and clinical factors. 
 
WBC
(10^9/L)
CD38
(%)
Age at
diag
T(D-S)
TFT
OS
Normalised
p75
0 100 200
0
50
100
50 100
40
60
80
40 60 80
0
100
200
0 100 200
0
100
200
100 200
0
100
200
100 200
0
.5
1
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2. Relationship between LEDGF/p52 expression and clinical factors. 
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3. Relationship between LEDGF/p52b expression and clinical factors. 
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4. Relationship between LEDGF/p52bΔE6 expression and clinical factors. 
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Appendix C 
 
Exploratory analysis of potential relationships between the mutation status of 
SF3B1 gene and clinical factors associated with CLL. 
1. The potential relationship between CD38 expression and SF3B1 mutation 
was investigated using a Fisher’s Exact Test. There was no relationship 
between the two variables. 
 
 
 
2. The potential relationship between age and SF3B1 mutation status was 
investigated using a two-sided t-test. There was no relationship between the 
variables.  
 
           Fisher's exact =                 0.245
     Total           6         12          18 
                                             
  Positive           0          4           4 
  Negative           6          8          14 
                                             
  category           m          u       Total
      CD38          Status
4
0
5
0
6
0
7
0
8
0
A
g
e
 a
t 
d
ia
g
m u
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SF3B1 status Age 
Observations Mean Standard Deviation 
mutated 9 60.44 8.23 
unmutated 30 63.4 10.59 
two sided t –test p-value = 0.39 
 
 
3. The potential relationship between the mutation status of the patient (dead 
or alive) and the mutation status of the SF3B1 gene was also investigated. 
There was no relationship between the variables. 
 
 
 
 
4. The relationship between other clinical variables and SF3B1 status was also 
examined but no relationship was detected in these cases. Factors 
investigated where white blood cell count, rai and binet stage, overall 
survival, if the patients had been treated, time-to-first-treatment and p53 
status. 
  
           Fisher's exact =                 0.063
     Total          59         11          70 
                                             
         u          52          7          59 
         m           7          4          11 
                                             
    status       Alive       Dead       Total
     SF3B1          status
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Maps of plasmids that were utilised or generated in this study. 
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